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There was a beginning of time. 
There was a time 
before the beginning of time. 
There was a time before the time 
before the beginning of time. 
There is being. 
If there is being, 
there must be non-being. 
If there is non-being, 
There must have been a time 
when even non-being didn’t exist. 
Suddenly there was non-being. 
But can any non-being really exist, 
And can being not-exist? 
I just said something, 
But did what I just said really 
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The intrinsic resistance of Mycobacterium tuberculosis (Mtb) to antibiotics is generally 
attributed to multiple factors, most significantly the low permeability of the mycobacterial 
cell wall, the operation of various drug inactivating systems, and the activity of efflux 
pumps. This study aimed to investigate the role of various components of the “intrinsic 
resistome” that limit the efficacy of antitubercular agents.  
The DNA damage response: the SOS response was hypothesized to play a role in antibiotic-
mediated cellular death, and that disabling the mycobacterial SOS response, by generating 
non-cleavable LexA mutants (lexAInd-), could be used as a tool to validate antibiotic-
mediated cell death. To this end, the M. smegmatis (Msm) cleavable LexA was shown to be 
essential for induced mutagenesis and damage tolerance and that an intact DNA damage 
repair system is required to respond to antibiotic-mediated DNA damage. In contrast, Mtb 
cleavable LexA was required for induced mutagenesis but not necessarily damage 
sensitivity. In addition, the Mtb SOS response does not contribute significantly to 
remediation of antibiotic-mediated DNA damage. Collectively, these data suggest that DNA 
repair mechanisms differ between the mycobacterial species and despite effectively 
inactivating the LexA-dependent DNA repair mechanism(s) in Msm and Mtb, these 
organisms are able to circumvent this pathway and successfully remediate damaged DNA 
sustained under various conditions. Furthermore, Mtb auto-bioluminescent reporter strains 
were generated by introducing the lux operon downstream of the recA or radA promoters. 
Analysis of a panel of antimicrobials against these strains allowed for the identification of 
true DNA-damaging agents and the evaluation of the kinetics of the DNA-damage response, 
in a concentration- and time-dependent manner.  
Efflux-mediated drug resistance: This study aimed to evaluate the interactions between 
pairwise combinations of selected antimicrobials and efflux pump inhibitors (EPIs), in vitro 
and ex vivo, and to identify a novel verapamil (VER)-analogue with improved efficacy against 
Mtb. Subsequently, a candidate EPI was identified, with equivalent in vitro synergistic 
effects to VER when used in combination with various antibiotics but with reduced cytotoxic 
effects, ex vivo, when compared to VER. 
iv 
Mycothiol-mediated protection: It was hypothesized that undetectable levels of mycothiol 
(MSH) in Mtb would potentiate the use of current antibiotics. To investigate the 
contribution of the cellular antioxidant, MSH, to the mitigation of antimicrobial efficacy, this 
study aimed to disrupt MSH production by conditionally knocking-down expression of the 
essential gene, mshC. The mshC knock-down mutants (in all configurations) were not 
anhydrotetracycline (ATC)-regulatable in liquid or on solid medium, which was subsequently 
validated with quantitative gene expression analysis. These data suggest that a tetracycline 
(Tet)-based conditional expression system may not be applicable to mshC.  
In conclusion, Mtb has a multitude of inherent mechanisms to subvert the effects of 
antimicrobial treatment. This study has contributed to the understanding of certain aspects 
of the intrinsic resistome and in doing so, established tools that can be used in future drug 
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Mycobacterium tuberculosis (Mtb), the aetiological agent of tuberculosis (TB), is a Gram 
positive, facultative intracellular pathogen that infects and persists within its obligate 
human host. Mtb infection is initiated upon inhalation of the tubercle bacilli, which are 
immediately phagocytosed by cells of the innate immune system, principally resident 
alveolar macrophages. A granuloma develops as lymphocytes, monocytes, and fibroblasts 
are recruited as a result of a proinflammatory response from the infection of naive alveolar 
macrophages and dendritic cells (Stallings & Glickman 2010). The bacilli successfully evade 
both innate and adaptive host immunity by various mechanisms including inhibition of 
phagosome maturation, resistance to innate bactericidal mechanisms and cytokine-
mediated host defences, as well as inhibition of antigen presentation (Harding & Boom 
2010). This ability to evade elimination by the host immune system results in primary 
infection with Mtb which is highly successful and subsequently leads to widespread 
dissemination of the bacilli to most organs in the body (Stallings & Glickman 2010). 
However, Mtb infection is usually asymptomatic in immunocompetent hosts and rarely 
leads to progressive TB (Philips & Ernst 2012). Based on immunological tests, up to one third 
of the world’s population is thought to be infected with this highly successful pathogen, yet 
latent and persistent infection is the predominant outcome (Carvalho et al., 2011). This 
unique ability of Mtb to cause latent TB infection (LTBI) creates a huge reservoir of potential 
cases of reactivation disease and subsequent transmission of the bacillus (Chao & Rubin 
2010).  
There were an estimated 9 million new cases and 1.5 million TB-related deaths in 2013 
(WHO 2014). As such, TB remains a major cause of morbidity and mortality worldwide, more 
so than any other bacterial infection, despite the existence of both chemotherapeutic 
interventions as well as vaccine prophylaxis. South Africa is ranked in the top ten countries 
with the highest incident rates, where about 1 person in every 100 develops active TB (WHO 
2014). The Human Immunodeficiency Virus (HIV) pandemic has exacerbated the high 
burden of TB disease as the virus weakens the immune system, increasing the risk of not 
only reactivating LTBI, but also rapid progression to active TB soon after infection (Godfrey-
Faussett & Ayles 2003; Sharma et al., 2005). In addition, the emergence of resistant Mtb 
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strains, both multidrug resistant (MDR) and extensively drug resistant (XDR), poses a major 
threat to control of TB worldwide: in 2013, there were an estimated 480 000 cases of MDR-
TB (defined as resistance to the two frontline drugs, isoniazid [INH] and rifampicin [RIF]) and 
9% of these were classified XDR-TB (MDR-TB plus additional resistance to a fluoroquinolone 
and any of the second-line injectable agents). Existing preventative measures include the M. 
bovis-derived bacille Calmette–Guérin (BCG) vaccine, which offers inconsistent protection 
(young children are protected against disseminated TB but protection against pulmonary TB 
in adolescents and adults remains variable) – and whose efficacy has been unequivocally 
demonstrated only in low-burden settings (Fine 1995; Trunz et al., 2006). Dishearteningly, a 
recent phase IIb trial in South African infants showed no efficacy against TB with the 
candidate vaccine, MVA85A (Tameris et al., 2013). There is, however, much optimism as 
there are several vaccine candidates at various stages of clinical trials, in a pipeline that was 
virtually empty in the early 1990s (Andersen & Kaufmann 2014). Until such preventative 
measures are established, management of the current TB global health crisis is massively 
dependent on therapeutic intervention in active TB disease. 
1.2 Antimycobacterial chemotherapy 
Following the discovery of penicillin in 1928, a significant number of antibiotics were 
discovered in the subsequent years, many of which were used for the treatment of Gram 
positive infections. Since Waksman’s discovery of streptomycin (STM) as the first 
antimycobacterial drug in 1944, the history of TB chemotherapy has evolved dramatically 
(Janin 2007; Da Silva & Palomino 2011). Shortly after its introduction as an effective 
chemotherapy, reports of STM-resistant (STMR) Mtb surfaced, and were later shown to be 
the result of STM monotherapy (Da Silva & Palomino 2011). By 1955, following the 
discovery of several drugs with antimycobacterial activity, multidrug therapy became the 
standard treatment for TB and a regimen of STM, para-aminosalysilic acid (PAS) and INH was 
developed, and shown to clear TB disease following 18–24 months of therapy (Lienhardt et 
al., 2012). The major breakthroughs in the treatment of TB came with the discovery in the 
late 1960s of RIF, which is inhibitory to both actively growing and slowly metabolizing bacilli, 
and the rediscovery of the antimycobacterial activity of pyrazinamide (PZA), which inhibits 
semi-dormant bacilli in acidic environments. These drugs ultimately replaced STM, 
4 
shortening the duration of treatment considerably, to 9 months (Jawahar 2004; Da Silva & 
Palomino 2011). Following the resurgence of TB in the 1990’s, driven largely by the HIV 
pandemic, a global TB control policy (directly observed therapy, short course – DOTS) was 
launched which centred on the direct supervision of drug intake by patients. This strategy 
relies on a complex regimen of administering several different drugs simultaneously. These 
include a two-month treatment (the so-called “intensive phase”) comprising four drugs – 
INH, RIF, PZA and ethambutol (EMB) – which is then followed by four months (the 
“continuation phase”) of INH and RIF. This regimen of first-line drugs is highly efficacious, 
with cure rates of around 90% in HIV-negative patients (WHO 2014). However, as described 
below, the extended therapy does pose several major challenges, especially in terms of 
public health resourcing and patient adherence. 
1.3 Limitations of current treatment regimens 
Several problems are associated with the current treatment for TB that has led to the 
widespread emergence of drug resistance. Mtb has an unusual propensity to down-regulate 
its metabolism and enter a state of non-replication (Chao & Rubin 2010). This phenomenon, 
referred to as non-replicating persistence or dormancy, is thought to be induced in response 
to various stresses (nutritional, hypoxic, nitrosative and acidic) and underlies the need for a 
long duration of treatment, to ensure sterilization. However, the lengthy and complex 
regimen leads to complications with patient adherence, resulting in high relapse rates which 
perpetuate the epidemic (Connolly et al., 2007; Cohen et al., 2013). Furthermore, irregular 
drug supply, inappropriately prescribed drugs, delayed or limited drug-susceptibility testing 
as well as the financial burden of treatment and the side effects associated with extensive 
drug therapy can, in many cases, result in “effective monotherapy”. In turn, this leads to 
emergence of drug resistance (Chatterjee 1997; van Helden et al., 2006; Guy & Mallampalli 
2008; Zhang & Yew 2009). The problem is intensified by the subsequent transmission of 
resistant Mtb strains from the index patient to others (Zhang & Yew 2009).  
Resistance has evolved to every antibiotic ever introduced into clinical practice (Figure 1.1) 
(Walsh 2003). Mtb acquires MDR and XDR through a step-wise accumulation of 
chromosomal mutations, each of which confers resistance to individual drugs (Trauner et 
al., 2014). In the early 1990s, several converging features led to the emergence of MDR-TB 
5 
(Sandgren et al., 2009). The perceived threat of MDR-TB is enormous as TB control has been 
put in jeopardy and the cost of treating MDR-TB patients is extremely high relative to 
treatment for patients carrying drug-sensitive strains (Dye & Williams 2000). Furthermore, 
treatment of MDR-TB is currently limited to second-line drugs which are significantly more 
expensive, less effective as evidenced by the low cure rate, more toxic with serious side 
effects, and treatment is for at least 18-24 months (Williams & Duncan 2007; WHO 2014). In 
addition to MDR-TB, reports of XDR-TB have exacerbated this health emergency. In South 
Africa, XDR-TB is considered endemic: a 2006 outbreak in the small town of Tugela Ferry, 
KwaZulu-Natal, highlighted the scale of the problem (Gandhi et al., 2006). This study 
reported that of the 221 patients diagnosed with MDR-TB, 53 of the cases were identified as 
XDR-TB (Gandhi et al., 2006; Singh et al., 2007), and the mortality rate among patients co-
infected with HIV was 98% (Gandhi et al., 2006). Since the Tugela Ferry study, over 100 
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Figure 1.1: Timeline of the discovery and introduction of antibiotics Resistance has 
developed against every antibiotic placed into clinical practice. Highlighted antimicrobial 
classes indicate those that have been approved for the treatment of TB (susceptible and/or 
resistant strains). Adapted from (Lewis 2013).  
 
Current efforts to control TB focus primarily on treatment of infectious cases, yet 95% of 
infection exists in an asymptomatic latent form (Young et al., 2009). Treatment of latent 
infection comprises a lengthy course of INH preventative therapy (IPT) for 9 months or 
more, but a more rapid and effective treatment is required (WHO 2014). An additional 
complication is co-infection with HIV: besides the well documented drug-drug interactions 
between TB drugs and anti-retroviral (ARV) medication, in which RIF causes cytochrome 
P450 induction and consequently decreases the levels of HIV protease inhibitors, several 
difficulties associated with TB/HIV combination therapy include high pill burdens (average of 
15 pills for 6-22 months), drug toxicities, immune reconstitution inflammatory syndrome 
(IRIS) directed specifically towards mycobacterial antigens, co-morbid diseases as well as the 
emergence of both drug resistant TB and drug resistant HIV (Pepper et al., 2007; Lawn et al., 
2013). 
The limitations of current efforts to control TB necessitates the need for either a constant 
supply of novel compounds, ideally with novel mechanisms of action (MoAs) that are 
shorter-acting and active against non-replicating mycobacteria. In addition, there is growing 
interest in the complementary approach of potentiating existing antibiotics by identifying 
(non-essential) targets for increasing susceptibility to specific antimicrobials, either in the 
host (Hawn et al., 2013) or the bacillus (Brynildsen et al., 2013). 
1.4 Drug Discovery 
Drug discovery has evolved into a multidisciplinary endeavour that includes a consolidation 
of genomic sciences, molecular biology, combinatorial and medicinal chemistry, 
pharmacology, and automated high-throughput screening (HTS) whereby “hits”, or 
compounds that respond positively in a specific assay, give rise to “leads”, or compounds 
that continue to respond positively in more complex downstream applications (Drews 
2000). In this way, the drug discovery pipeline is constantly being replenished with new hits 
and leads. The success of this drug discovery paradigm is evident in the availability of 10 
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new or repurposed drugs, at various stages of clinical trials, in the current TB drug 
development pipeline (NewTBDrugs.org 2015). 
1.4.1 Approaches to drug discovery 
The search for new antimicrobial compounds can be broadly divided into 2 strategies: the 
target-based or “rational” approach and the whole-cell, empiric or phenotypic approach. 
1.4.1.1 Target-based approaches 
The completion of the Mtb genome sequence in 1998 provided the possibility of 
systematically identifying novel drug targets (Cole et al., 1998). Thus began the exploitation 
of the target-based approaches in which inhibitors were designed to specifically target 
enzymes known to be essential in vital biosynthetic pathways (Coxon et al., 2012; Lechartier 
et al., 2014). Following validation of the specific enzyme target, molecular modelling and 
structural biology form the starting point of this approach. Briefly, structure-based 
molecular modelling of the target protein, such as high-resolution X-ray crystallography, is 
exploited to identify new ligands or dock compounds which in turn will guide medicinal 
chemists in generating compound libraries (Coxon et al., 2012). The target-based approach 
is advantageous as it aims to ensure that the compound of interest inhibits cellular function 
in a target-specific manner and so molecular selectivity is achieved. However, the success of 
this approach relies on the quality of the target as well as the level of validation (Balganesh 
et al., 2008). In TB drug discovery, several inhibitors have been successfully identified by 
rational drug design, whether structure-, ligand- or fragment-based (Coxon et al., 2012). 
However, in the general field of anti-infective drug development, this approach has been 
largely disappointing, as the majority of the rationally chosen targets were intractable, 
undruggable, non-essential during disease (due to lack of chemical validation), and/or 
compromised by the failure to translate potent, selective enzyme activity into whole-cell 
activity (Payne et al., 2006; Lechartier et al., 2014). In addition, the single-target approach is 
questionable, as there is increasing evidence that many antibacterials have multiple targets. 
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1.4.1.2 Phenotypic-based approaches 
Through the phenotypic-based approach, compounds are identified that exhibit activity 
against the whole organism, as opposed to engineering inhibitors for a specific target in a 
cell-free system. Large libraries of compounds are assessed at known concentrations for 
their ability to kill Mtb under specific growth conditions (Coxon et al., 2012). The 
identification of several promising drug candidates, including the diarylquinoline, TMC207 
(bedaquiline – BDQ); the nitroimidazoles, PA-824 (pretonamid) and OPC-67683 (delamanid); 
the imidazopyridine amide compound, Q203; the diethylamine, SQ-109; and the 
benzothiazinone, BTZ043, testifies to the success of whole-cell screening approaches 
(Lechartier et al., 2014). The major advantage of this approach is that compounds that are 
able to penetrate the cell wall are selected a priori (Williams & Duncan 2007). In addition, 
phenotypic screening enables early identification of compounds with cidal activity in 
different metabolic states of the pathogen and thus circumvents a major challenge early in 
the drug discovery pathway (Balganesh et al., 2008). The obvious disadvantage of this 
strategy is that the site(s) of action may not be known, and failure to identify the target may 
limit the ability to generate structure-activity relationships (SARs), whereby the on-target 
activity and selectivity of analogues based on the lead compound cannot be ensured (Coxon 
et al., 2012). However, whole-genome sequencing (WGS) to identify mechanisms of 
resistance (and, in some cases, the MoA), can alleviate this challenge. This is best 
demonstrated by the recent identification of the targets of BDQ (ATP synthase), the FadD32-
targeting diarylcoumarins, and the indolcarboxamides, NITD-304 and NITD-349, which 
appear to inhibit MmpL3 (Mdluli et al., 2014). An added disadvantage to this approach for 
TB discovery is the long generation time of Mtb (~24 hours) and its limitations on assay 
development as well as the stringent biosafety requirements that govern experimental 
manipulation of the bacillus (Williams & Duncan 2007; Coxon et al., 2012). 
1.4.2 Challenges with the TB drug discovery paradigm 
In 2012, the diarylquinoline BDQ (TMC-207, SirturoTM from Janssen) became the first new 
anti-TB drug to be approved by the US Food and Drug Administration (FDA) in more than 40 
years. Then, in 2013, delamanid (OPC-67683, DeltybaTM from Otsuka) was approved by two 
committees. Both drugs are reserved for the treatment of MDR-TB (Mdluli et al., 2014; WHO 
2014); therefore, despite the unquestionable significance of these events, enthusiasm is 
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tempered by the knowledge that the current TB drug pipeline is still not sufficient to curb 
the pandemic. Concerted efforts to increase the numbers of compounds at all stages of early 
dug discovery have prompted comprehensive analyses of the methodologies adopted in TB 
drug discovery programmes globally, in order to define “best practice”; that is, to identify a 
standard set of optimized assays for the evaluation of compounds against Mtb (Franzblau et 
al., 2012). It is evident that a number of significant challenges have hindered the process of 
early drug discovery, including the recurrent identification of hits structurally related to 
current anti-TB drugs or chemotypes with recognized anti-mycobacterial activity; for 
example, imidazo[1, 2-a]pyridine-3-carboxamides, and tetrahydropyrazolo[1, 5-a]pyrimidine-
3-carboxamides, from different small-molecule libraries by various organizations. This has 
been attributed to the bias imposed by the screening strategies (in vitro assay parameters 
such as oxygen tension, growth medium, etc.) as well as similarities between the libraries 
(Manjunatha & Smith 2014; Mdluli et al., 2014).  
In addition, there is a growing appreciation that screening and target identification 
programmes repeatedly identify the same set of “promiscuous” targets” (Goldman 2013) – 
that is, molecular targets to which multiple pharmacophores bind, but not necessarily at the 
same site. These include Ddn, DprE1, MmpL3, AtpE, and QcrB (Lechartier et al., 2014). The 
reasons for this are not clearly understood, but it may be due to the inherent properties of 
these targets that make them more accessible and vulnerable to the screening conditions 
and compound libraries used (Goldman 2013; Lechartier et al., 2014; Mdluli et al., 2014). 
This bias for membrane-localized targets correlates with compound lipophilicity and an 
average logP of 4.0, in contrast to current anti-TB drugs that were discovered more than 40 
years ago, and which are characterized by average logP values of -1.0 (Goldman 2013). 
Importantly, lipophilicity impacts pharmacokinetic (PK) parameters, toxicology properties 
and positively correlates with off-target promiscuity (Tarcsay & Keserű 2013), which severely 
limits the prospects for advancing highly lipophilic compounds through the development 
pipeline.  
Thus, the screening approach as well as the paucity of novel structural scaffolds may 
predispose the outcome and limit downstream applications such as the identification of 
novel targets and the development of screening hits into leads and candidate clinical 
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compounds. The key questions remain: how will new TB drugs be identified and where to 
look for them? 
1.4.3 Strategies to overcome limitations in TB drug discovery  
1.4.3.1 Revising screening approaches and platforms 
Diversifying current screening approaches to include the identification of inhibitors of 
latency, exploitation of conditional knock-down mutants of Mtb, siRNA screens, and 
targeting host functions by immunomodulation and pharmacological manipulation may 
divulge additional, novel targets (Lechartier et al., 2014). The identification of produgs - 
compounds that are activated intracellularly by bacteria-specific enzymes and may also have 
the potential to eradicate dormant persisters – offers an additional screening approach 
(Lewis 2013). The potential of the pro-drug approach is evident in the success of INH, PZA 
and ethionamide (ETH), the first two of which constitute the core of TB treatment, although 
none of these targets persisters. 
Target-based whole-cell screening (TB-WCS) overcomes the limitations of the two 
traditional approaches (target- versus phenotype- based screening) by bridging the two and 
combining the specificity of the target-based approach with the cell-permeation advantage 
that phenotypic screening provides (DeVito et al., 2002; Young et al., 2006). TB-WCS exploits 
conditional mutants that underexpress essential genes, as well as various counterscreens 
for validation of on-target inhibition. Thus, small molecule inhibitors against defined 
biochemical targets (PanC) or pathways (biotin biosynthesis or pH homeostasis) are 
identified, as demonstrated recently (Abrahams et al., 2012; Darby et al., 2013; Park et al., 
2014).  
A species-specific platform is attractive and has had much success with anti-TB drug 
discovery. The option of screening against the surrogate Mycobacterium smegmatis (Msm), 
not only evades the limitation of Mtb’s long generation time, but identifies potential hits 
targeting enzymes conserved among mycobacteria. The success of this approach is 
evidenced by the discovery of BDQ, which was initially identified from a library screen 
against Msm. It can be argued that screening against surrogate models may delay the 
development process, as all compounds will eventually be screened against Mtb, however a 
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more focused subset of compounds are selected for evaluation against Mtb, which surely 
expedites the hit triage process (Coxon et al., 2012). 
Before reaching their intended molecular target in the bacterial cell, anti-TB drugs need to 
permeate several barriers: from the blood vessels into the interstitial space of granulomas, 
followed by diffusion and accumulation in immune cells – including phagolysosomes in 
which the tubercle bacilli reside – or, in the case of necrotic granulomas and cavities, 
diffusion though the caseum and, finally, permeation of the lipid-rich mycobacterial cell 
envelope (Dartois 2014). Given the importance of drug concentration in the plasma and 
drug penetration in tissue, the PK and pharmacodynamics (PD) parameters should be 
considered during the lead-compound discovery and lead-compound optimization stages of 
early drug discovery and can be easily implemented with medium-throughput in vitro assays 
(Franzblau et al., 2012). Novel methods such as the MALDI mass spectrometry imaging 
(MALDI–MSI) and positron emission tomography (PET) using 11C-or 18F-labelled drugs have 
recently been used to quantify drug distribution and image drug penetration, respectively 
(Dartois 2014). 
1.4.3.2 Identifying novel chemical scaffolds 
The “golden era” of antibiotic discovery from 1940-1960 was dominated by natural products 
which further proved excellent scaffolds for remodelling and reengineering by medicinal 
chemists to create subsequent generations of semi-synthetic derivatives (Newman et al., 
2003). However, drug discovery programs have gradually shifted away from natural 
products and replaced these with high-throughput combinatorial chemistry methodologies 
in which large libraries of synthetic compounds are generated and optimized (Walsh 2003). 
Owing to limited structural diversity, combinatorial libraries were predicted to be unlikely 
sources of novel antibiotics when hits only ranging within 1 – 10 µM were identified. This 
prediction has proven accurate to some extent, as the experience of Novartis attests 
following a massive undertaking of 3 phenotypic HTS campaigns over a 5 year period with 
~2.2 million compounds (Walsh 2003; Manjunatha & Smith 2014). One solution offered to 
increase the structural diversity of combinatorial libraries is to introduce architectural 
complexity or functional group density approaching that of natural products. Interestingly, 
CPZN-45, spectinamides, and macrolides are natural product-derived chemical series that 
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are currently undergoing lead optimization, while a multitude of natural products 
themselves have been reported to possess novel structural architecture and exhibit activity 
against susceptible and MDR strains of Mtb (García et al., 2012; Mdluli et al., 2014). This 
suggests that the reinvestigation of natural product libraries using novel approaches may 
prove to be promising, as only a small portion of microbes are culturable, while 90-99% of 
the metagenome is yet to be discovered (Walsh 2003; Ling et al., 2015).  
The structural bias in current small-molecule libraries is also likely to be a contributing factor 
in the repeated identification of the same membrane-bound targets by multiple drug 
screening programmes. The empirical guidelines currently used to predict oral bioavailability 
and, by extension, cell permeability, address targets in human eukaryotic cells which have 
distinct membrane architectures compared to bacterial membranes (Veber et al., 2002; 
Lipinski et al., 2012). Therefore, the structural and physicochemical properties that govern 
compound permeability in Mtb may differ greatly. Recently, a systematic approach using 
quantitative tools was developed to evaluate the permeability of diverse small molecules in 
bacteria with distinct cell envelopes. Accumulation in Msm was not shown to correlate with 
size (molecular weight and surface area) but more weakly correlated with hydrophobicity 
and polarity. Analytical tools such as these provide a platform for the prediction of 
permeability of small molecules during the early stages of drug discovery (Davis et al., 2014). 
1.5 Mechanisms of drug resistance 
1.5.1 Acquired drug resistance 
Mtb is thought to be isolated in an ecologically sterile host niche for the bulk of its natural 
“lifecycle”. Therefore, unlike most other bacterial pathogens where horizontal gene transfer 
by mobile genetic elements such as plasmids, transposons or integrons, mediates acquired 
drug resistance, in Mtb the evolution of resistant strains is driven mainly by the sequential 
acquisition and accumulation of spontaneous mutations in chromosomal genes (Sandgren et 
al., 2009; Da Silva & Palomino 2011; Trauner et al., 2014). These mutations alter the drug 
target and thereby interfere with drug binding, compromise prodrug activation, or cause 
over-expression of the target (Sandgren et al., 2009; Trauner et al., 2014). RIF resistance 
(RIFR) is primarily associated with single-nucleotide substitution mutations in rpoB, the gene 
encoding the β-subunit of the DNA-dependent RNA polymerase, and results in 
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conformational changes that decrease the affinity for the drug (Da Silva & Palomino 2011). 
Resistance to fluoroquinolones is associated with amino acid substitutions in the putative 
fluoroquinolone binding region in gyrA and, rarely, in gyrB, for clinical isolates (Takiff et al., 
1994). EMB resistance (EMBR) is most often found in association with missense mutations at 
codon 306 of embB which encodes arabinosyl transferase (Starks et al., 2009). However, 
resistance to EMB has recently been reported to occur through the multistep acquisition of 
mutations in the embCAB operon (Safi et al., 2013; Korkegian et al., 2014). Missense 
mutations or deletions in the pncA gene constitute the main mechanism of PZA resistance 
(PZAR), by decreasing the pyrazinamidase activity (Scorpio et al., 1997). Resistance to INH 
(INHR) is complex and is associated with mutations in several genes including ahpC, kasA and 
ndh, however mutations in katG (resulting in a decrease or total loss of catalase/peroxidase 
activity) and in the inhA promoter region (causing overexpression) have been identified as 
the main molecular mechanisms of resistance (Zhang et al., 1992; Rawat et al., 2003; Da 
Silva & Palomino 2011). 
The mutation rate per base pair (bp) is inversely proportional to the genome size. For many 
anti-TB drugs, this is estimated at a rate of 10-9 mutations per cell division. Since mutations 
resulting in drug resistance are unlinked, combination therapy reduces the probability of 
developing resistance to three drugs to 10-27 (Da Silva & Palomino 2011). No single 
pleiotropic mutation has been associated with a MDR phenotype; instead, Mtb acquires 
MDR and XDR through a step-wise accumulation of chromosomal mutations, each of which 
confers resistance to individual drugs (Motiwala et al., 2010). In addition, drug resistance is 
also influenced by phenomena such as epistasis – the interaction between genes, where the 
phenotypic effect of one mutation is determined by the presence of one or more other 
mutations – and bacterial fitness – that is, where mutation(s) may impact growth rate, 
virulence, and transmissibility (Koch et al., 2014; Trauner et al., 2014). 
1.5.2 Intrinsic drug resistance 
It is now generally accepted that the molecular mechanisms that perpetuate antibiotic 
resistance in a clinical setting are not limited to a single resistance mechanism, but to the 
combined effect of both intrinsic and genetic resistance mechanisms (Viveiros et al., 2012). 
These intrinsic mechanisms include the permeability barrier of the mycobacterial cell wall, 
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mycothiol (MSH)-mediated protection, transcriptional regulation of multidrug resistance, 
the SOS response, drug modification and degradation and efflux-mediated resistance. These 
do not function as discrete mechanisms, but rather in a complex and overlapping interplay 
that constitutes the intricate, dynamic network termed the “intrinsic resistome.”  
1.5.2.1 The permeability barrier provided by the mycobacterial cell wall 
The mycobacterial cell wall is distinct from other microorganisms and presents a formidable 
permeability barrier to hydrophobic and hydrophilic compounds, a trait attributable to its 
structural complexity, molecular composition and architectural arrangement. Multiple layers 
of unique components enable this structure to efficiently impede entry of various antibiotics 
and also contribute to the survival of the organism under harsh conditions by providing 
resistance to chemical injury and dehydration (Niederweis et al., 2010). The cell envelop 
includes an inner plasma membrane, the mycobacterial cell wall core composed of the 
mycolyl arabinogalactan–peptidoglycan (mAGP) complex, the outer membrane which is 
covalently linked to the arabinogalactan and a capsule which forms the outermost layer. 
Interspersed in the outer membrane bilayer, are cell wall proteins and the “free” (non-
covalently linked) lipids: phosphatidylinositol mannosides (PIMs), the phthiocerol-containing 
lipids (PDIM and PGL), lipomannan (LM), and lipoarabinomannan (LAM) (Brennan 2003; 




















Figure 1.2: The mycobacterial cell envelope. The inner membrane is composed of diacyl 
phosphatidylinositol dimannoside, which contains four fatty acyl chains within a single 
molecule. Peptidoglycan consists of repeated alternating sugars N-acetyl glucosamine (NAG) 
and NA/GM (muramic acid with or without the glycolyl modification), which are cross-linked 
to a pentapeptide side chain and functions to maintain the shape and size of the cell. 
Arabinogalactan is the major cell wall polysaccharide and limits the entry of large 
hydrophobic molecules. Together, these structures form the mycolyl arabinogalactan–
peptidoglycan (mAGP) complex. The Corynebacterineae–specific cell wall lipid, mycolic acid, 
comprises 40-60% of the cell’s dry weight and is a major permeability barrier to hydrophilic 
compounds. Triacylglycerols (TAGs), diacyl gycerols (DAGs) and free mycolic acids form an 
outer leaflet that together with the inner leaflet of mycolic acids are arranged as an outer 
membrane. Nutrients and small hydrophilite uptake is facilitated by porins (Brennan 2003; 
Nguyen & Thompson 2006; Bansal-Mutalik & Nikaido 2014) the identity of which remains 
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The lipids, proteins and lipoglycans of the outer membrane function as signalling and 
effector molecules during the disease process, while the cell wall core is essential for viability 
(Brennan 2003). The current mycobacterial cell wall ultrastructure is based on a model 
suggested by Minnikin which proposed that an asymmetrical bilayer is fashioned by an inner 
leaflet of mycolic acids and an outer leaflet of free lipids that either intercalate with the 
mycolates (Minnikin 1982) or form a defined interlayer plane (Rastogi et al., 1991). The 
hypothesis of a mycobacterial outer membrane was disputed for many years due to 
contrasting results utilizing different techniques such as freeze-fracture experiments and 
electron microscopy of ultrathin sections (Puech et al., 2001; Etienne et al., 2005). The first 
breakthrough validating the existence of an outer membrane was achieved by the use of 
cryo-electron tomography (CET) and microscopy (CEM) of ultrathin cryosections in M. 
smegmatis, M. bovis BCG, and Corynebacterium glutamicum, to reveal that the outermost 
layer of the cell envelope exists as a morphologically symmetrical lipid bilayer (Hoffmann et 
al., 2008). Mutalik and Nikaido (2014) recently used the unique technique of reverse micellar 
solution (RMS) extraction to isolate and characterize the outer membrane lipids (Bansal-
Mutalik & Nikaido 2014) and thus validated the lipid bilayer structure. In addition, despite 
the well-established architecture of the inner membrane, it has also been shown that this 
layer comprises of an unusual lipid, diacyl phosphatidylinositol dimannoside, which contains 
four fatty acyl chains within a single molecule and thus creates a bilayer environment of 
unusually low fluidity (Bansal-Mutalik & Nikaido 2014). The existence of two bilayers 
contributes to the function of the mycobacterial cell wall as a permeability barrier. 
The presence or absence of a capsule surrounding the outer membrane has also been a 
source of controversy (Daffe & Etienne 1999). This structure appears as an electron-
transparent zone in conventional electron microscopy preparations as the outermost 
compartment of the cell envelope. However, CET and CEM of vitreous sections failed to 
identify this structure, questioning its existence (Chapman et al., 1959; Hoffmann et al., 
2008; Zuber et al., 2008). This layer consists of a mixture primarily of polysaccharide and 
protein, and insignificant amounts of lipid and is considered to have a different molecular 
composition in pathogenic and non-pathogenic species (Ortalo-Magne et al., 1995; Lemassu 
et al., 1996; Daffe & Etienne 1999). Recently, it has been shown by a plunge freezing CEM 
technique that pathogenic mycobacteria produce a thick capsule, only present under 
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unperturbed growth conditions and easily removed by mild detergents. In addition, the 
capsule has been reported to play a role in mycobacterial pathogenicity by enhancing the 
Mycobacterium-macrophage interaction and dampening the pro-inflammatory cytokine 
response (Sani et al., 2010). 
Mycolic acids are a specific and distinct cell wall component of all organisms classified 
within the Corynebacterineae suborder. These lipids represent the key permeability 
determinant, the hallmark of the mycobacterial cell envelope, and account for up to 40-60% 
of the cell’s dry weight. Mycolic acids covalently associate into a tight, closely packed lipid 
bilayer and thus form the primary hydrophobic barrier (Chatterjee 1997; Lambert 2002; 
Gebhardt et al., 2007). They are long chain (C70 – C90), α-alkyl branched, β-hydroxy fatty 
acids and disruption of biosynthesis of these lipids by antibiotic treatment or chemical 
mutagenesis dramatically alters hydrophobicity, permeability and morphology in Msm (Liu 
& Nikaido 1999; Wang et al., 2000). In addition, the composition and amounts of mycolic 
acids have been shown to affect the virulence, growth rate, colony morphology, 
permeability, cording and persistence of Mtb (Liu et al., 1996; Glickman et al., 2000). These 
lipids create a natural fluidity gradient such that the outside surface of the bacillus is the 
most fluid, providing for the promiscuous association of membrane peripheral components 
(Liu et al., 1996). Additionally, alterations of mycolyl-arabinogalactan properties affect the 
natural hydrophilicity of the membrane, while the cell wall integrity influences the surface 
exposure of the lipids, carbohydrates and proteins. The structure of mycolic acids is 
functionally important as mutations that affect modification or the length of these fatty 
acids results in phenotypic variations that affect the permeability properties. 
Essentiality of mycolic acids varies amongst the Actinobacteria as mutations that lead to 
complete loss are lethal to mycobacteria but not to corynebacteria; a mycolic-acid deficient 
mutant of the latter does not have an outer membrane bilayer and is more permeable to 
antibiotics, thus highlighting the significance of the outer membrane as a permeability 
barrier (Liu et al., 1996; Glickman et al., 2000; Gebhardt et al., 2007; Hoffmann et al., 2008; 
Zuber et al., 2008). There are three types of mycolic acids including α-mycolate, 
methoxymycolate, and ketomycolate, however, only pathogenic mycobacteria produce 
significant amounts of cyclopropanated mycolic acids (Barkan et al., 2009). In bacteria and 
plants, cyclopropanation is a common membrane modification, and although the exact 
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physiological function is poorly defined, it has a significant effect on membrane fluidity and 
permeability in various organisms, including Mtb (Nagamachi et al., 1991; George et al., 
1995; Grogan & Cronan 1997; Yuan et al., 1998). Cyclopropanation of mycolic acids is 
mediated by methyltransferases which synthesize the cyclopropane rings and methyl 
branches, and have been shown to be essential for Mtb viability, cell wall structure and 
intrinsic resistance to antibiotics. Recently, Barkan et al., 2009 demonstrated the chemical 
inhibition of multiple mycolic acid methyltransferases with a single compound, resulting in 
lethal dysregulation of membrane homeostasis. 
The exact mechanism by which many antimicrobials enter the mycobacterial cell wall 
remains unclear; however, passive diffusion, active transport, and facilitated uptake 
represent the three most common routes. The hydrophobic nature of the cell membrane 
allows the direct diffusion of lipophilic compounds which then equilibrate with the outside 
concentration unless there is a binding sink within the cell (Goldman & Scaglione 2004). 
Cooperative binding has been suggested as a mechanism by which drugs are restricted to 
the cell membrane, while still allowing diffusion and rotation within the membrane, thereby 
enhancing the interaction of the drugs with the specific membrane-bound targets. In 
addition, small, hydrophobic compounds partition into the phospholipid bilayer and then 
diffuse laterally through the membrane and inhibit metabolic function by interacting with a 
specific membrane protein (Goldman 2013). In Gram-negative bacteria, antimicrobials from 
the β-lactam, tetracycline and fluoroquinolone classes have been shown to use porins – 
proteins that comprise water-filled pores that allow the diffusion of small (typically < 600 
kDa) hydrophilic molecules through the barrier (Nikaido 1994; Jap & Walian 1996). 
Knowledge of porins in slow-growing mycobacteria remains limited, but based on the 
amphiphilic beta-barrel structure of Gram-negative outer membrane proteins (OMPs), 
bioinformatics approaches have led to the prediction of several OMP-like porins of Mtb 
(Song et al., 2008; Mah et al., 2010). The exploitation of pore-forming channels as a 
mechanism of entry for hydrophilic molecules through the cell wall of Mycobacterium 
chelonae was first described by (Trias et al., 1992). Subsequently, two classes of channel-
forming outer membrane proteins were defined in mycobacteria: OmpA-like porins in slow-
growing mycobacteria and MspA-like porins in fast-growing mycobacteria (Senaratne et al., 
1998; Niederweis et al., 1999). OmpA has since been disputed as a channel protein in the 
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outer membrane of Mtb, as deletion of ompA did not confer the expected increased drug 
resistance. Additionally, structural and functional studies have failed to reconcile the 
suggested porin activity of OmpA (Teriete et al., 2010; Song et al., 2011). A number of 
studies have subsequently shown a physiological role of OmpA in the adaptation of Mtb to 
an acidic environment, and thus contributing to the role of Mtb’s cell wall in pathogenicity 
(Raynaud et al., 2002; Song et al., 2011). In contrast, the role of the Msm mspA-encoding 
porin, which constitutes 70% of all pores in the Msm cell wall, has been established in mspA-
deletion mutants which displayed reduced uptake of hydrophilic fluoroquinolones, 
chloramphenicol, β-lactams and, surprisingly, vancomycin (VAN), erythromycin (ERY), and 
RIF, molecules thought to be too large to diffuse through the MspA pore (Stahl et al., 2001; 
Stephan et al., 2004; Danilchanka et al., 2008). In general, mycobacteria have 45-fold lower 
number of pores and 2.5-fold longer pore channels compared to E. coli, two determinants 
that are likely to have contributed to the species-specific, 100-1000-fold less efficient porin 
pathway for drug uptake (Jarlier & Nikaido 1990; Chambers et al., 1995; Stahl et al., 2001; 
Engelhardt et al., 2002). 
Several pathogenic mycobacteria, including Mtb and M. leprae, produce two structurally 
related groups of diesters called phthiocerol dimycocerosates (PDIMs) and phenolic 
glycolipids (PGLs) which are nonconvalently bound to the outer leaflet of the mycobacterial 
outer membrane. Earlier studies showed that loss of PDIMs in PGL-deficient Mtb strains 
correlates with reduced virulence in animal models (Camacho et al., 2001). In direct 
contradiction to these findings, a recent study in which H37Rv strains from several 
laboratories were whole-genome sequenced, showed that PDIM deficient strains are fully 
virulent in mice;  however, it is possible that compensatory mutation(s) may play a role in 
retaining virulence (Ioerger et al., 2010). In addition, PGL production has been implicated in 
the emergence of Lineage 2 (Beijing) Mtb strains, in particular the increased likelihood of 
developing drug resistance (Reed et al., 2007). Thus, PDIMs and PGLs might be considered 
potentially fruitful drug targets. The first PGL biosynthesis inhibitor was described in 2008 
(Ferreras et al., 2008) and was shown to inhibit PGL production in Mtb and other pathogenic 
mycobacteria. Additionally, through comprehensive genetic experimentation, Chavadi et al., 
(2011) demonstrated the role of M. marinum tesA (encoding a type II thioesterase) in PDIM 
and PGL biosynthesis and that inhibition of this enzyme results in hypersusceptibility to 
21 
various antibiotics in vitro (Chavadi et al., 2011). Reduction of PDIM and PGL in the outer 
leaflet of the mycobacterial outer membrane by tesA deletion results in structural or fluidity 
alterations which consequently influence the outer-membrane permeability.  
In addition to the ingenious architectural design of the mycobacterial cell wall, there are 
various cell wall-associated molecular components that contribute to the permeability 
barrier, many of which may prove to be rewarding drug targets in the future. These include 
the MtrAB two-component system, the only signal transduction system known to be 
essential in Mtb (Zahrt & Deretic 2000). MtrAB contributes to multiple cellular processes 
including cell wall and cell division homeostasis and alterations in expression of the two-
component regulator leads to variations in cell morphology, reduced antibiotic resistance 
and attenuated virulence (Möker et al., 2004; Fol et al., 2006). Classical two-component 
systems consist of a transmembrane sensor histidine kinase (HK) and a cytoplasmic response 
regulatory (RR) protein which are often genetically linked. The sensor kinase recognises 
specific stimuli and autophosphorylates one of the histidine residues in its cytoplasmic 
domain which transfers the phosphate group to an aspartate residue of the cognate RR. 
Phosphorylation activates the RR and modulates expression of RR-regulated genes resulting 
in alterations of cell behaviour in response to the stimuli (Nguyen et al., 2010). In other 
organisms, mutations in this system have multiple downstream effects including alterations 
to cell wall permeability, antibiotic resistance, lipid integrity, biofilm formation, cellular 
morphology, osmotic stress and virulence (Martin et al., 1999; Liu et al., 2006; Senadheera 
et al., 2007). In Mtb, the mtrA-encoded RR is constitutively expressed and transcription is 
regulated by the virulence σ factor C (sigC) (Sun et al., 2004). One of the genes upregulated 
by mtrA overexpression includes dnaA, a key component in cell division. Recently, it has 
been shown that the lipoprotein LpqB modulates MtrB activity through interaction with the 
extracellular domain, thereby altering MtrA phosphorylation which in turn affects the 
promoter activity of dnaA. Thus, in Mtb, cytokinetic and cell wall homeostatic processes are 
coordinated by a three-component system that includes LpqB, MtrB and MtrA (Nguyen et 
al., 2010). 
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1.5.2.2 Overcoming the permeability barrier 
Strategies to increase permeation include the identification of cell-penetrating peptides 
(CCPs), which have been shown to penetrate most biological cell membranes, even when 
attached to various cargos and acting as drug delivery vehicles (Pujals et al., 2006). Recently, 
a covalently linked conjugate of the CCP octaarginine and the antimalarial fosmidomycin was 
shown to reverse resistance of Mycobacteria to fosmidomycin (Sparr et al., 2013). It remains 
to be determined if octaarginine-antibiotic conjugates are effective against Mtb and even 
more interestingly, against non-replicating Mtb bacilli which have been shown to undergo 
cell wall structural alterations which affect the permeability of drugs (Boshoff & Barry III 
2006). Thus, the development of novel strategies that improve delivery and bioavailability - 
and thereby permeation - of existing or novel drugs aims to significantly increase efficacy 
and/or reduce toxicity effects via dose reduction. In addition, polyamines are naturally 
occurring aliphatic cations, endogenous to prokaryotic and eukaryotic cells. Although the 
exact function of these molecules remains unclear, they have recognized functions in various 
biological processes and are essential for cell growth and proliferation (Tabor & Tabor 1985). 
Recently, polyamines have been shown to reduce the permeability of the mycobacterial 
outer membrane to fluoroquinolones by inhibiting drug uptake. In addition it was shown 
that polyamines increase the survival of the bacillus following fluoroquinolone exposure, 
suggesting that these molecules may contribute towards the development of drug resistance 
of intracellular Mtb (Sarathy et al., 2013). Thus, targeting polyamines, which has been shown 
to be effective for cancer prevention, appears to be an interesting approach for increasing 
permeability of anti-TB drugs (Babbar & Gerner 2011). 
1.5.2.2 Transcriptional regulation of multidrug resistance  
In addition to the assault of antimicrobial treatment, Mtb is exposed to a multitude of 
environmental stresses, including hypoxia, nutrient starvation and oxidative and genotoxic 
stress (Hingley-Wilson et al., 2003). To survive these hostile environments, it is imperative 
for Mtb to sense and respond to these conditions appropriately. Mtb has complex and 
extensive regulatory pathways, including σ-factors, two component systems, protein kinases 
and > 150 transcription factors (TFs), that respond to signals from the changing environment 
by mediating gene expression (Bowman & Ghosh 2014; Minch et al., 2015). Given the 
significance of transcriptional regulation and its role in antimicrobial tolerance or intrinsic 
23 
drug resistance (Colangeli et al., 2007), a systems-level framework was developed in which 
the Mtb TF-controlled gene regulatory network was mapped and validated by the 
identification of furA, the transcriptional regulator of katG, derepression of which results in 
reduced susceptibility to INH (Rustad et al., 2014). Resources such as this will facilitate the 
identification of additional components of transcriptional regulation and their role in Mtb’s 
intrinsic resistome, and suggest the potential for systems biology approaches to elucidate 
the factors which contribute to intrinsic resistance which might be considered an emergent 
property of a functioning mycobacterial cell. 
Members of the whiB gene family are exclusive to the Actinomycetes. Seven whiB-like genes 
have been identified in Mtb and these perform critical roles in cell division, redox 
homeostasis, virulence and antibiotic resistance (Morris et al., 2005; Geiman et al., 2006; 
Singh et al., 2009). Deletion of whiB7 in various mycobacterial species results in a multidrug-
sensitive phenotype in vitro, suggesting that WhiB7 is an ancestral multidrug resistance 
determinant. Gene expression profiling analyses have shown that whiB7 determines drug 
resistance by activating the expression of at least eight genes, the functions of some of 
which are associated with intrinsic drug resistance (e.g. the efflux pump, tap, and a 
ribosome modifying enzyme, erm37) (Philalay et al., 2004; Morris et al., 2005). In addition, 
upon antibiotic treatment, whiB7 induces the eis (enhanced intracellular survival) gene 
suggesting that WhiB7 activation not only contributes to drug resistance, but to enhanced 
mycobacterial tolerance to host immunity. Thus, targeting WhiB7 might result in preventing 
the emergence of drug resistant bacilli as well as effective sterilization. Recently, it has been 
shown that upon antibiotic treatment, the transcriptional activation of whiB7-dependent 
intrinsic drug resistance is induced upon a reductive shift of redox metabolism in response 
to the inhibition of diverse cellular targets (in particular, inhibition of protein biosynthesis) 
(Burian et al., 2012). WhiB7 is activated in response to a metabolic shift to increased 
reducing potential. During normal growth conditions, whiB7 plays a key role in maintaining a 
reduced cytoplasmic environment by directly or indirectly regulating the MSH 
concentration. Upon antibiotic treatment, the oxidized form of MSH, mycothione (MSSM), 
decreases to undetectable levels, suggesting that whiB7 contributes in regulating MSSM 
reduction (Burian et al., 2012) (The role of MSH detoxification in Mtb’s intrinsic resistome is 
discussed further in Chapter 6). 
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In response to antibiotic treatment, Mtb generates a specific and coordinated 
transcriptional response. Certain antibiotic-induced transcriptional changes contribute to 
the adaptation of Mtb as they induce antimicrobial tolerance or intrinsic drug resistance. Of 
course, factors that regulate the expression of genes are also potentially significant. Lsr2 is a 
small histone-like protein which is highly conserved among mycobacteria and has been 
shown to regulate antibiotic-induced expression of the multidrug efflux pump-encoding 
iniBAC operon and efpA gene. Lsr2 was shown to repress a wide variety of DNA-interacting 
enzymes suggesting transcriptional regulation of several important pathways in 
mycobacteria (Colangeli et al., 2007). In addition to its role as a global transcriptional 
regulator, electron microscopy and DNA binding studies suggest that Lsr2 binds to DNA and 
physically protects it from reactive intermediates (Colangeli et al., 2009). Therefore, while 
the essentiality of the lsr2 remains controversial, its established role as a significant 
contributor to Mtb’s intrinsic resistome suggests it is a potential drug target. 
1.5.2.3 Drug modification and degradation 
Mycobacteria are able to inactivate antibiotics by chemical modifications, and this provides 
another mechanism for intrinsic resistance. A well-established example is the inactivation of 
aminoglycosides via three known chemical modifications: acetylCoA-dependent N-
acetylation of amino groups, catalysed by aminoglycoside acetyltransferases (AACs); ATP-
dependent phosphorylation of hydroxyl groups by aminoglycoside phosphotransferases 
(APHs); and ATP-dependent O-adenylation by aminoglycoside nucleotransferases (ANTs) 
(Wright 2005). In Mtb, limited data exist on the role of these enzymes in the intrinsic 
resistome: of the four predicted enzymes in the genome, only the Rv0262c-encoded AAC 
has been biochemically validated as a functional aminoglycoside-modifying enzyme, 
although it does not contribute to clinically relevant aminoglycoside resistance (which is 
uniquely attributed to point mutations in 16S rRNA) (Hegde et al., 2001; Draker et al., 2003). 
Interestingly, structural analyses of Mtb’s AAC suggest that this enzyme may play a role in 
MSH biosynthesis by regulating the flux of MSH precursors via acetylation and deacetylation 
(Vetting et al., 2003). Similarly, while resistance to RIF results primarily from mutations in 
rpoB, approximately 5% of clinical RIF-resistant Mtb isolates do not have mutations in this 
gene, suggesting a role for an alternative resistance mechanism (Telenti et al., 1993). Three 
mechanisms of RIF inactivation by chemical modifications have been described: 
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phosphorylation, glucosylation and ribosylation. Inactivation by ribosylation, catalysed by 
adenosine diphosphate (ADP) ribosyltransferase, has only been detected in Mycobacterium 
and closely related taxa (Dabbs et al., 1995; Tanaka et al., 1996).  
β-lactams are a class of antibiotics that inhibit cell wall biosynthesis, specifically via 
inhibition of peptidoglycan-modifying peptidases (D,D-penicillin binding proteins, PBPs, and 
the L,D-transpeptidases) (Zapun et al., 2008). Following β-lactam exposure, a number of 
molecular pathways to cell death have been identified including autolysis, induced autolysis, 
holin: antiholin and oxidative damage pathways (Wivagg et al., 2014). Consequently, there 
exist a number of mechanisms by which resistance to β-lactams is acquired, of which two 
are considered the principal mechanisms: decreasing the effective concentration of β-
lactams at the general site of action, and modification of the PBPs such that sufficient 
transpeptidase activity remains to permit survival even in the presence of the β-lactam. 
Alterations to β-lactam concentrations result from modifications to outer membrane 
permeability, changes in β-lactamase activity and changes in efflux pump activity. Mtb is 
highly resistant to β-lactams as a result of a strong, constitutive β-lactamase (encoded by 
blaC) that binds and degrades these antibiotics. The co-administration of β-lactams with β-
lactamase inhibitors, such as clavulanate or sublactam, or β-lactams which are resistant to 
β-lactamases such as the carbapenems with clavulanate has been shown to circumvent this 
resistance mechanism (Hugonnet & Blanchard 2007; Hugonnet et al., 2009). Therefore, 
resistance to β-lactams offers an instructive example of the interplay between intrinsic 
mechanisms by which permeability, drug inactivation by β-lactamase activity, and active 
efflux by multidrug pumps, each or in combination contribute to the resistance profile. 
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1.6 Aims and objectives of this study 
In addition to the low permeability of the mycobacterial cell wall, transcriptional regulation 
and the operation of various drug inactivating/modifying systems, there are three major 
mechanisms that contribute to the intrinsic resistome of Mtb and that limit the efficacy of 
anti-TB agents. This study aimed to investigate the roles of the DNA damage (or SOS) 
response, efflux-mediated drug resistance, and MSH-mediated protection as integral 
mechanisms of Mtb’s intrinsic resistome to subvert antibiotic efficacy. In conjunction with 
examining the physiological functions of these mechanisms, various tools were developed 
to aid drug discovery platforms in the search for novel agents that may inhibit these systems 
and so disarm the protective effect of the mycobacterial intrinsic resistome.  
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Chapter 2: General Materials and Methods 
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2.1 Strains and growth conditions 
Details on study-specific strains and plasmids are described in the relevant Chapters, with 
general strains and plasmids listed here (Table 2.1). All bacterial strains utilized in this study 
were stored at -80°C in 30% glycerol (v/v).  
Table 2.1: General bacterial strains used in this study 
Strain Description/ Genotype Reference/ Source 
Escherichia coli (E. coli)   
DH5α 
supE44 ΔlacU169 (F80 
lacZΔM15) hsdR17 recA1 endA1 






High frequency transformation 
mutant of Msm ATCC 706 





Virulent reference laboratory 
strain of Mtb ATCC 27294 
(Ioerger et al., 2010) 
 
E. coli. All strains were cultured overnight on Luria-Bertani (LB) Agar (IncoTherm Incubator, 
Labotec) or in LB Broth IncoShake Incubator, Labotec) at 37°C. Alternatively, strains 
harbouring large plasmids (≥ 8 kbp) were cultured at 30°C (IncoCool Incubator, Labotec) for 
48 hr to minimize plasmid rearrangements. 
Msm. Unless otherwise indicated, all strains were cultured on Middlebrook 7H10 (DifcoTM) 
supplemented with 0.5% glycerol and 10% (v/v) Middlebrook Oleic Acid Dextrose Catalase 
(OADC) enrichment (DifcoTM) (7H10/OADC), or in Middlebrook 7H9 supplemented with 0.2% 
glycerol, 10% (v/v) Middlebrook OADC, and 0.05% Tween80 (7H9/OADC). Liquid cultures 
were cultured in Erlenmeyer flasks at 37°C shaking (IncoShake Incubator, Labotec). For 
negative selection of transformants carrying the sacB gene, 2% (w/v) sucrose was used. For 
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positive selection, 2 mg/ml X-gal (5-bromo-4-chloro-3-indolyl-beta-D-galacto-pyranoside) 
was utilized. 
Mtb. Unless otherwise indicated, all strains were cultured on solid 7H10/OADC or in liquid 
7H9/OADC. Liquid cultures were grown at 37°C in tissue culture flasks that were placed flat. 
All culturing and manipulations of Mtb strains were performed in a Biosafety Level 3 
laboratory, in a Class II flow cabinet at negative pressure (160 - 170 kPa). Negative and 
positive selection of transformants was performed as described for Msm. 
2.2 Antimicrobial agents 
For E. coli, liquid and solid media were supplemented with antibiotics at the following 
concentrations: kanamycin (KAN), 50μg/ml; ampicillin (AMP), 200μg/ml; hygromycin (HYG), 
200 μg/ml; and Gentamycin (GEN), 20µg/ml. For Msm and Mtb strains, antibiotics were 
used at the following concentrations: KAN, 20 μg/ml; HYG, 50 μg/ml; GEN, 2.5 µg/ml. 
Antimicrobial stock solutions were stored at 4°C. 
Selection of transformants. For negative selection of E. coli and mycobacterial clones that 
carry the sacB gene, 5% (w/v) and 2% (w/v) sucrose (Suc), respectively, was used in solid 
media. For positive selection by disruption of lacZ, 50 µl X-gal (5-bromo-4-chloro-3-indolyl-
β-D-galactopyranoside; 20 mg/ml in deionised dimethyl formamide) was utilized per 25 ml 
plate. 
2.3 DNA Extraction 
2.3.1 Plasmid DNA extraction and purification from E. coli  
Small-scale plasmid preparation. Cultures were grown overnight (37°C) or over 48 hr (30°C) 
and harvested by centrifugation at room temperature (Eppendorf 5415D; 15000 × g for 1 
min). The supernatant was discarded and the pellet was resuspended in 100 µl Lysis 
Solution I (0.5 M glucose, 50 mM Tris-HCl pH 8.0, 10 mM EDTA), followed by the addition of 
200 µl Solution II (0.2 M NaOH, 1% SDS) and mixed gently. After a 5 min incubation at room 
temperature, 150 μl of neutralization Solution III (3 M potassium acetate, pH 5.5) was added 
and gently mixed followed by centrifugation at 15000 × g for 5min at room temperature. 
The supernatant was collected and treated with RNase A (1 μl of 10 μg/ml stock solution; 
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Sigma Aldrich) for 10 min at 37°C. Plasmid DNA was precipitated by adding 350 μl of 
isopropanol, incubation for 10 min at room temperature and centrifuging at 15000 × g for 
10 min. The pelleted DNA was washed with 70% ice cold ethanol and dried at 40°C in a 
vacuum centrifuge (MiVac DNA concentrator, GeneVac). The plasmid DNA was resuspended 
in 20 μl of sterile distilled water (sdH2O). 
Large-scale plasmid preparation. Cultures were grown overnight or over 48 hr in 50 ml of 
LB broth and harvested by centrifugation at 3901 × g for 10 min (Beckmann Allegra X-22R). 
Thereafter, the extraction method was as described for the small-scale extraction except 
that the solution volumes were increased by a factor of 10. The plasmid DNA was 
resuspended in 500µl dsH2O and precipitated with 1/10
th volume sodium acetate (3M). 
Equal volumes of phenol/chloroform (1:1; v/v) solution was added to purify the DNA, 
followed by vigorous mixing and centrifugation 15000 × g for 10 min (Eppendorf 5415D 
Centrifuge) at room temperature. The aqueous phase was collected and an equal volume of 
chloroform: isoamyl alcohol (24:1; v/v) was added, mixed vigorously, and centrifuged at 
15000 × g for 10 min at room temperature. The aqueous phase was collected and the 
plasmid DNA was further precipitated by adding 2.5 volumes of ice-cold 100% ethanol. The 
solution was incubated for 45 min at -20°C and the precipitated DNA was collected by 
centrifugation at 15000 × g for 20 min at room temperature. The DNA pellet was washed 
with ice cold 70% ethanol, dried in a vacuum centrifuge and resuspended in 50 μl sdH2O. 
2.3.2 Chromosomal DNA extraction and purification from mycobacteria 
Msm. Chromosomal DNA was isolated using a modified cetyltrimethylammonium bromide 
(CTAB) method (Larsen 2000). Briefly, cells were heat killed at 65°C for 20 min and 
harvested by centrifugation at 16100 × g for 1 min. The pellet was resuspended in 500 µl TE 
buffer (10mM Tris-HCl pH 8.0, and 1mM EDTA) and 50µl lysozyme (10 mg/ml) was added. 
After overnight incubation at 37°C, 70 μl 10% SDS and 6 μl proteinase K (10 mg/ml) were 
added and the mixture incubated for 2 hr at 65°C in a Thermomixer Compact (Eppendorf) 
set to 400 rpm. Thereafter, 80 µl pre-warmed CTAB (10% CTAB prepared in 0.7M NaCl) and 
100µl 5M NaCl were added and the mixture was further incubated for 10 min at 65°C. An 
equal volume of chloroform:isoamyl alcohol (24:1 v/v) was added to degrade residual 
proteins and mixture was centrifuges for 5 min at 16100 × g. The aqueous phase was 
collected and added to an equal volume of ice cold isopropanol and incubated on ice for 30 
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min. The precipitated DNA was collected by centrifugation at 16100 × g for 20 min at room 
temperature and the pellet was washed with ice cold 70% ethanol, dried in a vacuum 
centrifuge and resuspended in 100 µl sdH2O. 
Mtb. The CTAB method used for Mtb DNA extraction was similar to that described for Msm. 
All procedures prior to the overnight lysozyme step were performed in a Biosafety Level 3 
laboratory, in a Class II flow cabinet at negative pressure (160 - 170 kPa). Minor deviations 
from the previously described method were carried out. Briefly, Mtb cells were harvested by 
centrifugation at 3901 × g for 10 min and the pellet was resuspended in 500 µl TE buffer 
followed by heat kill at 80°C for 1 hr and 50 µl lysozyme treatment (10 mg/ml), overnight at 
37°C. The following day, 70 μl of 10% SDS and 50 μl of proteinase K (10 mg/ml) were added 
to the mixture and incubated 65°C for 2 hr in a Thermomixer Compact (Eppendorf) set to 
400 rpm. Thereafter, 100 µl pre-warmed 10% CTAB and 100µl 5M NaCl were added and 
incubated for 15 min at 65°C (Thermomixer). The mixtures were placed at -70°C for 15 min, 
then removed and allowed to thaw before a further incubation at 65°C for 15 min in the 
Thermomixer. An equal volume of chloroform:isoamylalcohol (24:1) was added  to the 
mixture and tubes were inverted several times to mix, then harvested by centrifugation at 
16100 × g for 10 min. The aqueous phase was collected and added to an equal volume of ice 
cold isopropanol and incubated overnight at 4°C. The following day, precipitated DNA was 
collected by centrifugation at 16100 × g for 20 min at room temperature and the pellet was 
washed with ice cold 70% ethanol, dried in a vacuum centrifuge and resuspended in 55 µl 
sdH2O. 
2.3.3 Small-scale chromosomal DNA extraction from mycobacteria 
The colony boil method was used for the isolation of genomic DNA for PCR screening. 
Colonies were picked from agar plates and resuspended in 100 μl of TE buffer (10 mM 
Tris·HCl pH 8.0, 0.1 mM EDTA). For reference, 10 µl of the suspension was spotted onto an 
agar plate. The remaining 90 μl was heat-killed at 95°C for 20 min. An equal volume of 
chloroform was added, and the mixture centrifuged at 16100 × g for 5 min. The aqueous 
phase was carefully extracted into fresh microfuge tubes and 2 μl was used as the DNA 
template for PCR. 
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2.4 DNA manipulations 
All DNA manipulations were and molecular biology techniques were performed according to 
standard protocols (Sambrook et al., 1989; Sambrook & Russell 2001)  
Agarose gel electrophoresis. Standard electrophoretic techniques were used. High 
molecular weight DNA fragments were separated on 1% agarose gels while low molecular 
weight fragments were separated on 2% gels. Gels were prepared with 1xTAE (40 mM Tris-
acetic acid, 1 mM Na2EDTA pH 8.0), agarose powder (Sigma-Aldrich) and 0.5 µg/ml ethidium 
bromide. DNA samples were loaded with tracking dye (0.025% bromophenol blue in 30% 
glycerol). Fragment sizes were assessed using lambda DNA molecular weight markers (III-VI; 
Roche Applied Science, Germany). Gels were electrophoresed in a Mini-Sub Cell GT mini gel 
horizontal submarine unit (Bio-Rad) at 80-100 volts and visualized under UV-light using the 
Gel Doc (WealTeach Keta Imaging System). 
Recovery of DNA fragments form agarose gels and quantification. DNA fragments were 
excised from the agarose gels and purified using the Nucleospin Extract II Kit (Macherey-
Nagel) as per the manufacturer‘s instructions. DNA was eluted in 30 µl sdH2O and quantified 
by agarose gel electrophoresis (by comparison to DNA molecular weight markers) or on a 
NanoDrop ND-1000 Spectrophotometer (Thermo Scientific). 
Restriction digests. Restriction enzymes were purchased from New England Biolabs Inc. 
(The Scientific Group) or Fermentas (Thermo Scientific). All restriction enzyme digests were 
performed at 37°C unless otherwise required by the manufacturer. Plasmid DNA (1 μg) was 
digested for 2 hr (or overnight) and mycobacterial DNA (5 μg) was digested overnight with 
the appropriate reaction buffer(s). For confirmation of point mutation/ restriction site, 
purified PCR fragments were digested for 2-3 hr with the appropriate reaction buffer(s). 
Digested DNA fragments were separated and analysed on agarose gels (as described 
previously). 
Dephosphorylation of vector DNA. To prevent vector re-ligation, linearized plasmid DNA 
was treated with Antarctic Alkaline Phosphatase (New England Biolabs Inc.) to ensure 
removal of the 5‘-phosphate. The dephosphorylation reaction was performed at 37°C for 1 
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hr after followed by heat inactivation of the enzyme at 65°C for 20 min (as per the 
manufacturer‘s instructions). 
Ligations of DNA fragments. Ligation reactions were carried out using the Fast-link™ ligation 
kit (Epicentre® Biotechnologies) as per the manufacturer‘s instructions. Following 
inactivation of the ligase at 70°C for 15 min, competent E. coli DH5α cells were transformed 
with the entire reaction. 
Polymerase Chain Reaction (PCR). To generate fragments to be used in subsequent cloning 
procedures, DNA was amplified with Phusion High-Fidelity DNA polymerase (Finnzymes), 
due to the low error rate of this polymerase (4.4 × 10-7). As per the manufacturer‘s 
instructions, 20-50 μl reactions contained: 1 × HF reaction buffer, 200 μM of each dNTP, 0.5 
μM of each primer, 3% DMSO, 0.02 U/μl of DNA polymerase and 10-100 ng of plasmid or 
genomic DNA. DNA amplifications were performed using the following parameters: initial 
denaturation at 98°C for 3 min, followed by 30 cycles of denaturation (98°C for 10 s), 
annealing (for 30 s), extension (72°C for 30s/kb), and final extension at 72°C for 7 min. The 
annealing temperature varied according to the melting temperature (Tm) of individual 
primer sets (according to the manufacturer’s instructions). For screening purposes, DNA was 
amplified using FastStart Taq (Roche) as per the manufacturer‘s instructions. Briefly, 20-50 
μl reactions contained 10-100 ng of plasmid or genomic DNA 1 × PCR reaction buffer 
(includes MgCl2), 200 μM of each dNTP, 0.5-1.0 μM of each primer, 1 × GC-rich solution, and 
2U/50 μl of DNA polymerase. The following thermal cycler parameters were used: initial 
denaturation at 95°C for 4 min, followed by 30 cycles of denaturation (95°C for 30 s), 
annealing (60°C for 30 s), extension (72°C for 60s/kb), and a final extension at 72°C for 7 
min. All PCR reactions were carried out in the MyCycler™ thermal cycler (Bio-Rad) with 
oligonucleotide primers purchased from Integrated DNA Technologies (IDT). 
2.5 Bacterial transformation 
2.5.1 Chemical transformation of E. coli 
Preparation of competent cells. The rubidium chloride method obtained from Dr P. Stolt 
was used to prepare competent cells. Briefly, 1 ml of an overnight culture of E. coli DH5α 
was inoculated into 100 ml LB and grown to an OD600 of 0.4-0.5. The cells were kept on ice 
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for 15 min then harvested by centrifugation at 3901 × g for 5 min at 4°C. The pellet was 
resuspended in 20 ml transformation buffer (Tfb) I (30 mM potassium acetate, 100 mM 
rubidium chloride, 10 mM calcium chloride, 50 mM manganese chloride, and 15% v/v 
glycerol; pH 5.8). The mixture was chilled on ice for 15 min and harvested by centrifugation 
(3901 × g for 5 min at 4°C). The pellet was resuspended in 2 ml TfbII (10 mM MOPS, 75 mM 
calcium chloride, 10 mM rubidium chloride and 15% v/v glycerol; pH 6.5). Aliquots of 500 µl 
were flash-frozen in ethanol and stored at -80°C until required. 
Transformation with plasmid DNA. Competent E. coli DH5α cells were thawed on ice and 
100 µl aliquots were incubated with up to 1 µg plasmid DNA on ice for 20 min. Thereafter, 
cells were heat-shocked at 42° for 90 s, immediately placed on ice for 1-2 min and rescued 
in 500 µl of 2TY (Tryptone Yeast broth) for 1 hr at 37°C. Cells were plated on LA plates 
containing the appropriate antibiotics, and incubated overnight at 37°C (Sambrook et al., 
1989; Sambrook & Russell 2001) or for two days at 30°C, for plasmids larger than 8 kbp 
(Parish & Stoker 2000).  
2.5.2 Transformation of mycobacteria by electroporation 
Mycobacteria were electroporated with plasmid DNA according to (Larsen 2000; Gordhan & 
Parish 2001). 
Msm. Briefly, 100 ml of 7H9/OADC medium was inoculated with an overnight culture and 
grown to an OD600 of 0.8-1.0 at 37°C. Cells were harvested by centrifugation at 3901 × g for 
10 minutes at 4°C and washed three times in pre-chilled 10% glycerol (v/v). After the final 
wash, cells were resuspended in 2 ml 10% glycerol (v/v). Four hundred μl aliquots were 
incubated briefly on ice with 1-5 µg of plasmid DNA in pre-chilled electroporation cuvettes 
(0.2 cm electrode gap, Bio-Rad) and pulsed once in a GenePulserTM (Bio-Rad) set at 2.5 kV, 
resistance 1000 Ω, capacitance 25 μF. Cells were rescued immediately after pulsing with 1 
ml Middlebrook 7H9/OADC, transferred to a clean microcentrifuge tube and incubated for 3 
hr at 37°C. The electroporation reactions were plated on 7H10/OADC agar containing the 
appropriate antibiotics and incubated for 3-5 days at 37°C. 
Mtb. Electroporation of Mtb was similar to that described for Msm, except that all 
manipulations were performed at room temperature (Wards & Collins 1996). Briefly, 1 ml of 
a log-phase pre-culture was inoculated into 100 ml of 7H9/OADC and grown to an OD600 of 
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0.8-1.0. Cells were harvested by centrifugation at 3901 × g for 10 min and then washed 
twice in 10% glycerol (v/v) and resuspended in 2-5 ml of 10% glycerol (v/v). Plasmid DNA (1-
5 µg) was mixed with 400 μl of competent cells in electroporation cuvettes (0.2 cm 
electrode gaps, Bio-Rad) and pulsed once in a GenePulserTM (Bio-Rad) set at 2.5 kV, 
resistance 1000 Ω, capacitance 25 μF. Cells were rescued immediately after pulsing in 1 ml 
7H9/OADC and incubated overnight at 37°C. The following day, electroporation reactions 
were plated on 7H10/OADC agar containing the appropriate antibiotics and incubated for 
21-28 days at 37°C. 
2.6 Sequencing 
All sequencing of plasmid constructs or PCR products was performed as a pay-for-service by 
the Central Analytical Sequencing Facility at Stellenbosch University. Whole-genome 
sequencing (WGS) of resistant mutant strains was performed by Professors Tom R. Ioerger 
and James C. Sacchettini (Texas A&M University, Texas, USA). 
2.7 Southern blot analysis 
Electroblotting. Genomic DNA (5 μg) was digested overnight with the appropriate 
restriction enzyme(s) at 37˚C after which the DNA was separated by electrophoresis on a 1% 
agarose gel at 80 V,and viewed and photographed with a fluorescent ruler with the Gel Doc 
(WealTeach Keta Imaging System). The agarose gel was shaken gently in depurination buffer 
(0.25M HCl) for 15 min, followed by denaturation buffer (1.5 M NaCl/0.5M NaOH) for 25 
min and finally neutralization (1.5 M NaCl, 5 M Tris·HCl, pH 7.5) for 30 min. The DNA was 
transferred to a nitrocellulose membrane (Hybond™-N+ membrane, Amersham) using a 
vacuum blotter (Model 785, Bio-Rad). Once transferred, the DNA was cross-linked to the 
membrane by irradiation in a UV Stratalinker 1800 (Stratagene) at 1200 mJ/cm2, and 
membranes were hybridized immediately. 
Synthesis and labelling of probes. All probes used for Southern blot analyses were 
synthesized by PCR using the oligonucleotides indicated in each Chapter. The ECL Direct 
Nucleic Acid Labelling and Detection System protocol (Amersham) was used to label probes. 
Briefly, 100 ng of probe DNA in a total volume of 10 µl was denatured by boiling for 5 min at 
95˚C in a water-bath and immediately chilled on ice for 5 min. Equal volumes of DNA 
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labelling agent and gluteraldehyde (Amersham) were added to the probe, mixed gently and 
incubated for 15 min at 37˚C. Following incubation, the labelled probe was added to the 
hybridization buffer. 
Hybridization. The ECL Direct Nucleic Acid Labelling and Detection System protocol 
(Amersham) was used to prepare the hybridization buffer. Briefly, for membranes 10cm2 in 
size, 20 ml of hybridization buffer, 5% w/v blocking agent and 0.5 M NaCl was combined and 
stirred at room temperature for 1 hr and then at 42°C for 1 hr. Subsequent to cross-linking, 
the membrane was pre-hybridized in roller bottles in the Hybridisation oven/shaker SI3OH 
(Stuart) for 1 hr at 42°C, after which the labelled probe was added and the membrane was 
hybridized overnight at 42°C. 
Detection. Following overnight hybridization, the membrane was washed twice in primary 
wash buffer (6 M Urea, 0.4% SDS, 0.5 × SSC) for 20 min each, at 42°C, and then twice for 5 
min at room temperature in secondary wash buffer (0.5 × SSC). Thereafter, detection 
reagents 1 and 2 (Amersham) were mixed in equal quantities transferred to the membrane 
and incubated for 1 min at room temperature. The membrane was then drained to remove 
excess detection reagent, saran wrapped and exposed to X-ray film (Amersham Biosciences) 
in a cassette for time periods ranging from 1 min to 2 hr at room temperature before 
developing. 
Development of X-ray film. Membrane exposure and subsequent development of the X-ray 
film (High performance chemiluminescence film, Amersham Hyperfilm™ECL) was carried out 
in a dark room with red-light facilities. Immediately after exposure, for the appropriate time, 
the X-ray film was submerged in developer solution (GBX Developer, Carestream® Kodak®, 
Sigma-Aldrich) for 3 min, rinsed briefly in H2O and submerged in fixer solution (GBX Fixer, 
Carestream® Kodak®, Sigma-Aldrich) for 3 min. X-ray films were air-dried completely before 
being photographed. 
2.8 Quantitative gene expression analysis 
RNA isolation. 30 ml cultures were grown to mid-log phase (OD600 of 0.5) and subsequently 
split into 2 × 15 ml volumes, to which one was treated with the drug and the other left 
untreated for the specified times. Total RNA was extracted using a FastRNA ProBlue Kit (MP 
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Biomedicals) per the manufacturer’s instructions. Briefly, cells were harvested at 1500 × g 
for 15 min at 4°C. The supernatant was removed and the pellet resuspended in 1 ml of 
RNApro™Solution and transferred to tubes containing Lysing MatrixB, provided in the kit. 
The samples were processed in the FastPrep®Instrument 3x at the following settings: set 
6.0, time: 40; samples were kept at 4°C for 5 min between each cycle. Samples were 
centrifuged at 13000 × g for 5 min at 4°C, after which the liquid (~750 µl) was transferred to 
a new microcentrifuge tube and incubate at room temperature for 5 min. Chloroform, 300 
µl was then added to the sample and incubated at room temperature for 5 min. Samples 
were centrifuged at 13000 × g for 5 min at 4°C. The aqueous phase transferred to a new 
microcentrifuge tube, to which 500 µl of cold absolute ethanol was added. RNA was 
precipitated overnight at -20°C. RNA was harvested by centrifugation at 13000 × g for 5 min 
at 4°C, washed with 500 µl of cold 70% ethanol (made with DEPC-H2O, provide with the kit) 
and dried for no longer than 5 min in vacuum centrifuge (MiVac DNA concentrator, 
GeneVac). RNA was resuspended in 30 µl DEPC- H2O, overnight at 4°C. A NanoDrop ND-1000 
Spectrophotometer (Thermo Scientific) was used to quantify the RNA. RNA was stored at -
80°C. 
DNase treatment. Two rounds of DNase I treatment of RNA were carried out using Turbo 
DNase (Ambion). In the first round, the reaction contained 2 μg of RNA, 2 μl DNase, 2 μl 10 × 
Buffer and sdH2O to a final volume of 20 μl. The reaction was incubated at 37°C, for 45 min 
followed by purification of the RNA. The reaction was made up to a total volume of 100 μl 
with sdH2O, to which 100 μl of acid phenol: chloroform: isoamylalchol (25:24:1) was added. 
After vortexing briefly, the sample was centrifuged at 15000 × g for 5 min. the aqueous 
phase was then collected (~80 μl) and the RNA was precipitated with 1/10th volume sodium 
acetate (3M) and 2.5 volumes of ice-cold 100% ethanol. The RNA was incubated at -80°C for 
1 hr and then centrifuged at 15000 × g for 15 min, The supernatant was discarded the RNA 
pellet was washed with room temperature70% ethanol(prepared in DEPC-H2O), dried in a 
vacuum centrifuge (MiVac DNA concentrator, GeneVac)for no longer than 5 min and 
resuspended in 11 μl DEPC-H2O. Following incubation overnight at 4°C, RNA was quantified 
and followed by a second round of DNase treatment, as described. Removal of DNA 
contamination was confirmed with conventional PCR and samples were kept at 4°C to 
prevent degradation.  
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cDNA synthesis. For cDNA synthesis, iScript™cDNA Synthesis Kit (Bio-Rad) was used, in 
which 100 ng of DNase-treated RNA was used as template with 1 μl iScript reverse 
transcriptase and 4 μl of 5 × iScript reaction mix and DEPC-H2O to a final reaction volume of 
20 μl. Reverse transcription was performed in a conventional T100 Thermal Cycler (Bio-Rad) 
at the following conditions: 5 min at 25°C, 30 min at 42°C and 5 min at 85°C. cDNA synthesis 
was confirmed by conventional PCR  and all samples were kept at 4°C. 
Droplet Digital™ PCR (dd-PCR™). Primers and TaqMan minor groove binder (MGB) probes 
were designed using Primer Express software version 3.0.1. To facilitate multiplexing, 
TaqMan MGB probes homologous to the target gene were labeled with 6-
carboxyfluorescein (FAM), and the reference gene, sigA, was labelled with 4,7,20-trichloro-
7’-phenyl-6-carboxyfluorescein (VIC). Primers-probe amplification conditions for duplex PCR 
were first optimized by gradient PCR, however all reactions worked optimally at 60°C 
Reaction mixtures (20 μl) containing 1 ng of RNA-equivalent cDNA, 1 × dd-PCR Supermix for 
probes (Bio-Rad), 500 nM of each primer, and 250 nM of each TaqMan probe were 
emulsified with droplet generator oil using a QX200 Droplet Generator (Bio-Rad). PCR 
amplification was performed using a two-step thermocycling protocol (95c for 10 min, 40 
cycles at 94°C for 30 s and 60°C for 60 s, and 98°C for 10 min) in a conventional T100 
Thermal Cycler (Bio-Rad). The droplets were then analyzed using a QX200 Droplet Reader 
(Bio-Rad). Controls included a negative control (H2O) as well as 1 ng of each DNase-treated 
RNA sample (DNA contamination control). Three technical replicates of each gene were 
performed. The QuantaSoft Software version 1.4.0.99 (Bio-Rad) provided the absolute 
number of gene copies, normalized to sigA. Standard deviations were calculated using 
Microsoft Excel 2010. 
2.9 Drug susceptibility testing by broth microdilution  
The broth microdilution method (Collins & Franzblau 1997; Collins et al., 1998) allows a 
range of antibiotic concentrations to be tested, on a single 96-well microtitre plate, to 
determine the minimum inhibitory concentration (MIC). Briefly, a 10 ml culture of Mtb or 
Msm was grown to an OD600 of 0.6 – 0.7. The culture was then diluted 1:500 in 7H9/OADC. 
In a 96- well, U-bottom microtitre plate (PGRE650180, Lasec, SA), 50 μl of 7H9/OADC was 
added to all wells from Rows 2-12. The antimicrobials to be tested were added to Row 1 at a 
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final concentration of 8 × MIC90 and serially diluted, 2-fold, using a multichannel pipette, by 
transferring 50 μl of the liquid in Row 1 to Row 2 and aspirating to mix. Fifty μl of the liquid 
in Row 2 was transferred to Row 3 and aspirated. The procedure was repeated until Row 12 
was reached, where 50 μl of the liquid in Row 12 was discarded to bring the final volume in 
these wells to 50 μl. Finally, 50 μl of the diluted culture was added to all the wells. The 
microtitre plate was stored in a secondary container and incubated at 37°C for 3 days (Msm) 
and 14 days (Mtb). On Day 3 (Msm) and Day 14 (Mtb) alamarBlue® (BUF012B, Celtic 
Molecular Diagnostics) was added to each well and plates were incubated at 37°C for 6 hr or 
24 hr, respectively. The lowest concentration of drug which prevented the colour change of 
alamar blue (from blue to pink) was considered the MIC that inhibited more than 90% of the 
bacterial population (MIC90).  
  
40 





3.1.1 The bacterial SOS response 
The existence in the Gram-negative E. coli of an inducible, global response to DNA damage 
was first hypothesized by Miroslav Radman in the 1970s (Radman 1974). The naval distress 
signal “Save Our Souls” was aptly invoked to describe this response, as subsequent 
extensive characterization established the SOS response as a system that involves the 
induction of more than 40 unlinked genes following exposure to exogenous or endogenous 
DNA-damaging agents (Courcelle et al., 2001; Erill et al., 2007). In most bacterial systems, 
the proteins LexA and RecA have been shown to be the key regulatory components of the 
SOS response (Erill et al., 2007). LexA is a repressor protein which binds to a specific 
sequence, termed the SOS box, that is located upstream of the start codon of LexA-
regulated genes, including lexA itself and recA (Figure 3.1) (Butala et al., 2009). LexA is 
widely distributed across the Bacterial Domain and has been shown in silico to regulate 10 – 
40 genes in different species. There are, however, some exceptions: some 
Pseudomonadaceae and Xanthomonadaceae have two functional, independent, copies of 
lexA while Streptococci have none; neither of the two lexA homologues encoded by 
Deinococcus radiodurans regulates recA (suggesting that an alternative regulatory 
mechanism coordinates resistance to γ radiation), whereas the lexA homologue of 
Spirochaete L. interrogans regulates recA, but not itself; and, lexA-like genes have been 
identified in green nonsulfur bacteria, Cyanobacteria and all Proteobacteria subclasses 
except for Epsilonproteobacteria (Abella et al., 2004; Erill et al., 2007; Butala et al., 2009). 
RecA is highly conserved and found in virtually all bacteria, with the only known exception 
to be certain endosymbionts (Cox 2007). 
In addition to regulating multiple genes, the expression of LexA is autoregulated by a 
feedback mechanism which enables a rapid response to even small amounts of inducing 
signal (Butala et al., 2009). The degree of identity with the consensus SOS motif determines 
the affinity of LexA binding and consequently, the level, timing and duration of induction. 
Differential derepression of certain genes may occur in response to the internal pH, which 
affects the DNA binding affinity of LexA, or even minor endogenous DNA damage, as LexA 
binds some operators more weakly than others (Butala et al., 2009). In E. coli, the SOS 
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response is not only induced upon exposure to exogenous DNA damaging agents, but can 
also be stimulated by DNA damage from metabolic intermediates or mistakes in replication, 
recombination and chromosome segregation (Foster 2007). The timing of gene repression 
and subsequent synthesis of the SOS-induced proteins varies for individual genes. In E.coli, 
SOS boxes that bind LexA weakly are the first to be derepressed (Janion 2008). These 
include lexA itself, uvrAB, cho and uvrD (involved in nucleotide excision repair – NER), ruvAB 
(recombinational DNA repair), the DNA polymerases Pol II, Pol IV, as well as recA and recN 
(recombination and recombinational repair). If these proteins are not sufficient to repair the 
damage, LexA is further degraded, enabling the expression of genes with stronger SOS 
boxes such as sulA which inhibits cell division and thereby prolongs the time during which 
the DNA may be repaired, as well as assembly of the components, UmuD’2C, of the error-


















Figure 3.1: The SOS response. A) During normal growth, SOS genes are negatively regulated 
by the LexA repressor, which binds to the SOS box in the promoters of SOS-regulated genes 
and thereby inhibits their expression. B) Following genotoxic damage (UV; reactive oxygen 
or nitrogen species, ROS/RNS), RecA protein binds to single-stranded DNA (ssDNA) at sites 
of DNA lesions and replicon arrest, to form nucleoprotein filaments. The RecA nucleoprotein 
filaments interact with LexA which stimulates the cleavage of LexA in an autocatalytic 
reaction that de-represses the SOS regulon genes. As DNA damage is repaired, the co-
protease activity of the RecA filament disappears, allowing functional LexA to re-accumulate 
and bind to the SOS boxes and subsequently switch off the response (Rand et al., 2003; 
Butala et al., 2009). Schematic adapted from (Nohmi 2006). 
  























3.1.2 The mycobacterial DNA-damage response 
The regulation of recA in a RecA/LexA-independent manner was initially reported in 
Acinetobacter calcoaceticus (Rauch et al., 1996) and subsequent homology studies suggest 
that a range of DNA damage response mechanisms, different from the typical SOS response, 
exists in all members of this genus Acinetobacter (Hare et al., 2006; Hare et al., 2012). 
Mycobacteria are intriguing in that there are two mechanisms associated with the 
regulation of DNA repair genes: a small number of genes are regulated by the classic SOS or 
RecA/LexA-dependent mechanism (referred to as the SOS response), while a larger subset 
of genes are regulated by an alternate, RecA/LexA-independent mechanism (referred to as 
the RecA-ND mechanism/response) (Figure 3.2) (Durbach et al., 1997; Rand et al., 2003; 
Gamulin et al., 2004; Smollett et al., 2012). During normal mycobacterial growth - or the 
“uninduced state” – binding of LexA to the SOS box restricts LexA expression and the 
expression of at least 25 other SOS regulon genes (Smollett et al., 2012). Comparative 
analyses with other bacteria enabled the identification of the consensus SOS box sequence 
TCGAAC(N4)GTTCGA in Mtb (Davis et al., 2002). Studies have shown that Mtb’s recA gene is 
inducible independently of RecA and LexA (Davis et al., 2002) and that expression is driven 
off two different promoters (Gopaul et al., 2003). The two recA promoters have been 
studied extensively: there is a distal RecAp2 promoter which is a typical sigma70 (σ70)-like 
promoter, and this overlaps with a LexA-binding site and a proximal RecAp1 promoter which 
lacks an apparent LexA-binding site (Gopaul et al., 2003). Interestingly, both promoters are 
inducible upon DNA damage, despite the lack of a LexA-binding site within RecAp1 (Davis et 
al., 2002). Subsequently, a promoter motif was identified in the upstream regions of genes 
induced independently of RecA and LexA in Mtb, termed the RecA non-dependent promoter 
(RecA-NDp) (Gamulin et al., 2004). The majority of RecA-ND genes (e.g., radA, lhr, alkA, 
ahpC, and mobile elements) are induced in the macrophage environment to a significant 
level (Schnappinger et al., 2003; Gamulin et al., 2004). In addition, genes that are involved in 
the basic DNA damage response as well as oxidative stress were shown to be regulated by 
this alternate mechanism (Gamulin et al., 2004). Some genes, including recA, possess the 
RecA-ND motif as well as an SOS box, suggesting the two DNA damage response 
mechanisms may partially overlap (Rand et al., 2003; Gamulin et al., 2004; Smollett et al., 
2012). The identified motif includes two consensus sequences tTGTC(G/A)gtg and TAnnnT, 
separated by eight nucleotides and are similar to σ70 recognition elements (Gamulin et al., 
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2004). Recently, in vitro electrophoretic mobility shift assays and in vivo chromatin 
immunoprecipitation was used to show that the Rv2745c, and the Msm homolog 
MSMEG_2694, encode the ClgR transcriptional regulator that specifically binds to RecA-NDp 
and may play an essential role in inducing expression of DNA repair genes in Mtb and Msm, 
respectively (Wang et al., 2011). In addition, ClgR, which acts as a regulator of the ATP-
dependent Clp protease system, has been shown to be essential for Mtb replication in 
macrophages and is implicated in diverse regulatory networks in response to a multitude of 
stress conditions, including intraphagosomal redox stress, hypoxia, reaeration, cell wall 
stress and heat shock (Estorninho et al., 2010; Mehra et al., 2010; Sherrid et al., 2010; 
McGillivray et al., 2014). 
Owing to its genetic composition, the SOS response can be an error-prone or mutagenic 
pathway that results in genetic diversity of the organism and thereby enables survival 
through adaptive evolution. In Mtb, this occurs by inducible mutagenesis and damage 
tolerance mediated by the upregulation of the low fidelity, or “mutator,” polymerase DnaE2 
(Boshoff et al., 2003). In addition, uvrB contributes significantly to Mtb’s resistance to UV 
irradiation in vitro, and to reactive nitrogen and oxygen intermediates (RNI and ROI) in vivo 
(Darwin & Nathan 2005). Furthermore, recent biochemical evidence supports the critical 
role of the entire UvrABC complex in repair of UV-damaged DNA via the NER pathway 

























Figure 3.2: Regulation of DNA repair and associated genes in Mtb. Multiple genes are 
regulated in the classical RecA/LexA-dependent (SOS response) manner and have are 
identifiable by the presence of the SOS box, TCGAAC(N4)GTTCGA . However, the majority of 
DNA repair genes are regulated independently of RecA and LexA (RecA-ND response) and 
have the characteristic tTGTCRgtg(N8)TA(N3)T (or RecA-NDp) motif in their promoters. In 
addition, a subset of genes is co-regulated as both motifs have been identified in the 
promoters of these genes (Gamulin et al., 2004; Smollett et al., 2012). *Essential genes 
(Sassetti et al., 2003). 
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3.1.3 A common mechanism of cell death 
It has been proposed that a common mechanism underlies antibiotic-mediated cell death in 
bacteria (Kohanski et al., 2007; Keren et al., 2013; Liu & Imlay 2013). Since the “universal 
mechanism” is independent of drug-target interaction, the proposal has met with 
considerable controversy (Keren et al., 2013; Liu & Imlay 2013; Dwyer et al., 2014). 
Nevertheless, there are aspects of the model which have been recapitulated in multiple 
systems, including Mtb (Grant et al., 2012). In essence, this mechanism centres on the 
generation in antibiotic-exposed cells of ROS such as superoxide, hydrogen peroxide and 
highly deleterious hydroxyl radicals (OH˙) (Kohanski et al., 2007; Dwyer et al., 2014). ROS are 
highly toxic and will readily damage proteins, membrane lipids and DNA. In addition, studies 
in E. coli suggest that antibiotic-mediated cell death results from the oxidation of the 
guanine nucleotide pool and subsequent incorporation of toxic oxidation products (8oxo-
dG) into nucleic acids (Foti et al., 2012). This is consistent with other evidence implicating 
the SOS response in intrinsic resistance to antibiotics including β-lactams, the ribonucleotide 
reductase inhibitor trimethoprim, and fluoroquinolones (Miller et al., 2004; Cirz & 
Romesberg 2007; Kohanski et al., 2007). To date, clofazimine, pretonamid and delamanid 
are the only anti-tuberculars which have been shown to generate ROS and/or RNS as their 
presumed mechanism of action against Mtb (Mdluli et al., 2014). Mycobacteria possess DNA 
repair systems such as HR (homologous recombination), BER (base excision repair), NER as 
well as a system for NHEJ (nonhomologous end-joining) (Gorna et al., 2010; Warner 2010). 
However, unlike other prokaryotes, mycobacteria do not possess mechanisms known to be 
required for MMR (mismatch repair) (Mizrahi & Andersen 1998). Bacteria appear to incur 
DNA damage unceasingly (partially attributable to normal aerobic cellular metabolism) as 
almost half of the Mtb DNA repair genes are continuously expressed during exponential 
phase growth in broth and similar findings have been reported in E.coli (Fu & Fu-Liu 2007; 
Pennington & Rosenberg 2007).  
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3.2 Aims and objectives  
Several lines of evidence implicate the SOS response in intrinsic resistance to antibiotics 
through its role in adaptive mutagenesis (Drlica & Zhao 1997; Miller et al., 2004; Cirz & 
Romesberg 2007; Kohanski et al., 2007). The SOS response and, as such, DNA damage 
responses, subsequently induce the synthesis of error-prone DNA polymerases upon 
exposure to sub-lethal doses of some commonly used antibiotics (Foster 2007). These 
include trimethoprim, the dihydrofolate reductase inhibitor that arrests DNA replication; 
the DNA topoisomerase inhibitor, ciprofloxacin; the RNA polymerase inhibitor, rifampicin; 
and, surprisingly, β-lactams, the cell wall inhibitors (Butala et al., 2009). Therefore, 
antibiotics can drive evolution by inducing the SOS response and subsequently accelerating 
mutagenesis, for example, by acquiring point mutations that result in inactivation or efflux 
of the drug. Consequently, antibiotic therapy can be counteracted at many levels by the SOS 
response. 
Numerous studies have utilized gene-deleted recA mutants in order to better understand 
the SOS response. However, RecA is not only involved in the SOS response but is central to 
the processes of recombination and replication restart (Cox et al., 2000; Cox 2003).  Thus, 
abrogation of RecA function is likely to have pleiotropic effects not solely related to the SOS 
response. To date, a lexAInd- mutant has not been constructed in Msm or Mtb. Davis et al. 
(2002) were not able to construct a Mtb lexA null (deletion) mutant (Griffin et al., 2011, 
recently demonstrated the essentiality of lexA, in vitro), but instead expressed a non-
cleavable Mtb LexA protein from a plasmid in Msm and used this strain to infer DNA 
damage-induced regulation of the recA promoter independently of LexA. In addition, the 
strain that was characterized not only had two copies of lexA, the native Msm lexA and the 
Mtb lexAS141A, but was also a marked mutant in that a hygromycin-resistance gene was 
present. 
Against this background, the overall aim of this study was to investigate the role of the SOS 
response in limiting the efficacy of antitubercular agents. It was hypothesised that the SOS 
response plays a role in antibiotic-mediated cellular death in mycobacteria and that 
disabling the mycobacterial SOS response could be used as a tool to validate antibiotic-
mediated cell death. The specific objectives were: 
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1. To generate unmarked Msm and Mtb lexAInd- mutants that each possess a single 
copy of the mutated gene. 
2. To evaluate phenotypically the extent to which the SOS response contributes to 
remediation of DNA damage, and to determine whether this impacts antibiotic-mediated 
cellular death in mycobacteria. 
3.3 Materials and Methods 
3.3.1 Mycobacterial strains, plasmids, and probes 
The strains used in this study are detailed in Table 3.1, plasmids are listed in Table 3.2, 
and primers in Table 3.3. 
 
Table 3.1: Strains used in this study 
Strain Description/ Genotype Reference/ Source 
Msm   
mc2155 
High frequency transformation 
mutant of Msm ATCC 706 
(Snapper et al., 1990) 
∆dnaE2 
dnaE2 knockout mutant of 
mc2155 
Edith E. Machowski, MMRU 
∆recA recA deletion mutant of mc2155 (Machowski et al., 2007) 
lexAS167A 




lexA K204A point mutant of 
mc2155 
This study 
Mtb   
H37RvMA 
Virulent reference laboratory 
strain of Mtb ATCC 27294 
(Ioerger et al., 2010) 
∆dnaE2::hyg 
dnaE2 knockout mutant of 
H37Rv, HYGR 
(Boshoff et al., 2003) 
lexAInd- 





Table 3.2: Plasmids used in this study 
Plasmid Description Reference/ Source 
p2NIL Cloning vector, KANR  (Parish & Stoker 2000) 
pGOAL19 
Plasmid carrying hyg, lacZ and sacB genes as a PacI cassette; 
AMPR 
(Parish & Stoker 2000) 
p2NIL::MsmlexA 
p2NIL harbouring 1957 bp PCR product containing 732 bp of 
mc2155 lexA plus 1225 bp flanking sequence; KANR 
This study 
p2NIL::S167A 
p2NIL::MsmlexA site-directed mutagenesis vector carrying Msm 
lexAS167A allele, KANR 
This study 
p2NIL::K204A 
p2NIL::MsmlexA site-directed mutagenesis vector carrying Msm 
lexAK204A allele, KANR 
This study 
p2NIL::S167A-P19 
p2NIL::S167A vector containing the PacI cassette from pGOAL19; 
KANR, HYGR, SucS  
This study 
p2NIL::K204A-P19 
p2NIL::K204A vector containing the PacI cassette from pGOAL19; 
KANR, HYGR, SucS 
This study 
p2NIL::MtblexA 
p2NIL harbouring 2345 bp PCR fragment containing 654 bp 
H37Rv lexA plus 1691 bp flanking sequence; KANR 
This study 
p2NIL::S141A 
p2MIL::MtblexA site-directed mutagenesis vector carrying Mtb 
lexAS141A allele, KANR 
This study 
p2NIL::S141A-P19 
p2S141A vector containing the PacI cassette from pGOAL19; 
KANR, HYGR, SucS 
This study 
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Table 3.3: Primers used in this study 
Name Sequence 5’-3’ Comments  
Msm lexAInd- point mutants 
MsmLexAF GATCGGGCGAAGCTTCGACGCGCGGGAC
ATCAGGA 1957 bp; MSMEG_2740 including 1225 bp flanking sequence with 




277 bp when used with LexAMegR; mutagenic forward primer with 
introduced StyI site and S167A mutation 
LexAK204A ACGGTCGCGACCTTCAAGCGCGCACGCG
GTC 
159 bp when used with LexAMegR; mutagenic forward primer with 
introduced NruI site and K204A mutation 
2740MegR CCCGCACGAACGGATTCGTACGGGCGA Reverse primer to generate megaprimer with LexAS167A or LexAK204A ; 
introduced BsiWI site 
2740MegF GGGATGTCGAGGATGGCCATCTGACT 1025 bp; forward primer used with megaprimer LexAS167A/ 2740MegR 
or LexAK204A/ 2740MegR; introduced BsaBI site 
2740Fsp ATAGAACGGGGTACCGAC 
1130 bp; forward and reverse primers for screening 
2740Rsp ACGCGGCGATCGAATTCG 
MsmFprobe CTTGCGGATGACGGT 




Mtb lexAInd- point mutant 
MtbLexAF CGCCACTAAGCTTGACTACG 2345bp; Rv2720 including 1691 bp flanking sequence with introduced 
HindIII sites MtbLexAR GCCGAGAAGCTTCCGGGT 
LexAS141A CGGTGACGCCATGGTCGA 254 bp megaprimer; mutagenic forward primer with introduced StyI and 
reverse primer with introduced BsaBI site 2720MegR ACGCGGATCAGCATCAGA 
2720MegF CGAGCGGGCCCCGCAGATT 1032 bp; forward primer used with megaprimer LexAS141A/ 2720MegR; 




1211 bp; forward and reverse primers for screening 
2720Rsp CTGCCGCTCGAGGACCCAT 
MtbFprobe GCAGGAACAGGGTGCCCT 
260 bp; probe for Southern blot 
MtbRprobe GCACCAGCTGCGCACCCT 
Restriction sites are underlined 
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3.3.2 Construction of suicide delivery vectors carrying lexA point mutations 
Msm: Site-directed mutagenesis (SDM) was used to mutate the key catalytic residues 
(S167A and K204A), and thereby interrupt the self-cleavage reaction of LexA. Briefly, the 
entire lexA gene, MSMEG_2740 (732 bp), including the 1225 bp flanking sequence, was 
amplified by PCR (oligonucleotides specified in Table 3.3). The resulting amplicon was 
purified and digested with HindIII and subsequently ligated with HindIII-linearized p2NIL 
(p2NIL::MsmlexA construct) and transformed into competent E. coli DH5α cells. Following 
confirmation of the construct, by restriction analysis, it was used as the template DNA for 
subsequent megaprimer-based mutagenesis for introduction of point mutations (Kammann 
et al., 1989). Briefly, two rounds of PCR were performed, using two flanking oligonucleotides 
and one internal mutagenic oligonucleotide. In the first round of PCR, the internal 
mutagenic forward primer and the flanking reverse primer were used and the resultant 
product was the “megaprimer”, 277 bp. The megaprimer was then used as the reverse 
primer with the second flanking forward primer to generate the complete DNA sequence 
with the desired mutation, 1055 bp (Datta 1995; Tyagi et al., 2004). This PCR product was 
then digested with BsaBI and BsiWI, two unique restriction sites that were introduced in the 
flanking forward and reverse primers respectively and ligated into BsaBI/BsiWI-digested 
p2NIL::MsmlexA to generate p2NIL::S167A or p2NIL::K204A. In this way, the wilt type (Wt) 
lexA allele is replaced with an allele with the desired point mutation. The PacI cassette from 
pGOAL19 was then cloned into the p2NIL::S167A and p2NIL::K204 constructs and positive 
constructs were confirmed as blue, KAN–resistant (KANR), HYG–resistant (HYGR), sucrose–
sensitive (SucS) and included the respective point mutations S167A – StyI site; K204A – NruI 
site – confirmed with restriction digest (detailed below). Both constructs were further 
confirmed by Sanger sequencing of the lexA locus. 
Mtb: Similarly, the key catalytic residue Ser-141 of Mtb lexA, Rv2720, was mutated to Ala by 
SDM. The entire lexA gene of 654 bp plus 1691 bp flanking sequence was PCR amplified and 
subsequently cloned into p2NIL (using HindIII), to generate the template construct for SDM 
(p2NIL::MtblexA). The S141A megaprimer was generated (254 bp) using a mutagenic 
forward primer and the flanking reverse primer, including the BsaBI restriction site. The 
S141A megaprimer was used as the reverse primer with the flanking forward primer that 
includes an ApaI restriction site, to generate the insert (1033 bp) with the desired point 
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mutation. This PCR product was then digested with ApaI and BsaBI, and ligated into 
ApaI/BsaBI -digested p2NIL::MtblexA to generate p2NIL::S141A. Similar to the Msm suicide 
delivery vectors, the PacI cassette was introduced and positive constructs were confirmed 
as blue, KANR, HYGR and SucS and included the point mutation S167A – StyI site, which was 
further confirmed by restriction digest (detailed below) and Sanger sequencing of the lexA 
locus.  
3.3.3 Screening of lexA point mutants  
To aid in the screening process, the Ser-Ala and Lys-Ala point mutations were engineered so 
as to introduce the unique restriction sites StyI and NruI, respectively. The screening was 
done in a two-step process: first, the lexA gene was amplified using the primer pair 
2740Fsp/2740Rsp or 2720Fsp/2720Rsp (Table 3.3), which generated a 1130 bp or 1211 bp 
fragment respectively. Then, in the second step the PCR product was digested with StyI (Ser-
Ala) or NruI (Lys-Ala), and positive transformants that harboured the point mutations 
yielded two fragments of 668 bp and 462 bp (S167A), 778 bp and 352 bp (K204A) and 791 
bp and 420 bp (S141A). 
3.3.4 Damaging treatments of mycobacteria 
3.3.4.1 UV irradiation 
Msm: For DNA damage by UV, 40 ml cultures were grown to an OD600 of 0.6–0.8. Cells 
were concentrated by centrifugation at 3901 × g for 10 min (Beckmann Allegra X-22R) and 
suspended in 5 ml and aliquoted into in 90 mm petri dishes. Open petri dishes were 
irradiated with 20 mJ/cm2 (UV Stratalinker 1800, Stratagene), after which cultures were 
rescued in final volumes of 40 ml for 3 hr at 37°C. Cultures were then plated on solid 
7H10/OADC without antibiotic (for viable CFU evaluation) or containing 200 μg/ml RIF (for 
determination of RIFR frequencies). Plates were incubated for 3 days for CFU determination 
and 5–6 days for RIFR determination, at 37°C. 
Mtb: UV-induced mutagenesis was performed similarly to Msm, except that cultures were 
recovered for 24 hr at 37°C before plating for CFU and RIFR frequencies determination. 
Plates were incubated for 21 days for CFU determination and 4–5 weeks for RIFR 
determination, at 37°C. 
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3.3.4.2 Survival assay 
Msm: 10 ml cultures were grown to an OD600 of 0.6–0.8, after which 10-fold serial dilutions 
were prepared and 5 μl of each dilution was spotted onto solid 7H10/OADC (untreated 
control) and MMC (0.02 μg/ml and 0.04 μg/ml). Plates were incubated for 3–4 d at 37°C. 
Mtb: As executed for Msm, except plates were incubated for 10–12 d at 37°C. 
3.3.5 Antimicrobial agents 
RIF; INH; KAN; STR; vancomycin (VAN); novobiocin (NOV); 5-fluorouracil (5-FU); norfloxacin 
(NOR); ofloxacin (OFX); ciprofloxacin (CIP); gatifloxacin (GAT); moxifloxacin (MOX); 
levofloxacin (LEV) and mitomycin C (MMC) were purchased from Sigma Aldrich. bedaqualine 
(BDQ) was purchased from Asclepia MedChem Solutions (Belgium, www.asclepia.com). For 
stock solutions, antimicrobials were all dissolved in the following solvents: INH; KAN; STR; 
VAN; NOV; 5-FU; GAT; MOX; LEV and MMC in nuclease-free water (Qiagen), CIP in 0.1N 
hydrochloric acid and  RIF; NOR; OFX; and BDQ in dimethyl sulfoxide (DMSO – Sigma 
Aldrich). Antimicrobial stock solutions were stored at 4°C. 
3.3.6 Quantitative RT-PCR of Mtb genes in response to MMC treatment 
Primers and probes used for droplet digital PCR (dd-PCR) were designed using the Primer3 
programme (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) (Table 3.4). All 
primers were designed to amplify DNA fragments internal to the coding sequence of the 
relevant genes with the same annealing temperatures (60°C). 
Table 3.4: Primers and probes used for dd-PCR used in this study 

















 TaqMan minor groove binder (MGB) probes were either labelled with 6- carboxyfluorescein (FAM) 
or with 4,7,2’-trichloro-7’-phenyl-6- carboxyfluorescein (VIC)   
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3.4 Results 
3.4.1 Disabling the Msm SOS response by mutating the key catalytic residues of LexA. 
Slilaty and Little (1987) showed that changing either Serine-119 or Lysine-156 to Alanine in 
E. coli LexA resulted in two mutant proteins that had normal repressor function and, 
apparently, normal structure, but were completely deficient in cleavage (Slilaty & Little 
1987). That is, the S119A and K156A alleles prevent LexA-dependent induction of the SOS 
response, effectively resulting in an SOS-deficient mutant. To determine the feasibility of 
adopting a similar approach in Msm and Mtb, an alignment of LexA was performed to 
compare the amino acid sequences of the E. coli, Msm and Mtb LexA proteins. This analysis 
revealed a high degree of conservation between the LexA proteins and, importantly, 
confirmed the conservation of the E.coli S-119 and K-156 residues among these organisms 
(Figure 3.3).  
Based on this analysis, site directed mutagenesis (SDM) was used to generate equivalent 
Msm LexA (MSMEG_2740) point mutants by changing S-167 and K-204 to A, respectively. 
The final constructs, p2NIL::S167A-P19 and p2NIL::-K204A-P19, were subsequently 
electroporated into mc2155 to generate the strains lexAS167A and lexAK204A (jointly referred to 
as lexAInd-). The presence of the mutations in the constructs as well as after genomic 
integration (single-cross-overs, SCOs and double-cross-overs, DCOs) following 
electroporations, was confirmed by restriction digest of the PCR-amplified lexA gene (Figure 
3.4). In addition, introduction of the S167A and K204A mutations was further confirmed by 













Figure 3.3: LexA protein alignment. The E. coli S-119 and K-156 residues are conserved between Msm and Mtb and correspond to S-167 and K-
































Figure 3.4: Construction and genotypic characterisation of the lexAS167A and lexAK204A 
mutants of Msm. (A) Schematic representation of the p2NIL::S167A-P19 and p2NIL::-K204A-
P19 suicide vectors in which the key catalytic residues of Msm LexA were mutated by site-
directed mutagenesis. (B) To confirm the presence of the mutation, the PCR-amplified 
(using primer set 2740Fsp/2740Rsp, as depicted in A) lexA gene product from each strain 
was digested at the unique restriction site that was introduced concurrently with the 
mutation: lexAS167A digested with StyI yields two fragments of 668 bp and 462 bp, lexAK204A 
digested with NruI yields two fragments of 778 bp and 352 bp, and Wt lexA remains 
undigested (1130 bp) by StyI and NruI; molecular weight marker VI (Roche) is shown in 
lane1. (C) Genotypic confirmation by Southern blot analysis. AluI-digested genomic DNA was 
hybridized to the 558 bp probe, depicted as the lined box (not drawn to scale). The 
merodiploid strains (SCOs) carry both Wt and mutant versions of the lexA gene whereas the 
parental Wt and allelic exchange mutants have either one or the other. The mutant lexA 































3.4.2 Cleavable LexA is required for induced mutagenesis and damage tolerance in Msm. 
In other bacterial systems, it has been shown that a disabled SOS response renders the 
organism susceptible to DNA damage (Kohanski et al., 2007). Therefore, to validate that 
mutating S167 and K204 to A in Msm disables the SOS response, we evaluated induced 
mutagenesis by exposing a panel of Msm strains, including Wt, ΔdnaE2 (Boshoff et al., 
2003), ΔrecA (Machowski et al., 2007), and the lexAInd- mutants (lexAS167A and lexAK204A), to 
UV irradiation to induce mutations that confer rifampicin resistance (RIFR) (Table 3.5). This 
technique has been used extensively in E. coli and has been validated as an appropriate tool 
to study induced mutagenesis in mycobacteria (Boshoff et al., 2003; Warner et al., 2010). 
However, the possibility of pre-existing mutants in the population provides an inherent 
inaccuracy to this assay; one that can be overcome by fluctuation analysis of the mutation 
rate whisch is more accurate and reproducible (Rosche & Foster 2000). Subsequently, the 
mutation frequencies of mc2155 (Wt), ∆dnaE2 and ∆recA were consistent with those 
previously reported (Boshoff, 2003). The lexAInd- mutants displayed decreased mutation 
frequencies, phenocopying ∆recA, and confirming that either S167A or K204A mutation in 
LexA disables the Msm SOS response.  
Table 3.5: UV-induced mutation frequencies to rifampicin resistance (RIFR). The lexAInd- 
mutants and the ΔrecA mutant show decreased UV-dependent mutation frequency 
compared to Wt and ΔdnaE2.  
Strain CFU/ml† Number of RIFR colonies Mutation frequency 
Wt 3.6 × 106 201 5.6 × 10-6 
∆dnaE2 3.4 × 106 73 2.1 × 10-6 
∆recA 4.0 × 106 0 0 
lexAS167A 3.7 × 106 0 0 
lexAK204A 3.8 × 106 0 0 
 Data are from a representative experiment performed in triplicate. 
† CFU/ml – colony forming units/ml 
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To evaluate the tolerance to DNA damage of these mutants, survival assays were performed 
in which the sensitivity was determined to mitomycin C (MMC), a DNA damaging agent that 
forms crosslinks between the complementary strands of DNA preventing their separation 
and inhibiting DNA replication (Tomasz 1995). Briefly, log10-fold dilutions of 10
6 CFU/ml 
cultures were spotted onto MMC-supplemented (0.02 µg/ml or 0.04 µg/ml) or 
unsupplemented media (Figure 3.5). For both concentrations, it appeared that the lexA non-
cleavable mutants were unable to tolerate, and thus unable to survive, the DNA damage 
induced by MMC, as reflected by the hypersensitivity to the agent. This is consistent with 
the ∆recA phenotype but contrary to Wt, which shows significant resilience to the effects of 
DNA damage. As observed previously (Warner et al., 2010 and Boshoff et al., 2003), the 
ΔdnaE2 mutant showed reduced, not abrogated, growth (4-fold and 8-fold growth reduction 





























Figure 3.5: Msm cleavable LexA is required for damage tolerance. Log10-fold dilutions of 
mc2155 (Wt), ΔdnaE2, ΔrecA, lexAS167A and lexAK204A were plated on standard OADC medium 
or medium containing MMC at 0.02 µg/ml or 0.04 µg/ml. Cultures were also plated onto 
standard 7H10/OADC to enumerate CFU/ml, to ensure equivalent numbers of cells were 
spotted (106 CFU/ml). The lexAS167A and lexAK204A mutants phenocopy ΔrecA, as all three 
strains show hypersensitivity to DNA damage and are unable to grow in the presence of 
MMC (0.02µg/ml or 0.04µg/ml). On the contrary, Wt is resilient to the effects of DNA 
damage, while ΔdnaE2 shows reduced, not abrogated growth. Data are from a 
representative experiment performed in triplicate. 
 
3.4.3 An intact Msm DNA damage repair system is required to respond to antibiotic-
mediated DNA damage. 
In E. coli, it has been shown that an intact DNA damage repair system mitigates the effects 
of antibiotic-mediated DNA damage (Kohanski et al., 2007). Therefore, it was determined 
whether disabling the mycobacterial SOS response could potentiate antibiotic efficacy. To 
this end, we subjected the panel of strains to a series of antibiotics from various classes 
(inhibitors of cell wall, transcription, etc.) and determined the MIC90 (Figure 3.6). In general, 
when compared to the Wt MIC90, the lexA
Ind- mutants displayed increased sensitivity (≤ 4-
fold) to established compounds from the quinolone class of drugs which target DNA gyrase, 
resulting in lethal DNA double-strand breaks (Malik et al., 2006). Surprisingly, only a 2-fold 
increase in MIC90 was observed for the fourth-generation fluoroquinolones, MOX and GAT. 
In addition, a 2-fold increase in susceptibility was also observed for RIF and 5-FU. 
Hypersusceptiblity (16-fold) of the the lexAInd- mutants to MMC was observed, consistent 
with the damage tolerance assay (Figure 3.5). The ∆recA strain displayed a similar MIC90 
profile to the lexAInd- mutants, although increased susceptibility was observed against 
certain antimicrobials (RIF, CIP, MOX, and GAT). Finally, the ΔdnaE2 strain displayed 













Figure 3.6: Susceptibility to DNA-damaging agents. The lexAInd-mutants and the ΔrecA mutant show increased sensitivity to the quinolone 
class of drugs, compared to Wt and ΔdnaE2. In addition, hypersensitivity to MMC complements the results from the MMC survival assay 

































3.4.5 Disabling the Mtb SOS response by mutating the catalytic Ser-141 residue in LexA. 
Characterization of the Msm lexAInd- mutants showed that S167A phenocopies K204A under 
all conditions assayed. Given the equivalence of these mutations, we generated a single Mtb 
mutant in which the Ser-141 catalytic residue (equivalent to Msm LexA S167A and E. coli 
LexA S119, Figure 3.7) was mutated by SDM, using the same approach as described for 
Msm. In addition, introduction of the S141A mutation was further confirmed by DNA 












Figure 3.7: Construction and genotypic characterisation of the lexAInd- mutant of Mtb. (A) 
Schematic representation of the p2NIL::-S141A-P19 suicide vector in which the key catalytic 
Ser-141 residue is mutated to an Ala by site-directed mutagenesis. (B) To confirm the 
presence of the mutation, the PCR-amplified (using primer set 2720Fsp/2720Meg, depicted 
in A) lexA gene product from Wt, the merodiploid (SCO) and the lexAInd-allelic exchange 
mutant was digested at the unique restriction site (StyI) that was introduced concurrently 
with the mutation: Wt lexA remains undigested (1211 bp), the SCO yields three fragments of 
1211 bp, 791 bp and 420 bp (as two copies of lexA are present in this strain) and the lexAInd-
mutant yields two fragments of 791 bp and 420 bp; molecular weight marker VI (Roche) is 
shown in lane1. (C). Schematic illustration of the Southern blot strategy in which StyI-
digested genomic DNA hybridized to the 260 bp probe, depicted as the patterned box (not 
drawn to scale).  
  


























3.4.6 Cleavable LexA is required for induced mutagenesis but not necessarily for damage 
tolerance in Mtb. 
The Mtb lexAInd- mutant (S141A) was then characterized using an analogous set of assays to 
those employed in Msm. Inactivation of the SOS response was validated by evaluating 
induced mutagenesis: a small panel of Mtb strains, H37Rv (Wt), ΔdnaE2 and lexAInd-, was 
exposed to UV irradiation to induce lesion-targeted, base-substitution mutations that confer 
rifampicin resistance (RIFR) (Table 3.6). An increased mutation frequency in Wt was 
observed, whereas the number of mutants was reduced significantly in ΔdnaE2 consistent 
with previous reports (Boshoff et al., 2003). The lexAInd- mutant displayed hypersensitivity to 
UV irradiation, confirming that the S141A mutation in LexA disables the SOS response. 
Although the number of RIFR colonies and subsequent mutation frequency of Wt and 
ΔdnaE2 was lower than previously reported (Boshoff et al., 2003), the overall trend was 
replicated. The discrepancy is likely due to the use here of 2-fold log10 lower CFU/ml in the 
initial cultures pre-UV irradiation, compared to previous reports.  
Table 3.6: UV induced mutation frequencies to rifampicin resistance (RIFR). The lexAInd- 
mutant shows hypersensitivity to UV irradiation, compared to Wt and ΔdnaE2.  
Strain CFU/ml Number of RIFR colonies Mutation frequency 
Wt 4.2 × 106 27 6.4 × 10-6 
∆dnaE2 4.2 × 106 0 0 
lexAInd- 4.0 × 106 0 0 
 Data are from a representative experiment performed in triplicate. 
 
Tolerance of the lexAInd- mutant to DNA damage was evaluated by damage survival assay: 
log10-fold dilutions of Wt, ΔdnaE2 and lexA
Ind- were plated on standard OADC medium or 
medium containing MMC at 0.02 µg/ml or 0.04 µg/ml (Figure 3.8). Consistent with reported 
data, Wt and ΔdnaE2 are able to tolerate MMC exposure, i.e. ability to survive in the 
presence of the DNA-damaging agent (Boshoff et al., 2003). A less pronounced phenotype 
was observed for the Mtb mutant compared to Msm (Figure 3.5): only a slight increase was 
detected in the sensitivity of Mtb lexAInd- to MMC exposure (~1 log10 and 2 log10, at 0.02 
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µg/ml and 0.04 µg/ml, respectively), compared to absence of growth with Msm lexAInd- 
mutants at the same MMC concentrations. Nevertheless, this suggested a damage tolerance 







Figure 3.8: Tolerance of Mtb lexAInd- to DNA damage. Log10-fold dilutions of H37Rv (Wt), 
ΔdnaE2, and lexAInd-were plated on standard OADC medium or medium containing MMC at 
0.02 µg/ml or 0.04 µg/ml. Cultures were also plated onto standard 7H10/OADC to 
enumerate CFU/ml, to ensure equivalent numbers of cells were spotted (106 CFU/ml).  Wt 
and ΔdnaE2 are resilient to the damaging effects of MMC, in comparison to the Mtb lexAInd-
mutant which is 2-fold and 4-fold more sensitive at 0.02 µg/ml and 0.04 µg/ml, respectively. 
Data are from a representative experiment performed in triplicate. 
 
3.4.7 The Mtb SOS response does not contribute to remediation of antibiotic-mediated 
DNA damage. 
It was hypothesised that an intact SOS response in Mtb might mitigate the effects of 
antibiotic-mediated DNA damage and that inactivation of LexA would potentiate the 
efficacy of agents that target DNA metabolism, as observed in Msm (Figure 3.9). To 
investigate the impact of disabled SOS function on Mtb, the MIC90 was evaluated by 
subjecting a panel of strains to a series of antibiotics, both current anti-TB drugs as well as 
novel drugs in various clinical phases of development, from different drug classes. The 
ΔdnaE2 strain displayed comparable MIC90 to Wt, with the exception of VAN, BDQ, OFX and 
MMC (2-fold increase in sensitivity). The lexAInd- mutant displayed slightly increased 
sensitivity (2-fold) to all compounds tested from the quinolone class of drugs and 
hypersensitivity (16-fold) to MMC only. Furthermore, a 2-fold increase in sensitivity was also 


























Figure 3.9: Susceptibility to DNA-damaging agents. The lexAInd- mutant shows a moderate increase in sensitivity to the quinolone class of 




























3.4.8 A RecA-ND mechanism remains functional in the Mtb lexAInd- mutant and contributes 
significantly to DNA repair. 
The hypersusceptibilty of Msm lexAInd- mutants to various quinolones (Figure 3.6) compared 
to the moderate susceptibility of the Mtb lexAInd- mutant to those same agents (Figure 3.9) 
suggested that, while the same two DNA damage-repair pathways have been identified in 
Msm and Mtb (SOS response and RecA-ND) (Gamulin et al., 2004), they might not 
contribute equally within the two organisms. To investigate this possibility, droplet digital 
(dd)-PCR was used to analyse the expression levels of three Mtb genes, each differentially 
regulated in response to DNA damage according to the presence of either a SOS box, the 
RecA-NDp motif, or both in the upstream regulatory region: dnaE2 is SOS-inducible, radA is 
a RecA-ND regulon gene, and recA has both an SOS box and a RecA-NDp motif (Figure 3.2). 
MMC was selected as the DNA damage inducer as hypersusceptibility to this agent, relative 
to other DNA damaging agents, had been observed (Figure 3.9). In addition to analysing 
expression levels in Wt and the lexAInd- mutant, the ΔdnaE2 mutant was included as a 
control (Figure 3.10). As expected, all three genes were upregulated in Wt upon MMC 
treatment. Interestingly, a substantial level of recA transcript was present, even before DNA 
damage, which is consistent with the function of RecA in multiple replication and repair 
pathways. In the lexAInd- mutant, dnaE2 levels were low relative to WT, and remained low 
upon MMC treatment. This confirmed that the SOS pathway had been disabled in this strain 
and, further, suggested that Mtb experiences constitutively low levels of DNA damage under 
normal growth conditions in vitro. In contrast, significant levels of radA and recA were 
detected in the untreated lexAInd- and were induced substantially upon exposure to MMC, 
consistent with reported data (Davis et al., 2002). This suggests that the RecA-ND pathway is 
functional and genes regulated entirely or partially by this mechanism are able to remediate 
the damage sustained by MMC treatment and possibly others types of DNA damage, 
consistent with observations from both the tolerance assay (Figure 3.8) and MIC 
determinations (Figure 3.9). Interestingly, upon treatment, there was a 2.3-fold 
upregulation of dnaE2 in the lexAInd- mutant which contradicts previous evidence that dnaE2 
is solely SOS regulated (Boshoff et al., 2003; Rand et al., 2003), and raises the possibility that 













Figure 3.10: Effect of lexAInd- on transcriptional responses of Mtb to DNA damage. dd-PCR 
analysis of dnaE2, radA and recA expression in Mtb Wt, lexAInd- and ΔdnaE2 after exposure 
to MMC (0.6 µg/ml for 6 hr), or untreated. Data are from a single experiment comprising 
three technical replicates. Error bars indicate standard deviations, calculated from the mean 




































Wt Wt + MMC lexAInd- lexAInd- +MMC ∆dnaE2 ∆dnaE2 +MMC
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3.5 Discussion 
The SOS response has an established role in remediation of DNA damage by various 
mechanisms, including cell cycle arrest, upregulation of detoxification proteins, DNA repair 
and damage tolerance (Butala et al., 2009). Therefore, recent evidence implicating a 
universal ROS-dependent mechanism in cell death in turn suggests that the SOS response 
should be considered part of the intrinsic resistome (Kohanski et al., 2007). Given the 
existence of an alternative DNA damage response in mycobacteria (Rand et al., 2003; 
Gamulin et al., 2004), corresponding Mtb and Msm lexAInd- (SOS-uninducible) mutants were 
generated to evaluate how the SOS pathway specifically contributes to antibiotic-mediated 
DNA damage tolerance and induced mutagenesis. This study is the first to report the 
construction of lexAInd- mutants in both Msm and Mtb. 
To investigate the role of the SOS response in damage tolerance, UV irradiation-induced 
mutagenesis and MMC sensitivity of the lexAInd- mutant were evaluated. UV irradiation of 
cellular DNA results primarily in cyclobutane pyrimidine dimers and pyrimidine (6–4) 
pyrimidine photoproducts, in which two adjacent pyrimidines are covalently linked (Janion 
2008). In addition, UV can also damage bases, producing cytosine hydrate and thymine 
glycol (Gorna et al., 2010). MMC damages DNA by specifically crosslinking the guanine 
nucleoside in the sequence 5’-CpG-3’ (Tomasz 1995). The SOS response induces specialized 
DNA polymerases that are able to catalyse translesion synthesis (TLS) across these sites of 
damage (Friedberg et al., 2002; Goodman 2002; Boshoff et al., 2004a). In Mtb, the DnaE2 
polymerase mediates TLS-catalysed DNA repair, and, importantly, has been shown to be 
regulated by the SOS mechanism in response to DNA damage (Boshoff et al., 2003). For 
these reasons, a ∆dnaE2 mutant was used a control throughout the study. Given the 
profound phenotypes associated with loss of DnaE2 function (Boshoff et al., 2003; Warner 
et al., 2010), and based on the fact that dnaE2 is included in the mycobacterial lexA/recA-
dependent SOS response, it was expected that the lexAInd- mutants might phenocopy the 
∆dnaE2 mutant in the induced mutagenesis assay. Indeed, both the Msm and Mtb lexAInd- 
mutants were severely impaired for UV-induced mutagenesis (Table 3.5 and Table 3.6, 
respectively). This might be attributable to loss of DnaE2 function, a conclusion that is 
supported by transcriptional analyses (Figure 3.10) which detected constant, low-level 
70 
dnaE2 expression in the Mtb lexAInd- mutant under standard conditions and elevated 
expression after MMC exposure.  
In contrast to UV-induced mutagenesis, differential abilities to tolerate MMC-mediated 
damage distinguished Mtb and Msm: whereas the Mtb lexAInd- mutant appeared only 2 log10 
more susceptible to MMC compared to Wt, the Msm lexAInd- mutants exhibited marked 
hypersensitivity as demonstrated by complete growth inhibition at the higher MMC 
concentration (Figure 3.8 and Figure 3.5, respectively). The observation that the phenotype 
of the Mtb mutant was mild relative to Msm suggests a role for an alternate mechanism of 
repair that is regulated in a RecA-ND manner. Although this was not tested in this study, it 
seems reasonable to speculate that this “alternate mechanism” is likely to be NER and/or 
HR as repair of inter-strand crosslinks is mediated by these mechanisms (Noll et al., 2006). 
Furthermore, NER-related genes uvrA, uvrB and uvrD2 are regulated by the RecA-ND 
mechanism, while RecA-mediated HR is co regulated by the SOS response as well as the 
RecA-ND mechanism (Gamulin et al., 2004; Smollett et al., 2012). Although both 
mechanisms have been identified in Msm (Gamulin et al., 2004) not nearly enough is known 
about the RecA-ND mechanism in this organism to explain the differential sensitivities of 
Msm and Mtb lexAInd- mutants to genotoxic agents. As expected, a minor (4-fold and 8-fold 
growth reduction) effect was observed on the DNA damage sensitivity to MMC of the 
∆dnaE2 mutant (Boshoff et al., 2003) However, abrogation of the SOS response in a lexAInd- 
mutant not only affects the expression of dnaE2, but also every other gene in the regulon – 
which includes proteins involved in DNA repair and cell cycle arrest. Therefore, the markedly 
increased sensitivity of the lexAInd- mutants compared to ∆dnaE2 is intuitive.  
As remediation of damaged DNA by SOS-regulated repair systems has been reported to 
mitigate the damaging effects of the antibiotics in E. coli (Kohanski et al., 2007), this study 
set out to evaluate the effect of an inactivated SOS response on antibiotic-mediated 
mycobacterial cell death. To this end, the lexAInd- mutants were exposed to antibiotics with 
various MoAs to examine the possibility that “a common mechanism” of cell death, 
regardless of the drug-target interaction, was prevalent in mycobacteria. With the existence 
of two damage response pathways in mycobacteria, it might equally be expected that 
different regulons respond to specific types of damage stress, especially given the limited 
overlap in gene composition, or that the regulons are redundant. Previous evidence 
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suggests that deletion of recA or key damage response components uvrB or dnaE2, results 
in hypersusceptibilty to some genotoxins (Boshoff et al., 2003; Rand et al., 2003; Darwin & 
Nathan 2005). Therefore, hypersensitivity of Msm lexAInd- mutants to DNA-damaging agents 
(MMC and quinolones) indicates a crucial role of the SOS response in remediation (and 
tolerance) of damage in this organism. In contrast, in Mtb the type of DNA damage appears 
to determine the response induced. For example, previous reports have shown differential 
SOS gene expression profiles in response to CIP and MMC (O'sullivan et al., 2008). In 
support of this, the Mtb lexAInd- mutant in this study displayed hypersensitivity to MMC, 
which damages DNA by crosslinking the guanine nucleoside, and moderate susceptibility to 
various fluoroquinolones, which cause lethal double-strand breaks (DSBs) by targeting the 
Type II DNA topoisomerase subunit, GyrA (Drlica et al., 2008). DSBs are repaired by NHEJ 
and HR, of which the LigD, Ku and RecBCD pathway components are fully functional in 
mycobacteria (Gorna et al., 2010). From transcriptional (Boshoff et al., 2003; Rand et al., 
2003; Smollett et al., 2012) and bioinformatic (Gamulin et al., 2004) analyses, none of these 
repair mechanisms appears to be subject to SOS or RecA-ND regulation in response to DNA 
damage. This suggests an alternative mechanism for repairing DSBs, possibly the single-
strand annealing (SSA) pathway (Gupta et al., 2011). Furthermore, equivalent 
susceptibilities were observed for the lexAInd- mutants and Wt to NOV, a coumarin which, 
unlike fluoroquinolones, targets the GyrB subunit without causing DSBs and therefore does 
not induce the SOS response (Boshoff et al., 2004a). This finding supports the notion that 
the type of DNA damage incurred determines the response induced. Moreover, the data 
also suggest that, unlike E. coli, inactivation of the SOS response does not sensitize 
mycobacteria to general antibiotic-mediated cell death.  
3.5.1 Evaluation of the RecA-ND mechanism 
Unlike Msm, an uncleavable LexA in Mtb does not increase susceptibility to 
fluoroquinolones which suggests that the RecA-ND mechanism is the major contributor to 
remediation of fluoroquinolone-induced damage, or that the RecA-ND response is able to 
compensate for loss of the canonical SOS. As ClgR has been proposed as the transcriptional 
regulator of the RecA-ND response (Wang et al., 2011), it might be proposed that 
inactivation or deletion of this gene in the lexAInd- background will generate a strain with a 
crippled ability to induce DNA-repair systems in response to DNA-damage. Application of a 
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ClgR-deficient mutant in the same assays described in this study might therefore allow the 
comprehensive evaluation of the proposed common mechanism of cell death in 
mycobacteria, as has been demonstrated in other organisms (Dwyer et al., 2007). 
A global analysis of the transcriptional profile of the Mtb lexAInd- mutant following treatment 
with various DNA damaging agents may provide some insight into the key players of the 
LexA-independent DNA repair mechanism. An alternative option for evaluating the RecA-ND 
mechanism would be the assessment of an Mtb lexA null mutant. In E. coli, a lexA null 
mutation causes lethal filamentation, which can be prevented by creating the lexA deletion 
in a sulA mutant background. SulA is lexA-regulated and is an inhibitor of cell division, 
resulting in long, filamentous structures (Drlica & Zhao 1997). A lexA deletion mutant has 
not been described in Mtb and may not be possible to construct as the gene has been 
predicted to be essential in vitro (Griffin et al. 2011). However, evidence suggests that 
Rv2719c, a potential regulator of cell division in Mtb may be a SulA-orthologue. In addition 
multiple parallels can be drawn between SulA and Rv2719c, including divergent 
transcription from lexA, induction by DNA damage, and regulation in a RecA-ND manner 
(Brooks et al., 2006; Chauhan et al., 2006). Therefore, it may be possible to delete Mtb’s 
lexA by deleting/ mutating the non-essential Rv2719c (Griffin et al., 2011). 
In summary, the DNA damage response in mycobacteria might be considered as comprising 
of damage tolerance (including error-prone TLS) and DNA repair (error-free) pathways 
(Figure 3.11). LexA plays a crucial role in damage tolerance via induction of DnaE2-mediated 
TLS. Overall, it is evident that DNA repair mechanisms differ between the mycobacterial 
species investigated in this study and, despite effectively inactivating the LexA-dependent 
SOS response in Msm and Mtb, these organisms are able to circumvent this pathway and 


























Figure 3.11: The DNA damage response in mycobacteria. A balance exists between error-
prone damage tolerance and error-free DNA repair to maintain genome integrity following 
DNA damage. The error-prone damage tolerance mechanism is mediated via translesion 
synthesis (TLS), specifically the SOS-regulated genes. High fidelity DNA repair is governed by 
base-excision repair (BER) and nucleotide excision repair (NER) mechanisms which comprise 
of RecA-ND-regulated genes. In addition, homolgous recombination (HR) and non-
homologous end-joining (NHEJ) repair mechanisms are co-regulated by the SOS response 
and RecA-ND response. The lexAInd- mutants generated in this study have an inactivated SOS 
response, but fully functional RecA-ND and co-regulated responses. Thus, error-prone 
damage tolerance (TLS) is compromised in these strains, but error-free DNA repair 

























Chapter 4: Construction and validation of auto-bioluminescent 




The identification of the molecular target of novel antimicrobials during the early stages of 
the drug discovery process is essential for progression of hit compounds or series towards a 
promising clinical candidate. The increasingly wide availability of next generation 
sequencing platforms has enabled WGS of bacteria to become high-throughput and 
affordable, and results are usually obtained promptly. In drug discovery, WGS is used 
extensively for target identification of hit compounds (Lechartier et al., 2014). Briefly, log-
phase cultures are plated onto solid agar media containing the hit compound at a range of 
concentrations that extend well above the minimum inhibitory concentration (MIC). The 
plates are incubated for 4-6 weeks, after which spontaneous drug-resistant mutants are 
isolated. Following DNA extraction, WGS is applied to identify single nucleotide 
polymorphisms (SNPs) or other mutations that confer resistance. The locus of resistance is 
often assumed to be the target gene/s (Ioerger et al., 2013); however, while in many cases 
the drug-target pair can be reliably interpreted from these results, in others, the resistance 
mutation might provide information regarding MoA without elucidating the direct target 
(especially where the compound functions as a pro-drug) (Manjunatha et al., 2006; Ioerger 
et al., 2013). There is a further category, too: that is, where resistance mutations map to 
“non-specific”’ cellular mechanisms, such as efflux (Ioerger et al., 2013). In addition to some 
of the difficulties associated with interpreting mutation data, related limitations to this 
technique include: (i) the fact that it is labour intensive and time consuming, especially 
where there are multiple hit compounds and active series, and, of course (ii) the risk of 
contamination as a consequence of the long incubation time required for resistant colonies 
to emerge on solid media.  
Cell-based reporter assays or bacterial biosensors offer a useful alternative for MoA studies 
of potent whole-cell active compounds (Alland et al., 2000; Boshoff et al., 2004b). Using this 
approach, multiple targets may be screened, enabling simultaneous identification of the 
pathway and/or target before extensive medicinal chemistry efforts are undertaken 
(Balganesh et al., 2008; Fan et al., 2014). At the inception of the current study, it was 
proposed that monitoring the response of antibiotics in real-time with high sensitivity might 
represent an efficient approach to be applied in addition to the traditional agar-based 
method for cases in which the target is novel and not readily resolved. Bioluminescence has 
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been profitably exploited to generate reporter mutants that can provide a rapid, sensitive 
and quantitative real-time readout of the mycobacterial response to antibiotics (Andreu et 
al., 2010; Andreu et al., 2012; Singh et al., 2014b). Therefore, the overall goal of this study 
was to generate novel bioluminescence-based reporters to detect the activation of the DNA 
damage response in Mtb.  
A remarkably diverse set of organisms possess the capacity for bioluminescence including 
bacteria, dinoflagellates, fungi, fish, insects, shrimp and squid. Luciferases are the enzymes 
that catalyse the bioluminescence reactions and in most cases, the substrates are 
designated luciferins (Meighen 1991). Bioluminescent bacteria are categorized into four 
genera: Photobacterium, Vibrio, Photorhabdus and Altermonas. The light-emitting reaction 
in bacteria involves the oxidation of reduced riboflavin phosphate (FMNH2) and a long-chain 
fatty aldehyde by luciferases with the concomitant emission of blue-green light at 490 nm. 
The bacterial Lux operon, luxCDABE, encodes the luciferase as well as the aldehyde 
substrate. Luciferase is a heterodimeric enzyme composed of α and β subunits encoded by 
luxA and luxB, respectively. The aldehyde for the bioluminescence reaction is synthesized by 
a multienzyme complex containing three proteins: a reductase (luxC), a transferase (luxD), 
and a synthetase (luxE) (Meighen 1991).  
4.2 Aims and objectives 
Studies in various organisms have utilized reporter assays, in particular green fluorescent 
protein (GFP)-based assays, for the determination of MoA (Hutter et al., 2004; Fan et al., 
2014). In mycobacteria, bioluminescence-based approaches have been used for the 
evaluation of drug and vaccine efficacy in vitro and in vivo (Andrew & Roberts 1993; Cooksey 
et al., 1993; Hickey et al., 1996; Al‐Attiyah et al., 2006; Andreu et al., 2010; Andreu et al., 
2012). Thus, reporter strains using pathway-specific promoters may provide a better 
alternative to currently available methods for MoA determination by allowing a limited 
screening of compounds interfering with only a particular metabolic pathway.  
This study aimed to utilize the Photorhabdus luminescens-derived luminescence system to 
exploit DNA metabolism as a target to identify novel genotoxins. The main advantage of this 
system is that exogenous luminescence substrate is not required. The specific objectives 
therefore included: 
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1. Introduction of the lux operon under the transcriptional control of Mtb promoters that 
are known to be DNA-damage-inducible, specifically recA and radA. 
2. Development and validation of an assay that measures the SOS-dependent induction of 
luminescence in a dose-dependent and time-dependent manner.  
3. Testing of novel compounds from an existing drug discovery platform in the DNA 
damage Lux assay. 
4.3 Materials and Methods 
4.3.1 Construction of the Lux reporter strains 
Andreu et al., 2010 previously reported the development of auto-luminescent mycobacteria 
in which exogenous substrate is not required to generate a luminescence signal. Their 
pMV306lux vector was purchased from Addgene Inc. and the putative promoter regions of 
Mtb H37Rv recA (Rv2737c), PrecA,  and radA (Rv3585), PradA, (481 bp and 487 bp, respectively) 
were synthesized by GeneWiz Inc, Sigma. Promoter replacement of Phsp60 was performed by 
ligating NotI/NcoI- digested PrecA or PradA with NotI/NcoI – digested pMV306lux to generate 
pMV306RecA and pMV306RadA, respectively (Table 4.1). Following selection on KAN, 
positive constructs were validated by restriction analysis. The constructs were then 
electroporated into Mtb H37Rv (Wt) and the Mtb lexAInd- backgrounds (described in Chapter 
3) to generate strains described in Table 4.2. 
Table 4.1: Plasmids used in this study 
 Phsp60 and PG13 are strong promoters derived from M. bovis BCG and M. marinum, respectively 
(Andreu et al., 2010). 
Plasmid Description  Reference/ Source 
pMV306hspLux 
Mycobacterial integrating vector, with luxAB 
under Phsp60 regulation and luxCDE under PG13 
regulation, KANR 
(Andreu et al., 
2010) 
pMV306radA 
Mycobacterial integrating vector, with luxAB 




Mycobacterial integrating vector, with luxAB 





Table 4.2: Strains used in this study 
Strain Description/ Genotype Reference/ Source 
Wt::precA-lux 
H37RvMA derivative carrying an integrating 
reporter vector in which the luxABCDE operon is 
fused downstream of the recA promoter, KANR 
This study 
Wt::pradA-lux 
H37RvMA derivative carrying an integrating 
reporter vector in which the luxABCDE operon is 
fused downstream of the radA promoter, KANR 
This study 
lexAInd-::precA-lux 
Mtb lexAInd- mutant carrying an integrating 
reporter vector in which the luxABCDE operon is 
fused downstream of the recA promoter, KANR 
This study 
lexAInd-::pradA-lux 
Mtb lexAInd- derivative carrying an integrating 
reporter vector in which the luxABCDE operon is 
fused downstream of the radA promoter, KANR 
This study 
 
4.3.2 Screening of transformants 
To test for bioluminescence, 10 randomly selected transformants on 7H10/OADC + KAN20 
were isolated and grown to an OD600 of 0.3 in 7H9/OADC +KAN
20. Cultures were treated 
with CIP or MMC at sub-MIC90 concentrations for 24 hr and aliquoted into 96-well microtitre 
plates for measurement of luminescence (described below). Positive isolates were sub-
cultured into larger volumes of media for archiving as freezer stocks. 
4.3.3 Antimicrobial agents 
RIF; INH; KAN; 5-FU; CIP; MMC; nitrofurazone (NFZ); 5-FU; 4-nitroquinoline-1-oxide (4NQO); 
D-cycloserine (DCS) and fusidic acid (FA) were purchased from Sigma Aldrich. For stock 
solutions, antimicrobials were all dissolved in the following solvents: INH; KAN; 5-FU and 
MMC in H2O, CIP in 0.1M hydrochloric acid and RIF; NFZ, 4NQO and FA in DMSO. 
Antimicrobial stock solutions were stored at 4°C  
4.3.4 Bioluminescence Assay 
The standard broth microdilution method (described in Chapter 2) was adopted to evaluate 
induction of DNA damage by various compounds. The protocol was adapted to include 
additional controls. The outermost wells of each 96-well microtitre plate (Greiner, white 
plates with clear lids– Lasec, P1PLA045W-000096ST) were used for controls: Media + cells 
(0% luminescence); Media only (contamination control) and Media + CIP (½ × MIC) + Cells 
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(100% luminescence) (Figure 4.1). All media used in this assay contained KAN (20 μg/ml) to 
maintain the pMV306 plasmid. Mtb Lux strains were grown to OD600 of 0.5 – 0.6. Cultures 
were diluted to an OD600 of 0.05 before inoculation of 96-well plates, such that final volume 
in each well was 100 μl. Plates were incubated in airtight containers at 37°C for 14 days. The 
FLUOstar OPTIMA (BMG LABTECH) plate reader was used to measure luminescence 
(recorded as Relative Luminescence Units, RLU) every 24 hr. The following settings were 
applied: measurement interval time for 1.0 s after a positioning delay of 0.2 s; top optic was 
used with an empty lens emission filter, gain adjustment of 4095 and plates were shaken for 









Figure 4.1: Bioluminescence assay plate layout. The outer wells were used for controls - 
Column 1 for the minimum luminescence control (media +cells), Column 12 for maximum 
luminescence (media + cells +CIP at ½ × MIC90) and Row A and H for media only. Three 
antimicrobials were tested per plate, each in duplicate (A, B and C). Antimicrobials were 
added to Column 2 and serially diluted, 2-fold, to Row 11.  
4.3.4 Data analysis 
Raw RLU data were provided by the MARS Data Analysis Software. All RLUs were normalized 
to the 100% luminescence sample to generate a fold-induction value for each treatment 
time-point. Values were then adjusted to take into account the 0% luminescence control 
resulting in the final % luminescence value. As each antimicrobial was tested in duplicate, 
the final % luminescence values were averaged and plotted as 3D surface charts (Microsoft 














































4.4.1 Mtb autoluminescent DNA damage reporter strains 
Andreu et al., 2010 previously reported the development of auto-luminescent 
mycobacterial mutants in which exogenous substrate is not required to generate the 
luminescence signal. Promoter replacement of Phsp60 in their pMV306hsp+LuxAB+G13+CDE 
vector (referred to as pMV306lux in this study) with the putative promoter regions of 
Rv2737c (recA) or Rv3585 (radA) resulted in two new DNA damage-responsive 
bioluminescent reporters: pMV306recA and pMV306radA (Figure 4.2). The constructs were 
confirmed by restriction analysis and electroporated into Mtb Wt and Mtb lexAInd- 
backgrounds (described in Chapter 3) to generate the strains Wt::precA-lux, Wt::pradA-lux, 













Figure 4.2: Construction of vectors for DNA damage-inducible autoluminescence. (A) 
pMV306lux::Phsp60 drives the expression of the luciferases (encoded by the luxAB genes), 
and the strong promoter PG13 drives the expression of the long-chain aldehyde substrate 
(encoded by luxCDE). The vector also carries a KANR marker for maintenance and selection 
(Andreu et al., 2010). Using the enzymes NcoI and NotI, Phsp60 was replaced with either the 
481 bp upstream region of recA (B) or the 487 bp upstream region of radA (C) to generate 





4.4.2 Assay development and validation 
RecA is the hallmark component of the DNA damage response in the majority of organisms 
and is induced by known DNA inhibitors in Mtb (Chapter 3). In addition, the same DNA 
inhibitors have been shown to induce expression of radA, which is regulated by the RecA-ND 
response (Boshoff et al., 2003; Rand et al., 2003; Smollett et al., 2012) (Chapter 3, Figure 
3.2). Therefore, the recA and radA promoters were selected to identify inhibitors of DNA 
metabolism that result in genotoxic stress. The broth microdilution method was used to 
measure the induction of luminescence in a concentration-dependent manner at 24 hr 
intervals. Initially, 10 randomly selected transformants from each strain were selected and 
tested for induction of luminescence (described in section 4.3.2). The transformation 
efficiency varied between the different promoter constructs as well as between the two 
strains (Table 4.3). As no transformants were isolated for the lexAInd- strains, only the Wt 
stains were selected for further assay development. The inability to isolate lexAInd-::lux 
strains may be attributable to the low transformation efficiency in general. As the Lux 
constructs were only electroporated once in the lexAInd- background and only 10 putative 
transformants were initially selected for screening of luminescence, electroporations will be 
repeated and considerably more colonies need to be screened in the future. From a 
research interest, characterization of the Wt Lux strains was of priority and due to time 
constraints the lexAInd-::lux strains were re-prioritized to future work. 
Table 4.3: Transformation efficiency of Lux constructs in Mtb H37Rv (Wt) and the Mtb 
lexAInd- backgrounds 






7 2 0 0 
Number of transformants out of 10 that displayed induction upon exposure to CIP or MMC, as a 
measure of luminescence.  
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Evaluation of the raw data highlighted a significant difference in the level of induction of the 
two promoters in response to CIP, as indicated by the ~38-fold higher induction of the recA 






Figure 4.3: Raw relative luminescence unit (RLU) data of Wt::lux strains in response to 
ciprofloxacin (CIP). Column 1 indicates the minimum luminescence (green) and Column 12 
indicates the maximum luminescence (blue). CIP was serially diluted, 2-fold from column 2 
to column 11, in duplicate. Induction of recA (A) was significantly higher than induction of 
radA (B), as indicated by the RLUs.  
 
CIP was selected as the maximum luminescence control as preliminary data indicated 
immediate (within 24 hr) and sustained (up to 12 d) induction (Figure 4.4). During initial 
screening of transformants, CIP was not the most potent DNA-damage inducer, therefore it 
was selected as the representative threshold inducer, to which compounds that induce 
significantly more or less could be compared. With such a large amount of data generated 
for each antimicrobial compound, representation of the normalized data presented a 
challenge. After some experimentation with visualization styles, 3-D plots were selected, as 
they incorporated concentration, time and RLU in a single image. The “bird’s eye view” 
representation (Figure 4.4A) was ultimately chosen as the standard format for presenting 
data in this study.  
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Figure 4.4: Kinetics of Wt::precA-lux induction in response to ciprofloxacin (CIP). A bird’s eye view (A) and 3-D surface (B) representation of 
recA induction in response to CIP, as a measure of luminescence (reported as % luminescence, normalized to CIP) at 10 different 
concentrations over a 12-day period. The colour gradient indicates low to no induction (-100 – 49%, blue), induction (50 – 149%, green), and 
elevated induction (150 – 300%, yellow). Data were normalized to CIP’s maximum % luminescence, such that CIP induction only ever reached a 
maximum of 100% luminescence. CIP induced recA within 24 hr and throughout the time course up to day 12 .The MIC90 is indicated by an 







































































To validate the assay, a panel of established DNA inhibitors including CIP, MMC, NFZ and 
4NQO, was selected and tested against Wt::precA-lux and Wt::pradA-lux. The luminescence 
signal detected in response to all antimicrobials was assayed with both strains, and 
normalized to CIP as the DNA-damage control. That is, CIP was assigned the maximum of 
100% luminescence (Figure 4.4). MMC exhibited the greatest induction of all antimicrobials 
assayed. Significant induction was observed within 24 hr of exposure, which then decreased 
slightly over the following 4 days, and then increased exponentially between days 7 and 12, 
with maximum induction observed at days 10 and 11 (Figure 4.5A). Interestingly, NFZ, a 
DNA-damaging agent that forms adducts at the N2 -position of deoxyguanosine (dG) (Jarosz 
et al., 2007), appeared to induce expression only after day 6. This suggests that NFZ might 
be required to accumulate to a certain level before sufficient genotoxic stress is achieved to 
trigger induction of Mtb recA (Figure 4.5B). In addition, 4NQO, a DNA-damaging agent that 
also forms dG lesions carrying adducts at the N2 position (Jarosz et al., 2007), exhibited 
moderate induction initially, which then tapered off by day 7 (Figure 4.5C). This suggests 
that this antimicrobial doesn’t induce significant genotoxic stress in Mtb, or that exposure to 
4NQO induces the DNA damage response by a mechanism alternate to recA; the latter 

































































































































Figure 4.5: Kinetics of Wt::precA-lux induction in response to known DNA-damaging 
agents. Induction of recA as a measure of luminescence (reported as % luminescence) in 
response to MMC (A), NFZ (B), and 4NQO (C). Each antimicrobial was tested at 10 different 
concentrations over a 12-day period. Data were normalized to CIP, which represents a true 
inducer. MMC strongly induced recA, NFZ displayed a delayed response, while 4NQO only 
exhibited a mild initial response. The MIC90 of each drug is indicated by the asterisk (). 
Data are representative of at least 3 biological replicates. 
 
In general, radA was induced similarly to recA by the same DNA damaging agents (Figure 
4.6). MMC exhibited the greatest induction of all antimicrobials assayed, as with Wt::precA-
lux. However, exponential induction was observed from 24 hr of exposure, reaching a 
maximum at day 7, and followed by a gradual decline to day 12 (Figure 4.6B). Again, 
significant induction by NFZ was delayed until day 5, followed by a gradual decrease from 
day 8 (Figure 4.6C). 4NQO exhibited moderate induction initially, as observed for Wt::precA-
lux, and then decreased between days 5 and 7. Unlike Wt::precA-lux, the radA reporter 
exhibited moderate induction at  the lower concentrations (≥ ¼ × MIC90) of drug up to day 
12 (Figure 4.6D). This indicates that the RecA-ND mechanism may play a role in remediation 





































































































































































Figure 4.6: Kinetics of Wt::pradA-lux induction in response to known DNA-damaging 
agents. Induction of radA as a measure of luminescence (reported as % luminescence) in 
response to CIP (A), MMC (B), NFZ (C) and 4NQO (D). Each antimicrobial was tested at 10 
different concentrations over a 12-day period. Data were normalized to CIP, which 
represents a true inducer. MMC strongly induced radA, NFZ displayd a delayed response 
and 4NQO exhibited a mild initial response. The MIC90 of each drug is indicated by the 
asterisk (). Data are representative of at least 3 biological replicates. 
 
To confirm that induction of luminescence was restricted to DNA-damaging agents, various 
antimicrobials of different classes were tested that were not expected to induce a DNA 
damage response, (Figure 4.7). These included INH (cell wall inhibitor), RIF (transcriptional 
inhibitor), FA (protein synthesis inhibitor) and DCS (cell wall inhibitor which is cidal against 
mycobacteria), all of which exhibited low to no (< 20% to < 0%, raw data not shown) 
induction (Figure 4.7, and Wt::pradA-lux, data not shown). This is an important result since 
it indicates that antibiotic-mediated cell death (or stasis) does not cause an increase in 
luminescence signal, and so eliminates the possibility that cell death (or stasis) might result 
in the erroneous assignment of an unknown compound as a “genotoxin”. That is, it suggests 




































































































































































Figure 4.7: Kinetics of Wt::precA-lux induction in response to antimicrobials with various 
MoAs . Induction of recA as a measure of luminescence (reported as % luminescence) in 
response to INH (A), RIF (B), FA (C) and DCS (D). Each antimicrobial was tested at 10 
different concentrations over a 12-day period. Data were normalized to CIP, which 
represents a true inducer. All four antimicrobials tested displayed low to no induction of 
recA. The MIC90 of each drug is indicated by the asterisk (). Data are representative of at 
least 3 biological replicates. 
 
In addition, the kinetic profile of 5-FU, an antimicrobial agent with a complex MoA (Singh et 
al., 2015), was evaluated (Figure 4.8). Interestingly, delayed induction was observed 
between days 3 and 7 and at day 6 for Wt::precA-lux and Wt::pradA-lux, respectively. In 
addition, recA is induced significantly more than radA, suggesting that the LexA/RecA-
dependent SOS pathway may be the governing response to 5-FU-induce DNA damage. The 
MoA of 5-FU was recently elucidated through an extended and multi-pronged approach 
which established that DNA damage is a minor component of a complex mechanism that is 
dominated by cell wall inhibition (Singh et al., 2015). It is encouraging that the results of the 
luminescence assay suggest the possibility that a simple (and rapid) bioreporter might have 


































Figure 4.8: Kinetics in response to 5-FU. Induction of recA (A) and radA (B) as a measure of 
luminescence in response to 5-FU at 10 different concentrations over a 12-day period. Data 
were normalized to CIP. In both strains, the response to treatment was delayed, although 
recA was induced significantly more than radA. The MIC90 is indicated by the asterisk (). 













































































4.4.3 Use of auto-bioluminescent reporter strains as screening tools 
Following validation of the auto-luminescent reporter strains, we selected two novel 
compounds of unknown MoA for assessment in the assays. The compounds, which had 
been synthesized as part of a medicinal chemistry programme at UCT, possessed structural 
and physicochemical properties suggesting the potential to act as DNA intercalators. The 
results of the assay suggest, however, that the compounds are not genotoxic: no to low 
luminescence (< 20% to < 0%, raw data not shown) was observed throughout the 12 day 





































































































































































Figure 4.9: Kinetics in response to novel antimicrobials. Induction of recA (A and C) and 
radA (B and D) as a measure of luminescence in response to 2 novel compounds at 10 
different concentrations over a 12-day period Data were normalized to CIP, which 
represents a true inducer. The kinetic profiles suggested the neither compound induced the 
DNA damage response. The MIC90 of each drug is indicated by the asterisk (). Data are 
representative of at least 3 biological replicates. 
 
4.5 Discussion 
The success of whole-cell screening in TB drug discovery is evident in the fact that all novel 
chemical entities discovered in the last 10 years have been identified through this approach 
(Lechartier et al., 2014). Critically, whole-cell screening circumvents the risk (substantial in 
the case of Mtb which has a notoriously complex and impermeable cell wall; (Jackson 
2014)]) of failing to convert (biochemical) target inhibition into (bacterial) growth inhibition 
(or death) - something which the target-driven approach is unable to achieve. On the other 
hand, an obvious drawback of the whole-cell screening approach is that it does not provide 
information regarding the MoA and possible host toxicity, both of which are especially 
relevant to TB chemotherapy given the prolonged duration of treatment (Balganesh et al., 
2008).  
The identification of the molecular target/ MoA is also critical in prioritizing and optimizing 
lead chemical series during early stage drug discovery. The advances in WGS technology 
have augmented the whole-cell screening approach by enabling more rapid target 
identification through the identification of resistance-conferring mutations (Lechartier et al., 
2014). However, mechanisms of resistance do not always provide immediate insight in to 
the mechanism of action (Grzegorzewicz et al., 2012; Singh et al., 2014c). In addition, and 
from a practical perspective, the long generation time of Mtb (~24 hr) impedes the drug 
discovery process as extended incubation periods on solid agar medium (5 – 6 weeks for 
resistant mutants) are required (Sharma et al., 2014). Reporter strains are an alternative 
approach that provides a rapid, sensitive real-time readout of the response to antibiotics. 
In this study, auto-luminescent DNA-damage reporter strains that allow for the 
identification of compounds whose MoA includes the induction of genotoxic stress in Mtb, 
were developed and validated. In addition, by exploiting the bacterial lux system, a 
bioreporter was developed, that enables the real-time monitoring and elucidation of the 
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kinetics of the DNA-damage response in a concentration- and time-dependent manner over 
~12 days. In general, recA was induced to higher levels than radA (Figure 4.3), suggesting a 
differential promoter strength between recA and radA, consistent with dd-PCR data 
(Chapter 3, Figure 3.10), whereby recA expression is higher than radA, both in uninduced 
and MMC-induced conditions, in Wt. As expression of recA is driven off two different 
promoters (Gopaul et al., 2003), induced by the SOS and RecA-ND mechanisms respectively, 
the higher recA expression suggests an additive effect of both responses. Fusion of the lux 
operon to various genes encoding proteins that are emerging as attractive drug targets may 
provide more insight into the dynamics of the Mtb damage response. These could include 
targets such as DnaE2, that is regulated by the SOS mechanism, or the clgR transcriptional 
regulator involved in regulation of not only the Clp protease system, but also the RecA-ND 
mechanism (Boshoff et al., 2003; Wang et al., 2011; McGillivray et al., 2014). 
For antimicrobials identified as “true” DNA-damaging agents (CIP, MMC and NFZ), significant 
induction (100% or more) was observed at sub-inhibitory concentrations in both reporter 
strains. Therefore, for future incorporation of these reporters into a drug discovery 
programme – either as frontline HTS of novel compounds or as part of the downstream SAR 
and target identification process – it is suggested that MMC and INH be included as the 
positive and negative controls, respectively. 
There are important parameters to be considered with this assay including the growth 
phase and concentration of cells used to inoculate the 96-well microtitre plate, as has been 
reported in previously (Andreu et al., 2010). An inverse correlation between luminescence 
and cell density was observed, and  is likely attributable to a decrease in metabolic activity 
as cells approach stationary phase, and a concomitant decrease in the availability of the 
FMNH2 and ATP substrates which are essential for Lux activity (Andreu et al., 2010). This 
feature may limit the use of these strains to screen novel compounds against non- or slowly-
replicating Mtb. In addition, we observed loss of auto-luminescence at the passage 6 – 
passage 8 generations, following successive rounds of propagation. This could be 
attributable to the presence of luxD, the expression of which has been suggested to be toxic 
to mycobacteria (Andreu et al., 2010). For this reason, precautions were taken during the 
development of this assay to minimize the potential toxic effects of the reporter itself.  
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The response to 4NQO is interesting in that, like NFZ, it forms adducts at the N2 -position of 
deoxyguanosine (dG) (Jarosz et al., 2007), yet its kinetic profile, both recA and radA was 
different from NFZ. TLS across the sites of damaged DNA has been shown to bypass certain 
N2-dG adducts efficiently and accurately in E. coli. In Mtb, the SOS response-mediate 
polymerase DnaE2 mediates TLS, therefore these agents are expected to induce recA, but 
not radA. In the case of 4NQO the absence of recA induction suggests that significant 
genotoxic stress may not accumulate with this agent, as not much is known about 4NQO 
penetration into the Mtb cell. Alternatively, it is possible that by normalizing data to CIP, the 
threshold set to identify “true” inducers may be too high. Continued optimization of this 
assay may lend some insight into these questions. 
The apparent delayed response to 5-FU suggested by the reporter assays is of particular 
interest. Recently, the complex MoA of 5-FU was elucidated, and shown to involve the 
accumulation of the downstream metabolites of 5-FU which exert toxic effects on various 
cellular processes including cell envelope biogenesis, RNA and DNA synthesis and 
thymidylate synthesis (Singh et al., 2014c). Importantly, this accumulation was shown to 
occur following extended periods of 5-FU treatment. Analysis of the Lux strains treated with 
5-FU show comparable data, in which recA and radA are induced between days 3 and 7 
(recA) and at day 6 (radA), respectively. This suggests the possibility for a reporter-based, 
real-time assay to give early indication of complex (and late) MoAs. Furthermore, the 
delayed induction of 5-FU and its MoA has been validated with a Wt::pini-lux reporter strain 
that measures changes to cell wall metabolism (Moosa, Warner, unpublished).  
In general, for quantitative gene expression experiments, Mtb is treated ≤ 24 hr with an 
antimicrobial agent. However, if such conditions were imposed on NFZ-treated cultures, the 
results may have been misleading. Thus, the insight into the time-dependent effects of 
antimicrobial action provided by the kinetic profiles generated with the Lux assay may 
provide further information to aid the design of currently available protocols. In addition, it 
might enable the inclusion of “late genotoxicity” (or equivalent stress on an essential 
metabolic pathway) as a desirable criterion in compound triage algorithms. 
As the bioluminescent reaction requires FMNH2 and production of endogenous reaction 
substrate, only viable cells are expected to luminesce (Sharma et al., 2014). Viability of cells 
in this assay is therefore expected to affect the RLU readout in a concentration-dependent 
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manner. This is consistent with the kinetic data, in which maximum luminescence tended to 
correlate with compound MIC90. Nevertheless, the observation that exposure to a cidal (and 
lytic) compound such as D-cycloserine did not result in detectable autoluminescence 
suggests that the assay is robust against false positive assignments of genotoxicity. 
Correlation of CFU values with luminescence should be explored as a rapid tool to allow 
cidal and static antimicrobials to be differentiated. Furthermore expression of recA and radA 
needs to be validated with protein expression levels.  
In conclusion, autobioluminescent reporter strains are useful tools for drug discovery 
platforms as they allow for the identification of pathway-specific inhibitors with high 
sensitivity. The lexAInd-::lux strains are actively being pursued, as the majority of genes in 
Mtb are regulated by an alternate, RecA-ND mechanism (Rand et al., 2003; Gamulin et al., 
2004; Smollett et al., 2012). As both recA and radA are expected to be fully inducible in the 
strains reported in this study, the attraction lies in the possibility of identifying novel 





Chapter 5: The identification of novel efflux pump inhibitors by in 




Efflux pumps are membrane-associated proteins or transporter complexes that actively 
extrude toxic compounds, including antimicrobials. Since their initial report in E. coli (Ball et 
al., 1980; McMurry et al., 1980), the significance of efflux-mediated drug resistance has 
been described in a wide range of organisms, and for almost all antimicrobial classes 
(Zechini & Versace 2009; Szumowski et al., 2013). Efflux pumps may select for a single 
substrate or may be non-selective, conferring a multidrug resistant phenotype (Zechini & 
Versace 2009).  
Gram-positive bacteria encode efflux pumps belonging to the MFS (major facilitator 
superfamily), ABC (ATP-binding cassette), SMR (small multidrug resistance) and the 
multidrug and toxic compound extrusion (MATE) families (Li & Nikaido 2009). 
Mycobacterium tuberculosis (Mtb) is unique in that transporters belonging to the MATE 
family have not been identified (Da Silva et al., 2011b). However, the Mtb genome encodes 
13 putative RND (resistance-nodulation division)-type transporters which are usually 
associated with Gram-negative bacteria. These are designated MmpL proteins 
(mycobacterial membrane proteins, large) (Cole et al., 1998; Li & Nikaido 2009). In fact, Mtb 
has the largest representation of RND-type transporters compared to all prokaryotes 
surveyed, and these are believed to play a significant role in the extrusion of lipids and other 
cell envelope constituents (Sarathy et al., 2012). MDR efflux pumps have significant clinical 
implications; MFS efflux pumps are associated with fluoroquinolone (Rv1634, Rv1258c, 
Rv2686c, Rv2687c) and RIF resistance (RIFR) (Rv1258c); the RND-like pump mmpl7 is 
associated with INH resistance (INHR); and the ABC efflux pump, DrrAB, is involved in 
resistance to Tet, ETH, macrolides, aminoglycosides, and chloramphenicol (Zechini & 
Versace 2009). 
Current strategies used to counteract efflux-mediated resistance include either the 
development of new antimicrobials that overcome the efflux systems (Lee et al., 2014) or 
the development and implementation of efflux pump inhibitors (EPIs) or ffflux inhibitors 
(EIs) (Amaral et al., 2007; Sharma et al., 2010; Adams et al., 2014). Different approaches 
include improving the structural design of existing antimicrobials to reduce/avoid their 
efflux (Lee et al., 2014), or blocking pump function (Amaral et al., 2007; Zechini & Versace 
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2009; Adams et al., 2014). The recent discovery of a new class of antituberculosis agents 
called spectinamides that circumvent intrinsic efflux pump-mediated resistance, provides an 
elegant example of the clever use of medicinal chemistry in evading an innate biological 
function as part of the continued search for novel antimicrobials (Lee et al., 2014). The 
development of EPIs provides an alternative approach to improve clinical efficacy of 
currently available antimicrobials, as a single EPI may be active against MDR pumps and can 
be used as adjunct therapy (Zechini & Versace 2009). The physiological role of efflux 
systems is complex and is associated with bacterial metabolism, physiology, and 
pathogenicity. Therefore inhibition of efflux systems may directly affect bacterial virulence 
in vivo (Zechini & Versace 2009) despite the fact that efflux pumps are generally not 
included among essential gene lists in vitro (Sassetti et al., 2003; Griffin et al., 2011). 
Previously, it was shown that Mtb develops efflux pump-mediated tolerance to both first-
line anti-TB antibiotics, RIF and INH, during macrophage residence (Adams et al., 2011). 
Subsequent work then demonstrated that macrophage-induced RIF tolerance could be 
reversed with the addition of the EPI verapamil (VER) (Adams et al., 2011). Interestingly, 
macrophage-induced INH tolerance was not inhibited with this EPI. Consequently, the efflux 
pump Rv1258c, which has been implicated in spectinomycin resistance (SPCR), was found to 
mediate tolerance of RIF, but not INH (Adams et al., 2011; Lee et al., 2014). EPIs have also 
been shown to increase the antibiotic susceptibilities of MDR Mtb strains in vitro, and co-
administration of VER, INH, RIF and pyrazinamide (PZA) to mice infected with MDR-TB 
strains reduced pulmonary bacillary loads (Louw et al., 2011). The same study provided 
evidence that susceptibility of a RIF mono-resistant Mtb strain to one antimicrobial (OFX) 
was reduced when exposed to another antimicrobial (RIF). However, upon introduction of 
the EPIs, VER or reserpine (RES), susceptibility to both RIF and OFX was restored. More 
recent work has evaluated the effect of EPIs on macrophage-induced tolerance to second 
and third-line anti-TB drugs used to treat MDR- and XDR-TB. Interestingly, macrophage-
induced tolerance developed broadly, including to the newer antimicrobials MOX, PA-824 
and BDQ. The addition of VER reduced tolerance to MOX and BDQ, while the VER 
metabolite, norverapamil (NOR), and various derivatives significantly reduced tolerance to 
RIF and INH (Adams et al., 2014). Thus, given the mounting evidence implicating the clinical 
significance of efflux pumps, the utilization of EPIs has become increasingly attractive as 
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part of the current effort to develop novel regimens for the eradication of drug resistant 
strains of TB. 
5.2 Aims and objectives 
Antimicrobial therapy with an EPI is, in effect, a form of combination therapy. Therefore, to 
maximize the synergy between the two agents, it is imperative that novel EPI’s are tested in 
combination from the initial in vitro stages of development. With the increasing 
attractiveness of EPIs, there is likely to be a significant increase in the number of novel EPIs 
that will require rapid and reliable analyses in in vitro and ex vivo assays.  
In this context, this study aimed to evaluate the interactions between pairwise 
combinations of selected antibiotics and efflux pump inhibitors (EPIs) in vitro and ex vivo, 
and to identify a novel VER-analogue with improved efficacy against Mtb. The specific 
objectives included: 
1. The development and validation of an in vitro assay in which novel EPIs can be tested in 
combination with current/ novel antimicrobials.  
2. The identification and development of candidate EPI(s) by ex vivo evaluation. 
 
5.3 Materials and Methods 
5.3.1 Antimicrobial agents and efflux pump inhibitors (EPIs) 
RIF, MOX, spectinomycin (SPC) and VER were purchased from Sigma Aldrich. BDQ was 
purchased from Asclepia MedChem Solutions (Belgium, www.asclepia.com), PA-824 was 
kindly provided by Dr. Helena. I. Boshoff (NIAID, NIH, Bethesda, Maryland, USA) and VER-
analogues were provided as lyophilized pellets with data sheets including the mass and 
molecular weight of each compound (Singh, Kumar, Chibale, Department of Chemistry, 
UCT). For stock solutions, antimicrobials were all dissolved in the following solvents: MOX, 
SPC and VER in nuclease-free water (Qiagen); RIF, BDQ, PA-824 and analogues in DMSO 
(Sigma Aldrich). VER and analogues were prepared at 100mM stock concentrations. All stock 
solutions were stored at -20°C.  
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5.3.2 Checkerboard synergy assay 
The fractional inhibitory concentration index (FICI) was determined in a 96-well plate format 
using an adaptation of the broth microdilution method, as described in Chapter 2, in which 
the antimicrobial agent (compound A) and the EPI (compound B), were 2-fold serially 
diluted across and down the plate, respectively (Ramon-Garcia et al., 2011). Briefly, 50 µl 
media was added to every well in the plate, except Row 1 and 12 (minimum and maximum 
inhibition controls, respectively). Additional 50 µl media was added to row B3-B11, and 
column 2A-2H, and 100 µl to well B2. Antimicrobials were prepared at concentrations 400x 
MIC and EPIs at a concentration of 10mM. Two µl of EPI (compound B) was added to every 
well, B3-B11 and serially diluted (50 µl) to H (50 µl was discarded from H). 4µl of the same 
EPI (compound B) was added to well B2 and serially diluted (100 µl) down column 2 (100 µl 
was discarded form 2H). Finally, 2 µl of antimicrobial agent (compound A) was added to 
every well in row 3 and serially diluted (50 µl) from row 2 to row 3 until row 11 (50 µl was 
discarded from 11). Mtb culture was added to every well as described previously in Chapter 
2. RIF at a final concentration of 0.2 µM (50 × MIC) was used for the maximum inhibition 
control, media only served as the minimum inhibition control and well A2 serves as a “no 
drug” control (Figure 6.1). The microtitre plates were stored in secondary containers and 
incubated at 37°C for 14 days, after which 10 µl of alamar blue (Celtic Molecular 
Diagnostics) was added to each well. After 24 hr of incubation, fluorescence was measured 
with a Fluostar Optima microplate reader (BMG Labtech) using excitation and emission 
wavelengths of 485 and 508 nm, respectively. The lowest concentration of drug that 












Figure 5.1: Checkerboard synergy assay plate layout in 96-well microtitre plates. Column 1 
contains minimum inhibition control (no drug/EPI) and column 12 contains maximum 
inhibition control (rifampicin). The drug (compound A) was 2-fold serially diluted across the 
plate (column 3 – 11) and the EPI (compound B) was 2-fold serially diluted down the plate 
(row B – H). Well A2 serves as the “no drug” control. 
The fractional inhibitory concentration (FIC) for each compound was calculated as follows: 
FICA (MIC90 of compound “A” in the presence of compound “B”)/ (MIC90 of compound “A” 
alone). Similarly, the FICB for compound “B” was calculated. Synergy curves were plotted 
using Microsoft Excel 2010. The FICI was calculated as FICA plus FICB. Synergy was defined by 
FICI values of ≤ 0.5, antagonism by FICI values of ≥ 4.0, and no interaction by FICI values 
from 0.5 to 4.0 according to the recommended classification (Odds 2003). Checkerboard 
synergy assays for each reported combination were performed in triplicate. 
 
5.3.3 Macrophage cytotoxicity assay 
Frozen stocks of macrophage THP-1 cells (ATCC TIB-202) were thawed in RPMI medium 
(Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS). Cells were passaged only 
5 times and maintained without antibiotics. Four thousand cells per well were allowed to 
differentiate in RPMI medium containing 200nM phorbol myristate acetate (PMA), and 10% 
FBS and left to adhere to the 96-well flat-bottom microtiter plate (PGRE655180, Lasec, SA) 
for 24 hr. Two-fold serial dilutions of EPIs were performed in RPMI medium containing 10% 
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medium was removed from the wells and 100 µl of EPI-drug-containing RPMI medium was 
added. Cells were incubated in the presence of the EPI-drug for 72 hr, after which 20 µl of 
alamar blue (Celtic Molecular Diagnostics) was added to each well. After 24 hr of incubation, 
fluorescence was measured with a Fluostar Optima microplate reader (BMG Labtech) using 
excitation and emission wavelengths of 485 and 508 nm, respectively. The IC20 was 
considered as the lowest concentration of compound that inhibited the ≥ 20% viability of 
the macrophages. EPIs with an in vitro FIC smaller than the macrophage toxicity 
concentration were analyzed further in ex vivo checkerboard synergy assays with RIF or BDQ 
(as described by the in vitro checkerboard synergy assay). Raw relative fluorescent units 
(RFU) data was provided by the MARS Data Analysis Software. All RFUs were normalized to 
the maximum and minimum fluorescent controls. Data were plotted as 3D surface charts 
(Microsoft Excel 2010). 
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5.4 Results  
5.4.1 Development and validation of the checkerboard synergy assay for in vitro 
evaluation of EPI efficacy.  
VER is a well-characterized compound and is often chosen as the preferred EPI (Louw et al., 
2011; Balganesh et al., 2012a; Adams et al., 2014). Adams et al., 2011 reported that 
macrophage-induced RIF tolerance was reversed with the addition of this EPI. Therefore, 
the checkerboard synergy assay was selected to measure the interaction between RIF and 
VER. To confirm the reported potentiation of RIF efficacy in the presence of VER, the 
fractional inhibitory concentration (FIC) of each compound was determined in the in vitro 









Figure 5.2: A concave FIC curve indicates a synergistic relationship between VER and RIF. 
The closest point to the intersection of the axes (zero) is the most effective combination for 
inhibiting bacterial growth, as indicated by the FICI. The concentrations (µM) of each 
compound required to achieve this effect are indicated. Data are representative of at least 3 


















Overexpression of the tap-like efflux pump, Rv1258c, is associated with RIF resistance 
(Siddiqi et al., 2004; Sharma et al., 2010). The ability of VER to sensitize a Rv1258c-
overexpressing strain to RIF has driven clinical interest in synergism between the two 
compounds. In addition, deletion of this efflux pump has recently been reported to reduce 
intrinsic SPC resistance (Ramon-Garcia et al., 2011; Lee et al., 2014). In the absence of the 
overexpressing strain, the checkerboard synergy assay was applied to VER and SPC. The 
compounds exhibited a significant synergistic interaction, thereby validating the specificity 
of this assay by recapitulating previous observations (Lee et al., 2014) that elimination of 









Figure 5.3: A concave FIC curve indicates a synergistic relationship between VER and SPC. 
The closest point to the intersection of the axes (zero) is the most effective combination for 
inhibiting bacterial growth, as indicated by the FICI. The concentrations (µM) of each 





















5.4.2 Application of the checkerboard assay in evaluating novel VER analogues. 
In total, 37 different VER analogues were synthesized by colleagues in the Department of 
Chemistry, UCT, and screened in vitro in combination with RIF against Mtb H37Rv. RIF was 
selected as the antimicrobial as it is a frontline anti-TB drug, whereas SPC has not been 
established for use in the treatment of TB. The checkerboard synergy assay was utilized to 
evaluate the effect of 21 VER derivatives on the susceptibility of Mtb to RIF (Singh et al., 
2014a). The commercially available VER-analogue, NOR, was synthesized under the ID 
MKV1/7a. The majority of the analogues were inactive (MIC90 ≥ 500 μM) on their own and 
either had no effect on susceptibility to RIF, or reduced the MIC90 by 2-fold, which was 
considered insignificant for this study (Table 5.1, structures in appendix 3). Furthermore, 
these inactive compounds exhibited additive/no effect profiles, as indicated by the FICI. 
However, analogues MKV4, KSV10, MKV8 and MKV9 (Table. 5.2) reduced the MIC90 of RIF by 
4-fold, with MKV4 exhibiting the only synergistic interaction, indicated by the FICI of 0.3. 
Although KSV21, also reduced the MIC90 of RIF by 4-fold, it displayed the highest FICI of 1.25 
and was therefore not included for further investigation. Furthermore, these data suggested 
that fold reduction in RIF MIC90, does not necessarily correlate with FICI.  
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Table 5.1: In vitro combinatorial evaluation of 21 VER-analogues with RIF against Mtb† 
Analogue ID/ 
Published ID** 










MKV1/7a 500 31.25 0.004 2 0.56 
MKV2/7b 1000 NC 0.008 NC 1.0 
MKV3/7c 500 250 0.008 NC 0.78 
MKV4/7d 1000 31.25 0.002 4 0.3 
MKV5/7e 125 31.25 0.004 2 0.75 
MKV11/12a > 1000 NC 0.008 NC ND 
MKV10/12b > 1000 NC 0.008 NC ND 
KSV5/14a 1000 500 0.004 2 1.0 
KSV4/14b 1000 500 0.008 NC 1.5 
KSV11/14c 1000 NC 0.008 NC 1.5 
KSV8/14d 500 250 0.004 2 1.0 
KSV14/14e 250 125 0.004 2 1.0 
KSV7/14f 250 62.5 0.004 2 0.75 
KSV10/14g 250 125 0.002 4 0.75 
KSV12/14h 62.5 31.25 0.008 NC 1.5 
MKV6/17a 1000 500 0.004 2 1.0 
MKV7/17b 1000 500 0.004 2 1.0 
MKV8/17c 1000 250 0.002 4 0.75 
MKV9/17d 500 125 0.002 4 0.75 
KSV19/17e 125 62.5 0.004 2 1.0 
KSV21/17f 62.5 62.5 0.002 4 1.25 
 RIF MIC90 against Mtb is 0.008 µM; NC-No change; ND-Not Done as FIC of EPI could not be 
determined. 
†Data are representative of 3 biological replicates. 
**Published ID (Singh et al., 2014a) 
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Table 5.3: Structures of VER and analogues. Exploratory SAR of VER included replacement of 
the methyl group on the tertiary nitrogen with a benzyl group (MKV4); replacement of the 
isopropyl group at the stereogenic carbon centre with an ethyl (MKV8) or propyl (MKV9) 
group; and replacement of the aminoethyl aromatic group with a heterocyclic group 














Preliminary combinatorial evaluation with the remaining 16 analogues indicated that the 
majority were inactive (MIC90 > 1000 μM) on their own and either had no effect on 
susceptibility to RIF, or reduced the MIC90 by only 2-fold (Table 5.4, structures in appendix 
3). However, 3 potential candidates (KSV43, KSV44 and MKVB1) were identified that 
exhibited a synergistic interaction with RIF, with KSV44 reducing the MIC90 of RIF by 16-fold 
(Singh, Kumar, Chibale, unpublished). The analogues HEPI-04X and HEPI-06 are hybrid 
compounds in which the dimethoxyphenyl group of VER has been replaced with a 
chemosensitizer. This structural modification may explain the potent anti-mycobacterial 
activity of these compounds on their own compared to VER (MIC90 of 500 µM) and all other 
analogues tested in this study. 















Table 5.4: In vitro combinatorial evaluation of 16 VER-analogues with RIF against Mtb† 
Analogue ID 










HEPI-04X < 15.625 NC NC NC ND 
HEPI-06 < 15.625 NC NC NC ND 
KSV-43 250 31.25 0.001 4 0.4 
KSV-44 250 62.5 0.00025 16 0.3 
MKV-R1 1000 500 0.001 4 0.8 
MKV-R2 250 125 0.002 2 0.6 
MKV-B1 500 125 0.001 4 0.5 
MKV-B2 > 1000 NC NC NC ND 
MKV-B3 > 1000 NC NC NC ND 
MKV-B4 > 1000 NC NC NC ND 
MKV-B5 > 1000 NC NC NC ND 
MKV-B6 > 1000 62.5 0.002 2 ND 
MKV-B8 500 250 0.002 2 1.0 
MKV-B9 > 1000 NC NC NC ND 
MKV-B10 > 1000 62.5 0.002 2 ND 
MKV-B11 > 1000 31.25 0.002 2 ND 
 RIF MIC90 against Mtb is 0.004 µM, NC-No change; ND-Not Done as FIC of EPI could not be 
determined. 
†Data are from a single experiment only, owing to limited compound availability 
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5.4.3 Validation of VER-potentiation of newer anti-TB drugs. 
During the course of this study, VER was reported to reduce tolerance to BDQ, MOX, and 
PA-824 (Adams et al., 2014). In vitro data from this study partially concurred with these 
reports, in that activity of BDQ, but not MOX, was potentiated by VER (Figure 6.3A and B). 
Moreover, the combination of VER and PA-824 tended towards antagonistic: the shape of 
the FIC curve was convex, although the FICI of 2.5 did not fulfil the strict requirements for 
classification of the combination as truly antagonistic (Odds 2003). This VER/PA-824 
interaction, as well as the additive effect of VER and MOX, is in contrast to recent reports 
(Adams et al., 2014), and suggests that reported EPI-potentiation of MOX and PA-824 may 















Figure 5.4: Interactions between newer antimicrobials and VER. The concave curve of VER 
vs. BDQ indicates a synergistic effect (A). VER vs. MOX indicates no interaction/ additive 
effect (B). The convex curve of VER vs. PA-824 suggests antagonism (C). The closest point to 
the intersection of the axes (zero) is the most effective combination for achieving the 
interaction (synergism/ additive/ antagonism), as indicated by the FICI. The concentrations 
(µM) of each compound required to achieve this effect are indicated. Data are 





















































5.4.4 Identification of novel EPIs with in vitro efficacy against newer anti-TB drugs. 
Since several VER-analogues showed comparable activity relative to VER in terms of their 
potentiation of RIF efficacy against Mtb (Table 5.5), a select panel of analogues was chosen 
for further investigation in combination with newer anti-TB drugs (Table 6.3). MKV4 
significantly reduced the MIC90 of BDQ by 16-fold, with a synergistic interaction, FICI 0.38, 
slightly worse than that of VER and BDQ, FICI 0.25. Interestingly, MKV9 reduced the MIC90 of 
BDQ by 32-fold, but displayed the same synergistic interaction as VER. In general, VER and 
its analogues did not synergize with MOX; instead, the interaction was additive. 
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 Data are representative of 3 biological replicates 
  
Compound ID Analogue 
MIC90 (µM) 











VER 500 0.14 8 0.25 0.14 4 1.0 
NOR 500 0.28 4 0.38 0.07 8 0.75 
MKV4 1000 0.07 16 0.38 0.14 2 1.0 
MKV8 1000 0.14 8 0.25 0.035 8 0.49 
MKV9 500 0.035 32 0.25 0.035 8 0.49 
KSV10 500 0.28 4 0.38 0.14 2 0.75 
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5.4.5 Identification of a novel, non-cytotoxic EPI. 
The mammalian cell toxicity profiles of the EPIs were evaluated against the monocyte-like 
cell line, THP-1. Compounds were initially tested for cytotoxic effects individually and MKV4 
was found to be 2-fold less toxic than the parent EPI, VER (Table 5.6). As MKV4 was the only 
EPI with an in vitro FIC lower than the THP-1 IC20, it was selected for further analysis in ex 
vivo checkerboard synergy assays (Ramón-García et al., 2011) with RIF or BDQ, and 
compared to the cytotoxicity profiles of VER and NOR (Figure 5.5). RIF and BDQ were 
selected as they demonstrated the most significant in vitro interactions with MKV4. When 
compared to the cytotoxicity profile on its own (Table 5.6), MKV4 was less cytotoxic in 
combination with RIF (IC20 ≤ 500 μM) and remained the same in combination with BDQ (IC20 
< 250 μM). However, MKV4 was the least cytotoxic EPI compared to VER (IC20 < 62.5 μM) 
and NOR, which was the most cytotoxic (IC20 < 62.5 μM). In general, MKV4 was 4-fold less 
toxic in combination with RIF, than VER with RIF and 2-fold less toxic in combination with 
BDQ, than VER and BDQ. 





NOR < 62.5 
MKV4 250 
MKV8 < 62.5 
MKV9 < 62.5 
KSV10 < 62.5 
RIF 0.4 
BDQ 56.2 
MOX < 90 
RIF + VER < 62.5 
BDQ + NOR < 62.5 
RIF + NOR < 62.5 
BDQ +NOR < 62.5 
RIF + MKV4 ≤ 500 
BDQ + MKV4 < 250 μM 
IC20 – Inhibitory concentration, the lowest concentration of compound at which ≥ 20% THP-1 

















































































































































































Figure 5.5: The analogue MKV4 is less toxic to THP-1 cells than its parent compound VER. 3D surface plots depicting % cytotoxicity of EPIs in 
combination with antimicrobials. The percentage (%) cytotoxicity of VER (A), NOR (C) and MKV4 (E) in combination with either RIF or BDQ. VER 
was cytotoxic in combination with either antimicrobial at concentrations < 62.5 μM (A – B). NOR was cytotoxic at all concentrations tested and 
was the most cytotoxic EPI (IC20 > 62.5 μM) (C –D). In general, MKV4 displayed the least cytotoxic profile, and was not toxic at concentrations ≤ 
500 μM when used in combination with RIF and was not toxic at concentrations < 250 μM when used in combination with BDQ (E – F). Data 

















































































Efflux pumps contribute directly to intrinsic resistance, and indirectly by providing a 
“window” for the emergence of high-level resistance through drug-target mutations (high-
level, adaptive resistance mechanisms). In addition, overexpression of – or mutations within 
– efflux pumps may result in antimicrobial resistance, as the drug is extruded more 
efficiently and the intracellular concentration of the drug decreases to sub-inhibitory 
concentrations, thus inducing genetic resistance (Figure 5.6) (Piddock 2006; Zechini & 
Versace 2009). 
The activity of efflux pumps can either be inhibited indirectly, by targeting the driving force 
of the mechanism, or directly, by blocking pump activity by competitive or non-competitive 
binding of substrates (Zechini & Versace 2009). The inhibition of the proton motive force 
dependent pump involves direct interaction with the pump and a reduction in the trans-
membrane potential. Compounds that affect the energy level of the bacterial membrane 
such as carbonylcyanide m-chlorophenylhydrazone (CCCP), valinomycin and dinitrophenol 
(DNP) are known as efflux inhibitors (EIs). The peptidomimetic phenylalaninearginyl β-
naphthylamide (PAβN) is the most widely studied compound in the second category, known 
as efflux pump inhibitors (EPIs), and is itself a substrate of efflux pumps, acting as a 
competitive inhibitor. The identification and development of EPIs is an interesting approach 
to retard the emergence of drug resistance by increasing drug efficacy. To date, VER, a 
calcium channel blocker long in clinical use, is the most promising inhibitor and is often 
chosen as the preferred inhibitor over other candidates such as piperine and reserpine 
(Balganesh et al., 2012a; Adams et al., 2014). VER can potentiate the efficacy of multiple 
antimicrobials in vitro, inhibit tolerance ex vivo, has well-characterized pharmacokinetic 
profiles in dog and rabbit models, and is significantly concentrated in the lung (Schwartz et 
al., 1986; Solans et al., 2000; Louw et al., 2011; Adams et al., 2014; Gupta et al., 2014). Thus, 
the discovery and development of novel VER analogues with improved safety, tolerability 
and the mechanism to enhance the efficacy of multiple antimicrobials is of significant 
importance. 
An in vitro assay was developed based on the checkerboard synergy assay in order to 
identify novel VER analogues. If the EPI also reduces the viability of Mtb, the observed effect 
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may be due to mechanisms other than efflux inhibition, depending on the concentration 
used, which in turn, may result in the EPI itself as a substrate of the intended efflux pump 
(Viveiros et al., 2012). Therefore, the aim was to find compounds which are relatively 
inactive on their own but, when applied in combination with an antimicrobial, have the 
ability to potentiate efficacy. In addition, a variation of the same assay was used in ex vivo 
assessments to identify compounds that were not cytotoxic at the concentrations required 

























Figure 5.6: Adjunct therapy with efflux pump inhibitors (EPIs) perpetuates clearance of 
infection and prevents the emergence of drug resistance and persistence. Following 
infection, macrophages are recruited to phagocytose the bacilli. Both macrophage residence 
and antimicrobial therapy induce the upregulation of efflux pumps which render the bacilli 
tolerant to antibiotic treatment (Adams et al., 2011). This results in low-level phenotypic 
antibiotic resistance, a phenomenon known as persistence. In addition, the active extrusion 
decreases the intracellular concentration of the antibiotics to sub-inhibitory levels, driving 
the emergence of target chromosomal mutations and subsequently accelerates the 
progression to high-level genetic resistance (Da Silva et al., 2011b; Viveiros et al., 2012). In 
addition, external factors that impact the emergence of resistant Mtb strains include 
treatment irregularities such as insufficient dosage, inadequate prescription and/or patient 
non-adherence. The use of EPI adjunct therapy has the potential to eliminate the 
emergence of antibiotic-tolerant populations, subsequent genetically resistant populations 
and possibly salvage control over treatment irregularities (Viveiros et al., 2012; Adams et al., 































Using this approach, a candidate VER analogue (designated MKV4) was identified with 
equivalent in vitro synergistic effects to VER when used in combination with various 
antimicrobials. Although MKV4 was only 2-fold less toxic than VER against THP-1 cells on its 
own, in combination with RIF, it was 4-fold less toxic. Considering that potential 
antimicrobial therapy with an EPI is a form of combination therapy, this observation may be 
of some significance. 
The in vivo profiles of this candidate EPI remain to be determined. In addition, as this study 
is currently in progress, further investigation of MKV-B2, KSV43 and KSV44, which displayed 
attractive FICI values in combination with RIF, is underway. It is hoped that a continuous 
supply of compounds in the EPI pipeline may yield a successful clinical candidate. In 
addition, evaluation of candidates against a RIF mono-resistant Mtb H37Rv strain may 









Bacterial thiols function both as redox buffer systems and as substrates in detoxification 
pathways to maintain the cell’s intracellular reducing environment and protect against 
damage by xenobiotics (oxidizing agents, alkylating agents and antibiotics). Mycothiol (MSH) 
is the major thiol in the genus Mycobacterium and is present in the cell in significant 
amounts (Newton et al., 2008). The essentiality of MSH in Mtb remains controversial, mainly 
due to conflicting reports on the capacity of the bacillus to tolerate deletion of  specific 
genes (mshA in particular) involved in MSH biosynthesis (Sareen et al., 2003; Vilchèze et al., 
2008; Griffin et al., 2011). Regardless of this controversy, MSH has an established role in 
tolerance of oxidative and other stressed conditions, and contributes to the survival of 
bacilli within macrophages. MSH functions in the intrinsic resistance of Mtb by serving as a 
substrate for enzymes involved in antibiotic detoxification (Rawat & Av‐Gay 2007; 
Jothivasan & Hamilton 2008; Newton et al., 2008). Decreased levels of MSH have been 
shown to increase susceptibility of Mtb to RIF, STR and ERY (Table 6.1) (Hayward et al., 
2004). However, resistance to  INH and ethionamide (ETH) (both pro-drugs that share a 
common target, inhA) has also been associated with decreased MSH levels (Vilchèze et al., 
2011).  
The defined role of MSH in antibiotic detoxification identifies this pathway as integral to 
Mtb’s intrinsic resistome. Enzymes involved in MSH-dependent detoxification and/or 
enzymes involved in MSH biosynthesis contribute to this pathway. MSH-dependent enzymes 
include Mtr (NADPH-dependent flavoenzyme), Mrx1 (oxidoreductase), MST (mycothiol-S-
transferase) and Mca (metalloenzyme). Mtr (mycothione reductase) is an MSH disulphide 
reductase and is a key component of the cellular thiol redox buffer system in Mtb 
responsible for maintaining MSH in its reduced form via reduction of mycothione (MSSM) 
(Patel & Blanchard 2001). MSH is critically dependent on functional Mtr, as it is only capable 
of protecting mycobacteria against oxidative damage in its reduced form. Thus, loss of Mtr is 
expected to reduce MSH levels and thereby sensitize mycobacteria to ROS and RNS. Studies 
utilizing various techniques (RNA antisense, transposon mutagenesis and a combination of 
high-density mutagenesis and deep sequencing) have identified mtr as essential in vitro 
(Sassetti et al., 2003; Hayward et al., 2004; Griffin et al., 2011). Upon oxidation of MSH, 
MSSM is formed, but it is rapidly reduced to MSH in an NADPH-dependent manner by MTR, 
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thereby maintaining the intracellular MSH/MSSM ratio that is essential in preserving a 
reduced intracellular environment crucial for various biological processes (Hayward et al., 
2004). In addition, there exists a well-established MSH-dependent pathway for the 
detoxification of electrophilic xenobiotics (such as INH) in which the mycothiol-S-transferase 
(MST) enzyme and the metalloenzyme, Mca, are central components. Following entry into 
the cell, MST catalyzes the conjugation of the electrophilic xenobiotic to the free thiol group 
on MSH, yielding mycothiol-S-conjugates which are then cleaved by an S-conjugate amidase 
(Mca) to form a hydrophobic mercapturic acid which is released from the cell and the 
intermediate 1-O-(2-amino-2-deoxy-α-D-glucopyranosyl)-D-myo-inositol (GlcN-Ins), which is 
recycled back into the MSH biosynthetic pathway. In Msm, MST has reasonable activity with 
MMC as a substrate, suggesting a possible role for MST in the detoxification of antibiotics; 
consistent with this notion, increased sensitivity to RIF and ERY has been observed where 
mca is mutated (Hernick 2013).  
The MSH biosynthetic pathway is complex: MSH is synthesized from glucose-6-phosphate in 
six steps by the enzymes myo-inositol-1-phosphate synthase (MIPS; inositol synthase), 
MshA (glycosyl transferase), MshA2 (phosphatase), MshB (deacetylase), MshC (ligase) and 
MshD (synthase) (Hernick 2013). In Mtb, mshC is the only essential gene confirmed by 
transposon mutagenesis (Sassetti et al., 2003; Newton et al., 2005; Griffin et al., 2011).   
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Table 6.1: Summary of enzymes involved in mycothiol biosynthesis and phenotypes of genetic mutants. Comparative analyses of the five 
mycothiol biosynthetic genes and the effect of mutations/ deletions corresponding with each enzyme in either Msm or Mtb.  
 




G32D Mutation: Slower cell 
growth; sensitivity to ROS 
and RNS; alkylating agents; 
RIF, STR and ERY; resistance to 
INH and ETH 
Essentiality initially 
controversial: ∆mshA only 
viable in presence of catalase 
- INH and ETH co-resistance; 
in vitro essential 
Msm: < 0.01 µmol/g  
Mtb: undetectable levels 
 
(Buchmeier et al., 2006; 
Vilchèze et al., 2008; 
Griffin et al., 2011; Xu et 
al., 2011) 
(mshA2) MSH phosphatase Identity of gene encoding MshA2 remains unknown: Possibly impC (Rv3137)- essential 
(Movahedzadeh et al., 
2010; Griffin et al., 2011) 
mshB MSH deacetylase 
∆mshB -  compensated by 
MCA; slight resistance to INH 
and resistance to ETH;  
sensitivity to RIF 
∆mshB : log-phase cultures 
display  sensitivity to RIF 
 
Msm: ~10% of Wt levels 
Mtb: ~20% Wt levels 
(exponential growth) 
Increases 20-fold – higher 
than Wt levels (stationary 
phase) 
(Buchmeier et al., 2006; Xu 
et al., 2011) 
mshC MSH ligase 
Transposon insertion: 
sensitivity to alkylating and 
oxidizing agents; RIF and ERY; 
resistance to INH and ETA 
Essential 
Msm: <0.004 µmol/g dry 
weight 
 
(Rawat et al., 2002; Sareen 
et al., 2003; Vilchèze et al., 
2008; Xu et al., 2011) 
mshD MSH synthase 
Transposon insertion: altered 
thiol content; No effect on 
sensitivity to oxidizing agents 
or antibiotic resistance – 
compensated by MCA and 
MTR 
∆mshD:  sensitivity to 
hydrogen peroxide. Essential 
for growth in macrophages 
 
Msm: 0.12 µmol/g dry 
weight 
Mtb: ~1% Wt levels 
(exponential phase) 
Increase 8-fold (stationary 
phase) 
(Newton et al., 2005; Xu et 
al., 2011) 
*Wt levels of MSH are 10 ± 3 µmol/g dry weight in Msm, 10 – 20 nmol/109 cells for exponential-phase Mtb and 30 – 40 nmol/109 cells for stationary-phase 
Mtb (Newton et al., 2008). 
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6.2 Aims and objectives  
Inducible gene expression systems offer a useful approach for studying gene function and 
have been validated as tools to identify inhibitors of prioritized drug targets in Mtb (Ehrt et 
al., 2005; Gandotra et al., 2007). These systems allow the expression of a single target gene 
to be silenced, either by addition (Tet-OFF system) or by removal of tetracycline (Tet-ON 
system). 
As the efficacy of various antimicrobials is mitigated by MSH, the overall aim of this study 
was to generate an Mtb mutant in which MSH production could be conditionally depleted, 
sensitizing Mtb to certain antimicrobials. The specific objectives included: 
1. Generation of an Mtb mutant strain in which expression of mshC is regulated using a 
conditional expression system based on the tetracycline (Tet)-regulatable promoter 
element (Ehrt et al., 2005). 
2. Phenotypic and transcriptional validation of anhydrotetracycline (ATC)-dependent 
regulation of mshC. 
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6.3 Materials and Methods 
6.3.1 Mycobacterial strains, plasmids, and probes 
The strains used in this study are detailed in Table 6.2, plasmids are listed in Table 3.3, 
and primers in Table 6.4. 
Table 6.2: Strains used in this study 
Strain Description/ Genotype Reference/ Source 
Mtb   
H37RvMA (Wt) 
Virulent reference laboratory strain of Mtb 
ATCC 27294 
(Ioerger et al., 
2010) 
mshC-SCO 
H37RvMA derivative in which expression of 




Derivative of mshC-SCO harbouring pGMCK3-




Derivative of mshC-SCO harbouring pGMCK3-




Derivative of mshC-SCO harbouring pGMCK3-
0X38-T10 integrated at the L5 attB site, HYGR, 
KANR 
This study 
 Strains were generated but not characterized. 
  
127 
Table 6.3: Plasmids used in this study 
Plasmid Description Reference/ Source 
pSE100 
E. coli-Mycobacterium shuttle vector 
carrying Pmyc1tetO; HYG
R 
(Guo et al., 2007) 
pGMCK3-0X21-T10 
L5-based integration vector harbouring 
modified Psmyc-tetR; KANR 
(Klotzsche et al., 
2009) 
pGMCK3-0X38-T10 
L5-based integration vector harbouring 
modified Psmyc-tetR; KANR 
(Klotzsche et al., 
2009) 
pGMCK3-0X38-T28 
L5-based integration vector harbouring 
modified Psmyc-tetR r1.7; KANR 
(Klotzsche et al., 
2009) 
pGA-0XP15-intL5 
Suicide vector harbouring L5 integrase; 
AMPR 
(Klotzsche et al., 
2009) 
pmshC-SCO 
Suicide plasmid for generating mshC-SCO. 
pSE100 derivative in which the 
mycobacterial origin of replication was 
replaced by the first 714 bp of mshC, HYGR 
This study 
pTT1B::Gm 
Derivative of pTT1B, a Tweety-based 
integration vector; GENR 
(Abrahams et al., 
2012) 
pTTB::2129c 
pTT1B::Gm derivative harbouring Rv2129c; 
used for genetic complementation of mshC 
conditional mutant; GENR 
This study 
 Plasmid was generated but not used. 
 
Table 6.4: Primers used in this study 
Name Sequence 5’-3’ Comments  
mshCF GCATGCTTTAGAGTCGAGGAC 725 bp; 5’ end of mshC including the 
ribosomal binding site with 
introduced SphI and NotI sites, 
respectively; probe for southern blot 
mshCR GCGGCCGCTCAGACATGCCA 
Rv2131F TCTAGAGGGCCAAAGGG 307 bp; amplification of the 5’-region 
flanking mshC for construction of 
p2129c-Comp; introduced XbaI site in 
forward primer 
Rv2131_SOER AACGTACCGCCGCGCCGGGTC 
Rv2129_SOEF CCGGCGCGGCGGTACGTTTTC 934 bp; amplification of the 3’-region 
flanking mshC for construction of 
pTTB::2129c; introduced XbaI site in 
reverse primer 
Rv2129R TCTAGAGAATCGAGCGCG 
Restriction sites are underlined. 
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6.3.2 Construction of plasmids 
The integrative plasmid pmshC-SCO was constructed by PCR amplification of the ribosomal 
binding site and first 705 bp of mshC. Following restriction with SphI and NotI, the PCR 
product was cloned into pSE100 (Guo et al., 2007). 
For the complementation construct, pTTB::2129c, PCR amplification of the operon encoding 
mshC, but possessing an in-frame deletion of the target gene, was performed by the splice-
by-overlap-extension method (Ho et al., 1989). Briefly, in the first-round of PCR, two 
fragments flanking mshC were amplified. These fragments contained overlapping extensions 
and were combined, following purification, and used as a template in a second-round of 
PCR. The full length PCR product was digested with XbaI and cloned into XbaI-linearized 
pTT1B::Gm. 
6.3.3 Construction and genotypic characterization of promoter-replacement mutants 
The suicide plasmid pmshC-SCO was electroporated into Mtb H37RvMA, and transformants 
selected on 7H10/OADC agar plates containing HYG. Following incubation at 37 °C for 21 
days, colonies were isolated and grown to mid-logarithmic phase in 7H9/OADC liquid 
medium, cells harvested and genomic DNA isolated. The site-specificity of homologous 
recombination was confirmed by Southern blot analysis. To generate conditional mutants, 
plasmids pGMCK3-0X21-T10, pGMCK3-0X38-T10 and pGMCK3-0X38-T28, were co-
electroporated with pGA0XP15-intL5 in order to facilitate transient integrase expression into 
the SCO recombinants (Klotzsche et al., 2009). In addition, the complementation construct 
pTTB::2129c, was co-electroporated with the TetR-expressing plasmids. Transformants were 
selected on 7H10/OADC agar plates supplemented with HYG, KAN, and GEN, where 
required, with or without ATC (500 ng/ml). To avoid the inactivation of inducer, all cultures 
containing ATC were grown in the dark and exposure to light was minimized. 
6.3.4 ATC-dependent growth in liquid and on solid media 
To assess the effect of ATC on growth in liquid medium, cells were inoculated at a final 
OD600 of 0.005 into 20 ml 7H9/OADC containing the appropriate antibiotic (unsupplemented 
– Wt; HYG – mshC-SCO; and HYG, KAN – mshC Tet-OFF) and/or ATC: Wt and mshC-SCO – 
500 ng/ml and mshC Tet-OFF – 500, 250, 125 and 62.5 ng/ml. Cultures were incubated at 
37°C and OD600 was measured every 24 hr. 
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To assess the growth effect on solid medium, Wt, mshc-SCO and mshC Tet-OFF cultures 
were initially grown in 7H9/OADC medium to an OD600 of 0.5 then serially diluted 2-fold, 
before spotting on 7H10/OADC agar plates on the following combinations: unsupplemented 
– Wt, HYG – mshC-SCO and HYG, KAN – mshC Tet-OFF in addition to 7H10/OADC agar 
supplemented with ATC at 500, 250, 125 and 62.5 ng/ml. 
6.3.5 Antimicrobial agents 
Anhydrotetracycline (ATC); RIF; INH; STR; plumbagin (PMB) and oxyphenbutazone (OPB) 
were purchased from Sigma Aldrich. For stock solutions, antimicrobials were all dissolved in 
the following solvents: ATC in 70% ethanol; INH and STR in nuclease-free water (Qiagen) and 
RIF, PMB and OPB in DMSO. Antimicrobial stock solutions were stored at 4°C, with the 
exceptions of PMB and OPB that were stored at -20°C. 
6.3.6 Checkerboard synergy assay 
To evaluate ATC-dependent depletion, the checkerboard assay was adopted, as described 
above (Chapter 5). The antimicrobial agent (compound A) and ATC (compound B), were 2-
fold serially diluted across and down the plate, respectively (Ramon-Garcia et al., 2011). The 
starting concentrations of antimicrobials were prepared to 4 × MIC and ATC at a 
concentration 100 µg/ml.  
6.3.7 Quantitative RT-PCR of Mtb genes in response to ATC treatment 
Primers and probes used for droplet digital PCR (dd-PCR; BioRad) were designed using the 
Primer3 programme (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) (Table 
6.5). All primers were designed to amplify DNA fragments internal to the coding sequence of 
the relevant genes with a standard annealing temperature (60°C). 
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Table 6.5: Primers and probes used for dd-PCR in this study 









 TaqMan minor groove binder (MGB) probes were either labeled with 6- carboxyfluorescein (FAM) 




6.4.1 Disruption of Mtb mycothiol production by conditional regulation of mshC. 
To generate a conditional mutant of Mtb, a two-step method was used in which the native 
promoter of the target gene, Rv2130c (mshC), was first replaced with a Tet-regulatable 
promoter element by SCO homologous recombination. Thereafter, plasmids expressing Tet 
repressors (TetRs) were introduced as per established protocols (Abrahams et al., 2012). 
The integrity of the mshC-SCO was confirmed by Southern blot (Figure 6.1), after which 
plasmids harbouring either the forward (TetR) or reverse (rev-TetR) tetracycline repressor 
was used to generate conditional mutants in the Tet-ON (intermediate and strong) and Tet-
OFF configurations, respectively. 
When generating promoter-replacement mutants the chromosomal arrangement of the 
gene under investigation is key. Expression of co-regulated genes downstream of the target 
gene may be affected by placement of the Tet-promoter upstream of a gene present in an 
operon (Abrahams et al., 2012). According to TBDB (http://www.tbdb.org/), the Pearson 
Correlation Coefficient for the gene pair Rv2129c – Rv2130c (mshC) is 0.23974, which 
indicates a relatively insignificant chance that the genes constitute an operon (strongest 
positive correlation is 1.0). As Rv2129c is characterized as a non-essential hypothetical 
protein, is not significantly operonic with mshC, a complementation strain was omitted from 
























Figure 6.1: Schematic overview of the construction of Mtb mshC conditional mutants. (A) 
The pSE100 suicide plasmid habouring the 5’ region of mshC (including the ribosomal 
binding site and first 704 bp of mshC). (B) Following homologous recombination, the SCO 
strain was generated in which mshC is under the control of the ATC-regulatable promoter-
operator element, Pmyc1tetO. Subsequently, plasmids expressing TetRs were introduced into 
the SCO to generate conditional mutants in the Tet-ON (intermediate and strong) and Tet-
OFF configurations. (C) Genotypic verification of the mshC-SCO strain. Schematic illustration 
of the Southern blot strategy in which NcoI-XbaI digested genomic DNA hybridized to the 
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 6.4.2 Growth of the mshC conditional mutant cannot be modulated with ATC. 
In the Tet-OFF strain, reverse TetR binds to the tet operator (tetO) in the presence of ATC, 
repressing gene transcription (Klotzsche et al., 2009). The Tet-OFF strain is advantageous 
under certain conditions, such as hypoxia, when ATC cannot be easily depleted (Klotzsche et 
al., 2009). Following electroporation of the SCO with the Tet repressors (TetR), only the 
mshC Tet-OFF strain was selected for further characterization. The mutant was evaluated 
for ATC-dependent growth in liquid and on solid media. In liquid medium, a slight growth 
impairment of mshC Tet-OFF was observed in the presence of ATC at all concentrations 
tested (500, 250, 125 and 62.5 ng/ml), compared to growth in the absence of ATC (Figure 
6.2). Furthermore, mshC Tet-OFF (with and without ATC) exhibited a definite growth defect 
when compared to the control strains, Wt Mtb and mshC-SCO. The presence of ATC slightly 
reduced the growth of Wt, and the mshC-SCO (with and without ATC) grew at a slightly, but 
reproducibly, slower rate than Wt, although it could not be considered significant. On solid 
medium, the Tet-OFF strain exhibited equivalent growth kinetics in the absence and 
presence of ATC at all concentrations tested (Figure 6.3). In addition, the mutant strain grew 
comparably to the control strains, Wt and mshC-SCO, both with and without ATC. 
Importantly, the concentrations of ATC used in this study did not have a growth effect on 













Figure 6.2: The mshC Tet-OFF strain is not ATC-regulated in liquid medium. Growth of 
mshC Tet-OFF in 7H9 medium in the absence or presence of ATC at the indicated 
concentrations. The parental Wt and mshC-SCO strains were included as controls. Data are 
from a representative experiment performed in duplicate. The numbers in parentheses 









Figure 6.3: The mshC Tet-OFF strain does not display ATC-dependent growth regulation on 
solid medium. Strains were grown to mid-log phase and equivalent numbers of cells spotted 
on plates containing no ATC or ATC at concentrations of 500 ng/ml or 250 ng/ml. Cultures 
were also spotted onto plates containing ATC at 125 ng/ml and 62.5 ng/ml (data not 



































6.4.3 Phenotypic characterization of mshC Tet-OFF. 
 
In general, depletion or elimination of mycothiol (MSH) is associated with increased 
sensitivity to RIF, STR and ERY as well as oxidizing and alkylating agents. In addition, 
resistance to INH and ETH has been reported in these mutants (summarized in Table 6.1). To 
determine the potential impact of mshC depletion on antibiotic susceptibilty, the mshC Tet-
OFF mutant was exposed to a subset of these agents and the MIC compared to that 
observed for Wt. As depletion of a target transcript has been shown to be ATC 
concentration-dependent (Abrahams et al., 2012), the checkerboard synergy assay was 
adopted to examine the effect of a range of concentrations of both ATC and the 
antimicrobial agent against mshC Tet-OFF and Wt. There was no change in susceptibility to 
the antimycobacterial agents RIF, STR and INH in the mshC Tet-OFF strain in the presence of 
ATC. This suggests that MSH was not depleted sufficiently to render the cells hypersensitive 
to antibiotics (Table 6.6).  
Table 6.6: The susceptibility of Wt and mshC Tet-OFF to antimycobacterial agents: A 
checkerboard synergy assay was used to evaluate the effect of ATC on susceptibility to RIF, 









 NC-No change; Data are from a representative experiment performed in triplicate. 
  
 Wt Tet-OFF 
RIF 0.004 0.004 
RIF + ATC NC NC 
STR 0.625 0.625 
STR + ATC NC NC 
INH 0.08 0.08 
INH + ATC NC NC 
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Furthermore, susceptibility to the oxidizing agents, plumbagin (PMB) and oxyphenbutazone 
(OPB), was evaluated. Interestingly, the mshC Tet-OFF strain displayed increased 
susceptibility to PMB with increasing concentrations of ATC (Figure 6.4). However an 
equivalent effect was observed against Wt, suggesting the synergistic effect of ATC and PMB 
is an mshC-independent outcome. There was no change in susceptibility to OPB in the mshC 
Tet-OFF strain in the presence of ATC and an equivalent effect was observed in Wt (Figure 
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Wt mshC Tet-OFF 
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Figure 6.4: The susceptibility of Wt and mshC Tet-OFF to oxidizing agents. A chequerboard 
synergy assay shows increased susceptibility of Wt (A and C) and mshC Tet-OFF (B and D) to 
plumbagin (PMB) in the presence of ATC at various concentrations. ATC has no effect on the 
susceptibility of Wt or mshC Tet-OFF to oxyphenbutazone (OPB). Bacterial viability was 
measured by the addition of alamar blue by which a transition from blue to pink colour 
indicates growth. The yellow line represents the minimum inhibitory concentration (MIC90). 
ATC concentrations are presented as ng/ml while oxidizing agents are in μg/ml. Data are 
from a representative experiment performed in triplicate. 
 
6.4.4 MshC is not ATC-regulated in the mshC Tet-OFF strain 
The lack of an ATC-dependent effect on the growth and phenotype of mshC Tet-OFF 
suggested that mycothiol biosynthesis was not sufficiently depleted. To investigate the 
effect of ATC treatment on target gene expression, droplet digital PCR (dd-PCR) was used to 
analyse the expression levels of mshC in response to ATC treatment (250 ng/ml [Figure 
6.5)]). No change to mshC expression was observed upon treatment with ATC in mshC Tet-
OFF. As a control, and to validate ATC as an inducer, the expression of coaBC in a coaBC Tet-
OFF strain (Evans and Mizrahi, unpublished) was evaluated. Additionally, expression of mshC 
was upregulated 2.5 fold in mshC-SCO relative to Wt, suggesting that the Pmyc1tetO is 
significantly stronger than the Wt promoter. Finally, ATC at a concentration of 250 ng/ml did 











Figure 6.5: Transcriptional response of mshC to ATC treatment. A. dd-PCR analysis of mshC 
expression in Mtb Wt, mshC-SCO and mshC Tet-OFF treated with ATC (250 ng/ml for 24 hr), 
or untreated. Similarly, coaBC expression was evaluated as a positive control. The results 
represent the average with standard deviation (SD) of two biological replicates, for each of 
































The ability to conditionally regulate the expression of essential genes with a simple inducer 
is extremely useful to examine the contribution of the target gene or other components of 
the same pathway (Abrahams et al., 2012; Park et al., 2014). In mycobacteria, several 
groups have reported the use of Tet-based systems for the conditional regulation of 
essential genes in vitro as well as for characterization during infection in animal models 
(Carroll et al., 2005; Ehrt et al., 2005; Hernandez-Abanto et al., 2006; Boldrin et al., 2010).  
In this study, to evaluate MSH-mediated fortification, application of the Tet-based 
conditional expression system to mshC was attempted. Although it was possible to generate 
an SCO mutant in which the native gene was placed under the control of a Tet-regulatable 
promoter, ATC-dependent regulation was not observed following introduction of the 
reverse Tet repressors (RevTetR). For different genes the level of expression at which 
growth impairment manifests is different; that said, the lack of regulation observed in the 
mshC Tet-OFF strain was intriguing, especially since genes with naturally low expression 
levels are expected to be unresponsive (Carroll et al., 2005). In addition, the concentration 
of ATC appears to play an important role due to the presence of multidrug efflux pumps in 
Mtb that actively extrude the inducer.  
Although the range of concentrations of ATC tested did not elicit a clear phenotype, it may 
be worthwhile to optimize the concentration as suggested previously (Carroll et al., 2005). 
Furthermore, the propensity of certain strains to lose Tet regulation when propagated in 
vitro has been previously reported and may possibly explain the phenotype observed in this 
study, although care was taken to not propagate beyond 5 generations (Abrahams et al., 
2012). Furthermore, validating the behaviour of this strain in response to ATC was especially 
challenging since, unlike auxotrophs (Abrahams et al., 2012), this strain could not be 
stabilized by supplementation. Although we generated two Tet-ON strains in which Wt TetR 
were expressed from strong (S) and intermediate (M) mycobacterial promoters, these were 
not selected for further characterization. The disadvantage of the Tet-ON strains is that the 
inducer needs to be removed in order to silence the gene, and this can be challenging 
depending on the nature of the assay as well as the nature of the target gene.  
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Mycothiol has been advocated as a drug target. The first MSH biosynthesis inhibitor 
identified, NTF1836, was initially found in a screen for inhibitors of the native Mtb MshC. 
This compound was optimized and demonstrated activity against non-replicating Mtb 
(Newton et al., 2006; Newton et al., 2011). In addition, in a separate screen, two 
quinaldinium derivatives were recently identified which exhibit micromolar inhibition of 
MshC (Gutierrez-Lugo et al., 2009). Its defined role in the survival and adaptation of 
mycobacteria to oxidative stress promotes MshC as a drug target (Hayward et al., 2004). 
However, the resistance to INH and ETH associated with mycothiol depletion is of definite 
concern. Together with RIF, INH is the foundation of the current regimen for the treatment 
of susceptible tuberculosis (TB). Therefore, in addition to prophylactic treatment to prevent 
progression from latent to active TB, it is unlikely that an MshC inhibitor will be 
administered concurrently with either INH or ETH or any other novel drug that may target 
inhA. Additionally, it has been suggested that functional defects in the mycothiol pathway 
may result in low level INH resistance or later development of high-level mono- resistance 
(Hayward et al., 2004). 
 
The ultimate generation of a “knock-up” mutant in turn suggests that a Tet-based 
conditional expression system is not applicable to this gene. This is not a new observation: 
this approach has previously been shown to result in differential regulation of essential 
genes (Abrahams et al., 2012 and Evans and Mizrahi, unpublished).  
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Chapter 7: General Conclusion 
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It is now generally accepted that the molecular mechanisms that perpetuate antibiotic 
resistance in the clinical setting are not limited to a single resistance mechanism, but to an 
amalgamation between intrinsic and genetic resistance mechanisms (Viveiros et al., 2012). 
These include the low permeability of the mycolic acid-containing cell wall, the operation of 
various antibiotic-modifying or -inactivating systems, and the activity of efflux pumps.(Louw 
et al., 2009; da Silva et al., 2011a; Balganesh et al., 2012b) Subsequently, intrinsic resistance 
mechanisms limit the antibiotics available for treatment and drive the emergence of strains 
with high levels of antibiotic resistance. This study aimed to investigate the role of various 












Figure 7.1: Mechanisms that contribute to the mycobacterial intrinsic resistome. The 
individual mechanisms that contribute to Mtb’s intrinsic resistance do not function as 
discrete mechanisms, but rather a coordinated interplay of one or more mechanisms to 
form an intricate, dynamic network termed the intrinsic resistome. These intrinsic 
mechanisms include the permeability barrier of the mycobacterial cell wall, mycothiol-
mediated protection, transcriptional regulation of multidrug resistance, the SOS response, 
drug modification and degradation and efflux-mediated resistance. The intrinsic resistome 
thus presents a formidable opponent in the quest for the discovery and development of 
novel antituberculosis drugs and limits currently available drugs by driving the emergence of 
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Several lines of evidence implicate the SOS response in intrinsic resistance to antibiotics 
through its role in adaptive mutagenesis (Drlica & Zhao 1997; Miller et al., 2004; Cirz & 
Romesberg 2007; Kohanski et al., 2007). Mycobacteria are intriguing in that there are two 
mechanisms associated with the regulation of DNA repair genes: a small number of genes 
are regulated by the classic SOS or RecA/LexA-dependent mechanism (referred to as the 
SOS response), while a larger subset of genes are regulated by an alternate, RecA/LexA-
independent mechanism (referred to as the RecA-ND mechanism/response) (Figure 3.2) 
(Durbach et al., 1997; Rand et al., 2003; Gamulin et al., 2004; Smollett et al., 2012). Given 
the existence of an alternative DNA damage response in mycobacteria (Rand et al., 2003; 
Gamulin et al., 2004), corresponding Mtb and Msm lexAInd- (SOS-uninducible) mutants were 
generated to evaluate how the SOS pathway specifically contributes to antibiotic-mediated 
DNA damage tolerance and induced mutagenesis. This study is the first to report the 
construction of lexAInd- mutants in both Msm and Mtb. However, inactivation of the SOS 
response still renders a fully functional RecA-ND response. Thus, error-prone damage 
tolerance (TLS) is compromised in these strains, but error-free DNA repair (BER/NER) and 
repair of double-strand breaks (DSBs, HR/NHEJ) remains functional. Furthermore, Mtb auto-
bioluminescent reporter strains were generated by introducing the lux operon downstream 
of the recA or radA promoters. Analysis of a panel of antimicrobials against these strains 
allowed for the identification of true DNA-damaging agents and the evaluation of the 
kinetics of the DNA-damage response, in a concentration- and time-dependent manner.  
Efflux pumps contribute directly to intrinsic resistance, and indirectly by providing a 
“window” for the emergence of high-level resistance through drug-target mutations (high-
level, adaptive resistance mechanisms). In addition, overexpression of – or mutations within 
– efflux pumps may result in antimicrobial resistance, as the drug is extruded more 
efficiently and the intracellular concentration of the drug decreases to sub-inhibitory 
concentrations, thus inducing genetic resistance (Piddock 2006; Zechini & Versace 2009). 
Current strategies used to counteract efflux-mediated resistance include the search of 
either new antibiotics that overcome the efflux systems or efflux pump inhibitors (EPIs). 
Utilization of EPIs has become increasing attractive, given the mounting evidence 
implicating the clinical significance of efflux pumps. Ultimately, antimicrobial therapy with 
an EPI is a combination therapy. Therefore to maximize the synergy between the two 
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agents, it is imperative that novel EPI’s are tested in combination from the in vitro stages of 
development. With the increasing attractiveness of EPIs a deluge of novel EPIs are 
predicted, that will require rapid and reliable analyses in in vitro and ex vivo assays. In this 
context, an in vitro assay has been established in which novel EPIs can be tested in 
combination with current/ novel antimicrobials, to indicate efficacy of the prospective EPI in 
downstream applications (ex vivo and in vivo). Using this approach, various candidates have 
been identified and it is hoped that a continuous supply of compounds in the EPI pipeline 
may yield a successful clinical candidate. 
MSH has an established role in tolerance of oxidative and other stressed conditions, and 
contributes to the survival of bacilli within macrophages. MSH functions in the intrinsic 
resistance of Mtb by serving as a substrate for enzymes involved in antibiotic detoxification 
(Rawat & Av‐Gay 2007; Jothivasan & Hamilton 2008; Newton et al., 2008). The attempt to 
disrupt MSH production by conditionally knocking-down expression of the essential gene, 
mshC, was futile, highlighting the difficulties of knocking down a pathway in which the 
essentiality of the gene(s) involved remain contraversial.  
In conclusion, Mtb has a multitude of inherent mechanisms to subvert the effects of 
antimicrobial treatment. This study has contributed to the understanding of certain aspects 
of the intrinsic resistome and in doing so, established tools, such as the autobiolumiscent 
reporter assay for early identification of DNA-damaging agents and the chequerboard 






Appendix 1: List of abbreviations 
2TY Tryptone Yeast broth 
4NQO 4-nitroquinoline-1-oxide 
5-FU 5-fluorouracil 
AAC Aminoglycoside acetyltransferases 
ABC ATP-binding cassette 
AMP Ampicillin 
ANT Aminoglycoside nucleotransferases 
APH Aminoglycoside phosphotransferases 
ARV Anti-retroviral 
ATC Anhydrotetracycline 
BCG Bacille Calmette-Guérin 
BDQ Bedaquiline 
BER Base excision repiar 
bp Base pair 
CCP Cell-penetrating peptides 
cDNA Complementary DNA 
CEM Cryo-electron microscopy 
CET Cryo-electron tomography 
CFU Colony forming unit 
CIP Ciprofoxacin 
CTAB Cetyltrimethylammonium bromide 
DAGS Diacyl gycerols 
DCS D-cycloserine 




DNA Deoxyribonucleic acid 
dNTP Deoxynucleotide triphosphate 
DOTS Directly Observed Therapy – Short Course 
DSBs Double-strand breaks 
EDTA Ethylenediaminetetraacetic acid 
EMB Ethambutol 
EPI Efflux pump inhibitor 
ERY Erythromycin 
ETH Ethionamide 
FA Fusidic acid 
FAM 6-carboxyfluorescein 
FBS Fetal bovine serum 
FDA US Food and Drug Administration 
FIC Fractional inhibitory concentration 
FICI Fractional inhibitory concentration index 
146 
FMNH2 Riboflavin phosphate 
g Gravitational force 
GAT Gatifloxacin 
GEN Gentamycin 
HCL Hydrochloric acid 
HIV Human Immunodeficiency Virus 
HK Histidine kinase 
HTS High throughput screening 
HYG Hygromycin 
IC20 Inhibitory concentration 
INH Isoniazid 
IPT INH preventive therapy 
IRIS Immune Reconstitution Inflammatory Syndrome 
KAN Kanamycin 
LA Luria-Bertani agar 
LB Luria-Bertani broth 
LEV Levofloxacin 
LTBI Latent tuberculosis infection 
mAGP Mycolyl arabinogalactan–peptidoglycan 
MALDI Matrix-assisted laser desorption/ionization 
MALDI-MSI MALDI- mass spectrometry imaging 
MATE Multidrug and toxic compound extrusion 
MDR Multidrug resistant 
MFS Major facilitator superfamily 
MIC90 Minimum Inhibitory Concentration 
MMC Mitomycin C 
MMR Mismatch repair 
MoA Mechanism of action 
MOX Moxifloxacin 
MSH Mycothiol 
Msm Mycobacterium smegmatis 
MSSM Mycothione 
Mtb Mycobacterium tuberculosis 
NAG N-acetyl glucosamine 
NaOH Sodium hydroxide 
NaOH Sodium chloride 
NER Nucleotide excision repair 
NFZ Nitrofurazone 
NHEJ Nonhomologous end-joining 
NOR Norfloxacin 
NOV Novobiocin 
OADC Oleic acid-albumin-dextrose-catalase 
OFX Ofloxacin 
OH˙ Hydroxyl radical 
OMP Outer membrane protein 
OPB Oxyphenbutazone 
PAS Para-aminosalysilic acid 
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PBP Penicillin binding proteins 
PCR Polymerase Chain Reaction 
PD Pharmacodynamics 
PDIM Phthiocerol dimycocerosate 
PET Positron emission tomography 
PGL Phenolic glycolipids 
PIMS Phosphatidylinositol mannosides 
PK Pharmacokinetic 
PMA Phorbol myristate acetate 
PMB Plumbagin  
PZA Pyrazinamide 
RecA-ND RecA/LexA-independent mechanism 
RecA-NDp RecA/LexA-independent promoter 
RevTetR Reverse Tet repressor 
RIF Rifampicin 
RLU Relative Luminescence Units 
RMS Reverse micellar solution 
RNA Ribonucleic acid 
RND Resistance-nodulation division 
RNS Reactive nitrogen species 
ROS Reactive oxygen species 
SAR Structure-activity relationship 
SCO Single crossover 
SD Standard deviation 
sdH2O Sterile distilled water 
SMR Small multidrug resistance 
SNPs Single nucleotide polymorphisms 
SPC Spectinomycin 





TbI Transformation Buffer I 
TbII Transformation Buffer II 




TF Transcription factor 
TLS Translesion synthesis 
Tris Tris(hydroxymethyl)aminomethane 
UCT University of Cape Town 
UV Ultraviolet 
v/v Volume per volume 





WGS Whole-genome sequencing 
Wt Wild-type 





Appendix 2: Culture media 
All media were made to a final volume of 1L with distilled water. Media were sterilized by 
autoclaving at 121°C for 15 min. 
Luria-Bertani Agar 
10 g tryptone, 10 g NaCl, 5 g yeast extract, 15 g bacteriological agar 
Luria-Bertani Broth 
10 g tryptone broth, 10 g NaCl, 5 g yeast extract 
2TY  
5 g NaCl, 10 g yeast extract, 16 g tryptone 
7H10/OADC Agar 
19 g Middlebrook 7H10 agar powder (DifcoTM, USA), 5 ml glycerol (Merck, Germany) 
100 ml Middlebrook OADC Enrichment (BD Microbiology Systems, USA) added after 
autoclaving. 
7H9/OADC Liquid  
4.7 g Middlebrook 7H9 broth powder (DifcoTM, USA), 2 ml glycerol (Merck, Germany) 
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